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Abstract 
 
Hyaluronan (HA) is a naturally occurring polysaccharide and well known for its exceptional 
properties such as high biocompatibility and biodegradability, along with a low 
immunogenicity. Besides its use for various biomedical applications it recently came into 
focus as a favorable excipient for the formulation of various ocular therapeutics. This review 
article summarizes the ocular distribution of HA and its most heavily investigated binding 
protein “cluster of differentiation 44” (CD44) which is the rationale for the clinical use of 
HA, primarily as an additive in ocular applications ranging from eye drops to contact lenses. 
Moreover, examples will be given for using HA in various pre-clinical approaches to generate 
entirely new therapeutics, most notably in the field of nanotechnology. 
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1 Introduction 
Ocular diseases are numerous and diverse. Some present few symptoms or a mild 
progression, while others may be associated with pain, double vision, inflammation, and 
ultimately vision loss. In the past decade, significant progress has been achieved toward a 
better understanding of the pathogenesis and genetics of many ocular diseases such as 
glaucoma or ocular neovascularization (e.g., age-related macular degeneration (AMD) or 
diabetic retinopathy (DR) [1]). Over the same time period, the field has seen a substantial 
expansion of both therapeutic options and routes of delivery. For many years, ocular 
medicines have been applied predominantly as eye drops. Despite their potency, these 
medications have a long list of drawbacks, including poor compliance, inadequate application 
by patients, poor bioavailability, and systemic side effects [2]. In addition, these therapeutic 
options fail at treating diseases that originate in the posterior segment of the eye. The 
emergence of biologics has helped fill this therapeutic gap; intra-vitreal injections are now 
routine procedures [3]. In addition, research and development on novel drug delivery 
materials and strategies for therapeutics, ranging from small molecules to biologics and 
nucleic acids, have advanced the field tremendously (for reviews please refer to [4–8]).  
More recently, the polysaccharide HA has come into focus as a favorable excipient for the 
formulation of various ocular drug delivery systems. HA is a naturally occurring structural 
component of the extracellular matrix (ECM) and can be gained by extraction from animal 
tissues such as the rooster comb but also via bacterial fermentation in Streptococci or Bacilli 
[9,10]. Its non-immunogenic, non-fouling and favorable physicochemical properties (e. g. 
high water binding capacity, pseudoplasticity, optical transparency) have made the use of HA 
in biomedical applications quite popular. For example, it has been applied as an artificial 
lubricant in joints [11], a substitute material for the vitreous body [12], and a scaffold material 
for tissue engineering [13]. Additionally, HA has contributed to the development of cancer 
diagnostics and therapy [14,15]; for instance, HA-based hydrogels have been used for local 
delivery of macromolecular drugs (e.g., for interferon-ơ2 [16,17], trastuzumab [18], and 
nucleic acids [19]). HA-drug conjugates have also shown promise when formulated to 
improve drug solubility and stability, in a similar fashion to PEGylation [20]. Lastly, HA has 
been used successfully as a targeting sequence to guide drug-loaded nanoparticles (NPs) to 
their final destination [15]. Despite these efforts, HA-based excipients are just beginning to 
garner recognition as powerful catalysts for new drug delivery applications in the field of 
ocular pathology.  
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Here, we first present a general overview of HA and its properties. Then, we describe the 
distribution of HA and its binding protein CD44 in the anterior and posterior segment of 
the eye. Finally, we provide a critical review of recent developments in the field of HA-
assisted ophthalmic drug delivery and highlight HA’s potential therapeutic effects.  
2 HA and its interaction with the CD44 receptor 
 
Figure 1. Chemical structure of HA. HA is a natural heteropolysaccharide composed of the 
repeating disaccharide unit D-glucuronic acid / N-acetyl-D-glucosamine. The monomers are 
linked via Ƣ-1,4- and Ƣ-1,3-glycosidic bonds until the molecular weight reaches values of up to 
107 kDa. 
HA is the main component of the ECM and can therefore be found ubiquitously in the 
human body. The largest amount is present in the skin, which accounts for over 50 % of 
total body HA [15]. However, the concentration is also high in the vitreous body, from which 
it was originally isolated in 1934 [21]. Its significant role in the body is underlined by its high 
synthesis rate and an extremely rapid turnover of 5 g per day in an adult of 70 kg [22].  
HA is composed of alternating units of D-glucuronic acid and N-acetyl-glucosamine 
(Figure 1). The monomers are linked via Ƣ-1,4- and Ƣ-1,3-glycosidic bonds and form a long, 
linear polymer chain. The pKa value of the carboxylic acid groups is between 3 and 4 [23]. 
Consequently, the polysaccharide is negatively charged at physiological pH. Native HA is 
present as high molecular weight (MW) material up to 107 kDa and is well known for being 
biocompatible, biodegradable, non-toxic, and non-immunogenic [24]. Although the chemical 
structure is very simple, HA exhibits exceptional properties and various biological functions 
[25]. Due to its hydrophilic character and long chain length, HA can bind enormous amounts 
of water and may thus swell up to a volume 1000-fold greater than its original solid volume 
[15,26]. HA solutions are viscous and characterized by shear thinning and pseudo-plastic 
flow behavior [27]. Consequently, the polymer is ideally suited as a lubricant in several 
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biological functions and was rapidly deployed as an artificial viscosupplement, which 
diminishes friction and abrasion in the joint gap [28]. 
HA promotes the structure formation and hydration of the ECM throughout various tissues 
in the body and enables their mechanical functionality and stability [26,29]. Interactions with 
several extracellular binding proteins (e.g., versican, aggrecan, and neurecan), distributed 
unevenly across tissues, strengthen the structure of the matrix [30]. In addition, hydration 
and electrostatic repulsion of anionic carboxyl groups on the polysaccharide chain contribute 
to the expansion of the polymer [25]. The resulting pressure caused by the swelling is strong 
enough to separate neighboring tissues, allowing cells to migrate within the newly emptied 
spaces. This HA-induced “cell migration highway” is of special importance in tissue 
development, wound healing, and cancer metastasis. Cellular receptors for HA such as 
CD44, receptor of hyaluronan mediated mobility (RHAMM) and lymphatic vessel 
endothelial hyaluronan receptor 1 (LYVE-1) link cells to the ECM, mediate cellular mobility, 
transduce signals from the extracellular environment to the intracellular space and are 
responsible for HA internalization and degradation. Some HA-binding proteins share a 
structural domain known as “link module” but other binding sites have also been identified 
[31].  
The most heavily investigated of the HA-binding proteins is the CD44 receptor, which exists 
in multiple isoforms due to a significant degree of alternative splicing [32]. Glycosylation also 
broadens CD44 structural diversity and influences receptor activity. Given the polyanionic 
character of HA, it is at first glance surprising that hydrogen bonding and van der Waals 
forces dominate the CD44-HA interaction (at least for the murine CD44 receptor), as found 
by Banerji et al. via co-crystallization [33]. However, the anionic charges are unevenly 
distributed over the polymer, resulting in a substantial hydrophobic surface along the 
polyelectrolyte chain. A minimum chain length of six monosaccharides is necessary for 
monovalent binding of HA to the CD44-receptor [34]. Multivalent binding enhances 
receptor affinity and can be observed when the polysaccharide chain length exceeds 20 
monomers. Mizrahi et al. implemented a model to estimate both, the binding strength 
between HA and its receptor CD44 and the receptor coverage by HA of different MW [35]. 
They immobilized a recombinant human CD44-Fc chimera on a surface plasmon resonance 
(SPR) sensor chip and evaluated the number of receptors occupied by free HA. Additionally, 
they assessed binding of HA-functionalized NPs. Strong binding of free HA was measurable 
at or above an HA MW of 132 kDa and coverage was found to match theoretical predictions 
(Table 1). In contrast, when the HA-chains were affixed to the NP surface, binding strength 
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was strongly reduced, most likely due to restricted polymer mobility. However, when the 
MW was increased to 700 kDa, free and immobilized HA exhibited similar binding 
characteristics. As these results were achieved using a planar and cell-free model, one should 
exercise caution when extrapolating results to an in vivo environment. 
Table 1. Estimated CD44-Fc coverage by free HA at different MWs. Assuming a receptor 
density of 3 receptors per 1000 nm² and taking into account the radius of gyration of differently 
sized HA-chains, the receptor coverage was calculated. With permission taken from [35]. 
HA MW  
[kDa] 
Radius of  
gyration [nm] 
Area  
[nm²] 
CD44 coverage (CD44 molecules  
available per HA) 
6.4 4 49 1 (0.16) 
31 10 327 1 
132 24 1709 5-6 
700 66 13678 44 
1500 105 34365 110 
 
After binding to the CD44 receptor, HA can be internalized via receptor-mediated 
endocytosis and degraded [25,36]. Subsequently, downstream signaling cascades may be 
activated, triggering cell survival, migration or inflammation. HA-CD44-interactions thus 
play a role in physiological and pathophysiological processes like embryonic development or 
tumorigenesis. Depending on the tissue, the degree of polymerization and the binding 
proteins involved, HA mediates different – and often opposing – effects as a messenger 
molecule. Whereas high MW HA has non-immunogenic and anti-proliferative properties, 
smaller degradation products seem to promote angiogenesis, inflammation and tumor 
growth [15]. However, very short HA fragments may in turn transduce an entirely different 
set of signals that effect suppression of tumor growth [26]. The complex interplay between 
HA, its receptors, synthases and cleaving enzymes, along with the therapeutic concepts based 
on these findings, are the subject of several review articles [26,37–39]. These investigations 
do not primarily refer to ocular cells because a deeper analysis and understanding of the 
CD44 receptor characteristics of primary ocular cells or ocular-derived cell lines, respectively, 
has to the best of our knowledge not been addressed so far. 
It is important to mention that the use of HA is also associated with some drawbacks. 
Because HA is of natural origin, variations are possibly more important than they are for 
synthetic polymers [40]. Significant batch-to-batch variations may complicate further 
downstream processing. But the clinical use of several biopolymers – therapeutically or as an 
excipient (e. g.  heparin, alginate, protamine or gelatin to name just a few) has demonstrated 
that detailed specifications of individual characteristics such as MW, grade of purification or 
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biological offspring, can diminish differences between batches thereby facilitating further 
processing. In addition, the production of HA by extraction from animal sources is a 
common procedure – but contamination with proteins or viruses are possible and might 
become a problem in certain applications. Equally, the fermentation in bacteria carries the 
chance of mutation of the bacterial strain and the co-production of toxins or pyrogens [41]. 
Especially if the usage is not limited to topical administration, the allergic potential and the 
risk of developing an anaphylactic reaction cannot be denied. Luckily, the microbiological 
production and purification methods have made tremendous progress in the past few years. 
Another point is the pharmacological effect of HA itself. As discussed earlier, depending on 
the MW and concentration, HA is involved in tumor metastasis, cell migration and 
proliferation on the cellular level. These effects also depend on the organ and tissue type and 
are not fully understood yet. Consequently, it is hard to fully estimate the overall effect of 
HA-based formulations. 
3 Anatomy of the eye 
 
Figure 2. Anatomy of the eye. A) General structure of the eye bulb. B) Anterior chamber of the 
eye. Arrow shows the outflow pathway of the aqueous humor produced in the ciliary body. 
C) Cross-section of the back of the eye. 
The structure of the eye is unique and provides many advantages for drug delivery, e.g. 
immune privilege – the absence of immunological reactions against diverse antigens – and 
accessibility for local administration [42]. In the following section, the prevalence of HA and 
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CD44 in the eye is described to provide support for the notion of using HA as a component 
in ocular drug delivery formulations. 
The eye can be divided into two functional regions as illustrated in Figure 2. The anterior 
segment makes up approximately one third of the total volume of the eye and comprises the 
cornea, iris, ciliary body and lens (Figure 2B) [43]. Aqueous humor (AH), which provides 
nutrients to the cornea and lens, fills the spaces within the anterior segment. It is produced 
in the ciliary body, flows through the gap between lens and iris into the anterior chamber 
where it drains through the trabecular meshwork (TM) and Schlemm’s canal into the 
episcleral vein (arrow in Figure 2B) [44]. By adjusting the AH production and drainage, the 
intraocular pressure (IOP) is regulated and adapted to guarantee the correct shape – and 
thus, optimal optical properties – of the eye bulb under changing conditions [45]. Belonging 
to the posterior segment, the vitreous body represents the largest part of the eye bulb. This 
clear, highly hydrated gel fills the space between the lens and the retina and serves structural, 
optical and developmental functions [46]. The back of the eye contains the retina, the choroid 
and the optic nerve (Figure 2C). The retina is composed of several structures: neuronal 
ganglia and sensory cells, separated from the vitreous by an inner limiting membrane [47]. 
Rods and cones, responsible for perception of light/dark and colors, respectively, are two 
types of photoreceptors found in the retina. Müller glia cells in the neuronal layer stabilize 
the retina and support the functions of the photoreceptors, for example by providing 
nutrients, removing metabolic products and regulating neuronal excitability [48]. The retinal 
pigment epithelium (RPE) is the outermost layer of the retina, and plays an important role 
in maintaining the viability of the photoreceptors. Among other tasks, the pigmented cells 
absorb scattered light, protect retinal cells against photo-oxidative stress, transport 
substances between photoreceptors and choroidal capillaries, and help to regenerate sensory 
cells [49]. Bruch’s membrane divides the retina from the choroid, which is the vascular layer 
of the posterior segment of the eye [47]. Blood vessels provide the outer retinal areas with 
nutrients and oxygen. 
Albeit to a varying extent, HA is present in all described structures of the eye and is often 
found in close proximity to CD44 receptors. To improve the comprehensibility of the 
following, the distribution of HA and CD44 is described from front to back of the eye.  
3.1 Anterior segment of the eye 
HA is an integral component of the cornea, typically collocated with its receptor CD44. In 
particular, immunostaining revealed high CD44 receptor density in the corneal epithelium 
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and endothelium, whereas lower density was observed in the hydrophilic corneal stroma 
(Figure 3) [50,51]. Interestingly, inflammation and other destructive processes affecting the 
cornea lead to a change of CD44 isotype (alternative splicing) and an increase in receptor 
density [52–54]. These observations are consistent with the influence of HA on epithelial cell 
mobility during wound healing; re-epithelialization occurs at a faster rate in the presence of 
HA [55,56]. In this case, interactions between epithelial CD44 receptors and HA on the 
ocular surface likely facilitate cell movement along this polysaccharide chains. Additionally, 
high MW HA seems to have a protective effect in UVB (radiation) exposed corneal epithelial 
cells due to its inhibitory effect on apoptotic signals and inflammatory cytokines [57]. The 
HA “reservoir” in tears is produced by corneal epithelial cells [58,59] and contributes 
significantly to the integrity of the ocular surface. 
 
Figure 3. Central portion of the human cornea illustrating the distribution of HA and CD44 in 
the corneal epithelium and stroma. A) HA (brown) is localized on the basal and superficial 
epithelium but hardly in the stroma. Magnification: x 132. B) Intense staining for CD44 (brown) 
can be detected on the basal and superficial epithelium and is similar to the distribution pattern 
of HA. Magnification: x 150. Counterstaining with light green. With permission taken from [51].   
HA has also been detected and quantified in the AH of enucleated eyes from humans, 
mammals and birds [60]. It might be involved in maintaining IOP, as it is capable of binding 
large amounts of water and therefore generating a high swelling pressure. IOP regulation is 
controlled primarily by varying outflow resistance to AH in the TM. In the TM, HA makes 
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up 20-25% of the total glycosaminoglycans of the ECM [61] and is mainly associated with 
the sieve-like networked epithelia of the trabecular beams [62,63] (Figure 2B). HA therefore 
co-determines the structure of the aqueous outflow pathway and as such is directly involved 
in regulating IOP. Interestingly, the aqueous HA concentration increases with age in healthy 
individuals, but is reduced in patients suffering from primary open angle glaucoma (POAG), 
a severe eye disease characterized by elevated IOP damaging the optic nerve [64,65]. Low 
HA concentrations are accompanied by an increased level of free CD44s, a soluble 
degradation product of the CD44 receptor [66], since the quantity of available HA is 
insufficient to inactivate CD44s. As CD44s – especially the hypophosphorylated form – is 
toxic to retinal ganglion cells and supporting cells in the prelaminar portion of the optic 
nerve, it might contribute to the degradation of neuronal cells and vision loss in POAG, 
provided its concentration exceeds a certain limit [67]. Consequently, Nolan et al. have 
proposed the use of CD44s as a protein marker for visual field loss in POAG [68].  
Finally, HA has been detected in the iris and lens. Similar to observations made in the cornea, 
HA concentration and CD44 receptor density have been found to rise upon injury to these 
structures [69,70]. Apparently, HA also promotes tissue regeneration in the internal space of 
the anterior segment [71,72]. It has been shown via in vitro cell culture that migration of 
human lens epithelial cells on laminin or collagen coated plates is dependent on CD44 
receptor interactions [73]. However, as very few HA-based therapeutics have been 
investigated for this site of application, scant detail is available. 
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3.2 Posterior segment of the eye 
 
 
Figure 4. Schematic drawing of the vitreous structure. Collagen fibrils form the hydrogel 
scaffold. HA immobilizes water within the spaces and leads to stretching of the collagen fibers. 
With permission taken from [46]. 
The vitreous of the eye was the first structure in which HA was detected in 1934 [21]. Today, 
the distribution and function of HA is well-known; HA is the principal glycosaminoglycan 
of the vitreous and found in concentrations varying from 65 to 400 µg/mL in humans, 
increasing with age [74]. A network of collagen fibers of different types forms the scaffold 
of the vitreous. High MW HA chains fill the spaces between the protein fibers and 
immobilize large amounts of water. The resulting swelling pressure leads to stretching of the 
collagen fibers, which mediates the internal tension of the vitreous (Figure 4) [46]. 
Experimental ex vivo treatment of vitreous with hyaluronidase reduces its water content and 
stiffness, but also increases contraction of its collagen fibers. These first two properties 
generated clinical interest (including a phase III clinical trial [75]) around use of hyaluronidase 
as a liquefaction agent to be applied prior to vitro-retinal surgery, which is often required to 
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treat retinal detachment or DR. However, intensified traction on retinal structures may 
increase the risk of exacerbating retinal damage, with the potential for subsequent vision loss 
[76]. Hyaluronidase also promotes natural HA turnover, and is partially responsible for 
maintaining the gel structure [77]. Depending on the species, the half-life of vitreal HA is 
estimated to range from 10 to 70 days. This differs significantly from other tissues, where 
half-life is no more than one week, and typically less than one day [78]. This extremely long 
half-life could be due to a combination of high vitreal HA concentration and scarce HA-
secreting cells. Thus, faster replacement of the polymer would impair vitreal functionality. 
In the back of the eye, Müller glia and cells of the RPE produce extracellular HA for the 
retina and the choroid [79,80]. In vitro studies have been conducted to investigate the 
synthesis of HA by RPE cells [81]. RPE cells secrete HA preferentially from the apical 
surface and are thus responsible for the significant amount of HA present in the 
interphotoreceptor matrix. Other cell types are involved in HA homeostasis. Gross-
Jendroska et al. showed that the production of a paracrine factor by fetal RPE stimulates HA 
synthesis in neighboring choroidal mesenchymal fibroblasts [82]. The corresponding CD44 
receptor can be found on Müller glia microvilli in the retina (Figure 5) [83]. There, the 
receptor can be detected during all stages of fetal development and is regarded as a surface 
marker for progenitor cells destined to become Müller glia [84,85]. The interactions between 
HA and its receptor contribute to structuration of the ECM around photoreceptors and 
neurons and enhance the internal strength of the tissue [86,87]. Again, CD44 expression has 
been shown to increase after retinal injury. This observation supports evidence of CD44 
upregulation in proliferating cells in vitro and informs an understanding of the impact of HA 
on healing processes in the cornea and lens, as discussed earlier [88–90]. 
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Figure 5. A) Immunoperoxidase labeling on sections of fixed adult mouse retina illustrating the 
presence of CD44 at the outer limiting membrane and directly adjacent tissue. These structures 
include the Müller glia microvilli and the lower portion of the photoreceptor inner matrix. 
However, discrimination between both structures was not possible. Hence it was not clear if the 
staining included only one or both components. B) No label was seen if an isotype control was 
used. pe = pigment epithelium; os = outer segments; is = inner segments; onl = outer nuclear 
layer; opl = outer plexiform layer; inl = inner nuclear layer; ipl = inner plexiform layer; gcl = 
ganglion cell layer. Magnification: A x450, B x460, C x500. With permission taken from [83]. 
HA and CD44 are also involved in pathological alterations of the posterior segment. In 
particular, the Mochimaru group has investigated the impact of HA and CD44 on the 
development of choroidal neovascularization (CNV) [91]. CNV is characterized by an 
abnormally high degree of new blood vessel formation in the choroid. These blood vessels 
are not restricted to the choroid but rather grow through Bruch’s membrane into the retina. 
As vessels developed in this way are prone to bleeding and leakage, the retina can be 
damaged, potentially impacting a patient’s vision. Treatment with a hyaluronsynthase-2 
inhibitor (4-methylumbelliferone) or with an anti-CD44-antibody reduced CNV-severity by 
25% (Figure 6): an impressive result, given that many other factors contribute to the 
development of CNV. This observation was explained in reference to the proangiogenic 
effect of HA and its potential to recruit macrophages; a high number of HA receptor LYVE-
1-positive macrophages were found in healthy human choroids [92]. Similarly, the interaction 
of HA with its receptor CD44 is involved in inflammatory cell migration [93]. In 
experimental autoimmune uveoretinitis, a model for serious inflammatory reactions in the 
eye, the rolling of CD44 positive leukocytes along the HA-rich endothelium of venules and 
postcapillary venules in the retina enables blood cells to cross the blood-retina-barrier. In 
this case, too, the administration of anti-CD44-antibodies reduced the severity of 
inflammation and showed promise as a potential therapeutic strategy. 
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Figure 6. Reduction of CNV severity by antibody blockade of CD44. The anti-CD44 antibody 
was significantly more effective in reducing the CNV volume compared to a non-targeting 
isotype-control antibody. n = 44 for all. *p < 0.01. With permission taken from [91]. 
HA fulfills other functions in the choroid. During the process of developing clear and sharp 
vision (emmetropization), the choroidal thickness is adjusted to an individual’s requirements 
via choroidal deposition of HA and osmotically driven water retention [94–96]. This adjusts 
the length of the optical path (distance between lens and retina). Even though the 
investigations uncovering this mechanism were performed in chickens, HA is expected to 
play a role in this process in humans, as well.
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4 Applications of HA in the eye 
 
Figure 7. Possible sites of HA application in the ocular environment. Topical administration of 
therapeutics by eye drops, lenses or inserts is preferred due to ease of accessibility. However, 
some substances must be applied by injections into the vitreous cavity or the retina. 
Figure 7 summarizes typical therapeutic agent application sites in and on the eye. The topical 
route is the preferred mode of administration due to ease of accessibility. This works well 
for substances which have their effect in the anterior segment of the eye, such as lubricating 
eye drops or glaucoma therapeutics. However, if the drug must reach a structure in the 
posterior eye, like the retina, topical administration is ruled out; intravitreal injection is 
necessary to bring the therapeutic closer to its target. The broad distribution of HA and its 
binding proteins in the eye feature prominently in HA’s potential as a component of new 
therapeutic modalities. In this section, we discuss a broad range of applications for HA: as 
an excipient to improve the effectiveness of ocular dosage forms, as a therapeutic itself and 
as an enabling compound for novel drug delivery approaches. For an overview refer to 
Table 2. 
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Table 2. Overview of HA-related applications in the eye according to the type of administration. 
Formulation 
Type 
Target Benefits of HA formulation Possible Challenges References 
Topical administration 
Lubricating 
eye drops 
Ocular 
surface 
Long-term lubrication without 
foreign item sensations or 
induced lacrimation; 
accelerated healing of corneal 
lesion 
Application several 
times a day 
[97–101] 
Drug 
containing 
eye drops 
Cornea, 
conjunctiva, 
anterior 
segment of 
the eye  
Increased viscosity and 
mucoadhesivity prolongs 
ocular residence time of 
applied eye drops, increased 
bioavailability 
Incompatibility 
between drug 
substance and HA 
[102–108] 
Nanoparticles Ocular 
surface 
“solubility enhancement” of 
poorly water soluble drugs, 
mucoadhesivenes and HA-
CD44 interactions prolong 
precorneal residence time 
Complex 
manufacturing, 
possible difficulties 
during approval 
[109–111] 
 Corneal 
epithelial 
cells 
Reduced toxicity, high NP 
uptake (HA-CD44-
interactions), bypass of 
lysosomal degradation 
Complex 
manufacturing, 
possible difficulties 
during approval 
[112–116] 
Contact 
lenses 
Ocular 
surface 
Long-term delivery of HA as 
lubricant; improved 
characteristics of CLs with the 
possibility of an extended 
wearing time: enhanced 
wettability, reduced protein- 
and bacteria adsorption with 
lower risk of infection and 
inflammation 
Tailoring HA release 
profile 
Immobilization of HA 
in CL material 
[117–123] 
Ocular inserts Ocular 
surface, 
anterior 
chamber 
High biocompatibility of 
system for sustained drug 
delivery 
Challenging 
application because 
handling may be 
difficult especially for 
older patients 
[124,125] 
Intracameral administration 
Intraocular 
lenses 
Lens Reduced adhesion of lens 
epithelial cells and bacteria, less 
posterior capsule opacification 
and infection 
No routine 
application 
[126] 
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Formulation 
Type 
Target Benefits of HA formulation Possible Challenges References 
Intravitreal administration 
 Vitreous 
substitutes 
Vitreous 
body 
Biocompatibility, easy 
injection, biodegradability, 
suitable optical properties 
Biodegradation too 
fast, batch-to-batch 
variation 
[12,127] 
Nanoparticles Retina Enhanced mobility in 
vitreous without impaired 
interaction with cells; 
possibility of specific 
targeting 
Complex 
manufacturing, possible 
difficulties during 
approval 
[128–130] 
Retinal administration 
Retinal patches Retina Non-toxic, self-adhesive Visit to doctor 
necessary because 
application not possible 
by patients  
[131,132] 
Hydrogels for 
protein and 
stem cell 
delivery  
Retina High biocompatibility, 
suitable mechanical 
properties 
Still in experimental 
stadium, no clinical trial 
so far 
[133–135] 
4.1 Topical administration 
Many medicines are applied topically to the eye, and for good reason. Accessibility, proximity 
to target structures and a reduced risk of side effects when compared with systemic dosing 
are all positive features of topical administration. In addition, this application route has 
economic benefits. 
Lubricating and drug containing eye drops 
Instillation of eye drops is a procedure which can easily be managed by the patient, reducing 
costly visits to the ophthalmologist. Unfortunately, not all topical treatments are effective. 
Sometimes the active ingredients drain too quickly or are unable to overcome ocular barriers, 
the latter of which represents a major hurdle for retinal therapeutics in particular [136]. 
Corneal epithelia and endothelia, corneal stroma, attached mucins or AH flow are just some 
of the main hurdles that must be traversed with topical application, depending of course on 
the physicochemical properties of the drug (e.g., partition coefficient and MW). 
Nevertheless, eye drops remain a valuable method for ocular drug delivery. 
Lubricating eye drops (e. g.  HyloVision®, ArtelacSplash®, Hyabak®) are one of the most 
prominent applications for HA in the ocular environment. Several artificial tear solutions 
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utilize HA as a viscosity-enhancing and mucoadhesive excipient for the treatment of dry eye 
disease (DED). The world prevalence of DED is approximately 6 to 34 %, and an age over 
50 years and being female are known risk factors [137]. Patients are affected by ocular 
irritation, pain and transient visual impairment [138] caused by tear film instability, increased 
hyperosmolarity of the tear film and inflammation of the ocular surface [139]. The first-line 
therapeutic option is supplementation with artificial tears to lubricate the eye, replace missing 
tear fluid and normalize tear film osmolarity [140,141]. Viscous HA solutions or higher 
concentrated hydrogels are frequently applied to slow drainage of the eye-drop formulation, 
prolonging its therapeutic effect [142,143]. Compared to other excipients, such as polyvinyl 
alcohol or celluloses, the main advantage of high-viscosity HA solutions is their shear-
thinning behavior [144]. Consequently, foreign item sensations and induced lacrimation, 
unpleasant symptoms themselves, are avoided.  
To quantify the moisturizing potential of eye drops, one can measure tear film thickness. 
Following application of a 0.15 % HA formulation, tear film thickness was elevated for up 
to 40 minutes. Supplementation with 3 % trehalose increased tear film thickness by 30 % 
compared to the baseline value and extends the duration of the effect for up to 3 hours 
(Figure 8) [100,101]. These features could lead to decreased eye drop application frequency 
with no loss of therapeutic effect, representing a substantial benefit for the patient. 
 
Figure 8. Relative tear film thickness as a surrogate parameter for the moisturizing potential of 
different types of eye drops. (TH-SH: 3 % trehalose + 0.15 % HA, HA: 0.15 % HA, NaCl: 0.9 % 
NaCl). HA-containing eye drops are able to stabilize the tear film for 40 minutes. With addition 
of trehalose, the effect can be extended for three hours. With permission taken from [101]. 
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HA solutions have also been investigated as a treatment for pathologically elevated tear fluid 
osmolarity, regarded as a key factor in the pathogenesis of DED. Troiano et al. compared 
two unpreserved 0.4 % HA eye drops, one of them isotonic (300 mosmol/l), the other 
hypotonic (150 mosmol/l) [99]. After a treatment period of one week, hypotonic eye drops 
were more effective at reducing the symptoms of dry eye compared to isotonic drops. Rose 
Bengal staining also showed that hypotonic drops improved the vitality of corneal epithelial 
cells. Importantly, two thirds of the treated patients preferred the hypotonic formulation at 
the end of the study.  
HA eye drops have also demonstrated additional beneficial effects in the treatment of 
pathological alterations in DED. In particular, an impressive correlation between the velocity 
of corneal lesion healing and the concentration of the instilled HA solution was reported in 
rabbits (Figure 9) [97]. Relative to a 0.1 % HA solution, healing was accelerated by a factor 
of 2 within 24 hours when 0.2 % HA was applied. It seems like improvement of epithelial 
cell migration and proliferation is a dose-dependent and therefore a pharmacological effect. 
Additionally, viscosity and lubrication of the eye drops increase with higher HA 
concentrations, reducing mechanical damages like friction or abrasion during blinking to the 
ocular surface. Investigations in diabetic rats have arrived at similar results [98]. 
 
Figure 9. In vivo effects of HA (800 – 1400 kDa) on corneal epithelium wound healing. Eye 
drops were applied directly after corneal denudation of rabbits and again 2, 4, 6, 24, 28 and 30 
hours later. Wound closure was measured by staining with 1 % fluorescein. n=4, p=0.05. 
Control: 0.9 % NaCl-solution. With permission taken from [97]. 
Beside its usage as a wetting and lubricating agent, HA is also used as a viscous, 
mucoadhesive excipient in general to prolong ocular residence time and reduce the systemic 
drainage of drug-containing eye drops [106,107]. For example, HA was used to increase the 
bioavailability of anti-glaucoma parasympathomimetic pilocarpine eye drops in rabbits [108]. 
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Bioavailability of the drug, measured as the area under the curve (AUC) for miosis (pupil 
constriction) after topical instillation, was increased with increasing HA concentrations in 
the formulation. The prolongation of drug response, rather than an amplification of its effect, 
confirms similar findings found in previous studies [102]. Additionally, increasing the MW 
of HA applied led to lower concentrations of the excipient being required to obtain the same 
pupil-constricting effect, e. g. 0.75 % for 1600 kDa HA but only 0.125 % for 4600 kDa HA 
[108]. 
Bernatchez et al. have investigated the potential of HA in regards to enhancing the 
bioavailability of the antibiotic gentamicin in eye drops [105]. In comparison to buffered 
aqueous solution, the concentration of gentamicin in the tear fluid was increased by a factor 
of 2 for at least ten minutes upon inclusion of HA in the formulation. While these 
characteristics would not reduce application frequency, the increased concentration might 
improve the corneal penetration and bioavailability of the drug, enhancing its therapeutic 
efficacy. Herrero-Vanrell et al. have described the mucoadhesive properties and surface 
tension of corneal mucin and HA along with other excipients such as carboxymethylcellulose 
or polyacrylic acid; they then combined these polymers with the antimuscarinic drug 
tropicamide and investigated its bioavailability and mydriatic potential [103]. HA was found 
to increase the bioavailability by 70% relative to the excipient-free drug solution mainly due 
to prolongation of the mydriatic response. The effect was explained by reference to the 
similar properties of mucus and HA, as acidic groups of the polymers interact with the sialic 
parts of ocular mucins in a comparable fashion to mucus glycoproteins itself. Since 
tropicamide is used as a short-term mydriaticum, the benefit of using HA in formulations of 
this drug is limited. However, the results may be generalized and applied to other therapeutic 
substances with higher clinical relevance.  
In general, increasing the solution viscosity is a common approach for prolonging the ocular 
residence time of eye drops. The usage of in situ gelling excipients represents a particularly 
elegant approach, combining the simple administration of common low-viscosity eye drops 
with the favorable features of a more viscous formulation. Poloxamers or polyethylene 
glycol-polypropylene glycol block co-polymers are a frequently used class of thermogelators 
that may be used for this purpose; gelation occurs upon warming to body temperature as the 
hydrophilicity and hydration of the polyethylene part decreases, enabling stronger 
hydrophobic interactions and the formation of poloxamer micelles. The volume fraction of 
micelles increases and the liquid becomes a gel when it exceeds a certain limit [145]. Cho et 
al. combined the thermogelation of poloxamer 407 with the mucoadhesivenes of HA by 
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grafting both polymers with EDC/NHS chemistry (a technique for linking two educts via 
their reactive esters with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-
hydroxysuccinimide) [104]. The two polymers’ properties combine to extend drug release 
profiles, as shown below for the model substance ciprofloxacin (Figure 10). An HA amount 
of at least 7 % by weight must be exceeded to observe a relevant effect. 
 
Figure 10. Release profile of ciprofloxacin from in-situ-gelling poloxamer 407-HA-hydrogels. 
(a) poloxamer 407 alone (b) graft copolymer (HA, 1.18 wt.%), (c) graft copolymer (HA 6.87 
wt.%) and (d) graft copolymer (HA 13.99 wt.%), all with 1.75 wt.% ciprofloxacin. With 
permission taken from [104]. 
NP formulations 
NP formulations represent another therapeutic opportunity to take advantage of HA’s 
unique properties. Development of HA-modified NPs for topical ocular instillation has been 
motivated by two end goals. The first is – again - prolongation of ocular residence time for 
a drug substance. Drainage of NPs is slower than that of common eye drop formulations 
because they are able to interact with the corneal epithelium. Second, NPs can serve as a 
delivery vehicle for entry of various therapeutics into corneal cells. If the NP composition is 
chosen carefully, cellular specificity and the degree of cellular uptake can be enhanced, for 
example by leveraging NP-cell surface receptor interactions.  
If a drug substance is poorly water soluble, extension of the precorneal residence time is of 
special importance, as it provides a straightforward and easy way to enhance bioavailability. 
An excellent example is cyclosporine A (CyA), an immunosuppressive drug used to increase 
tear production in patients with DED. Loading of CyA into NP composed of benzalkonium 
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chloride and poly-ε-caprolactone boosted corneal CyA concentration by a factor of 6 to 8 
compared to that achieved with a castor oil formulation (Figure 11) [111]. This effect was 
attributed amongst others to the formulation as a NP and the presence of benzalkonium 
chloride. Corneal CyA concentration was even higher for HA-modified NP, possibly due to 
increased mucoadhesion and interactions with corneal CD44 receptors. 
 
Figure 11. CyA concentration in rabbit corneas. 25 µl of CyA formulation was applied four 
times with a delay of ten minutes in between applications to both eyes of New Zealand rabbits. 
Samples were obtained following the last instillation. Corneal CyA levels were significantly higher 
for the NP formulation composed of poly-ε-caprolactone and benzalkonium chloride 
(CyA/PCL/BKC) compared to that of the castor oil formulation (CyA in oil). If the NPs were 
modified with HA 1000 kDa (CyA/HA/PCL/BKC), corneal CyA accumulation exhibited 
further increase. With permission taken from [111]. 
Similar results concerning corneal CyA concentrations were observed for nano-sized 
microgels formed in situ [110]. Thermoresponsive N-isopropylacrylamide was grafted to 
11 kDa HA to combine the unique properties of both polymers. An increase in temperature 
to a value greater than the critical solution temperature of the polymer, upon application of 
the eye drops, led to the formation of microgels. Corneal CyA levels reached their maximum 
value two hours after application and were 6-fold higher than those of the castor oil 
formulation. Ibrahim et al. have also demonstrated use of HA’s mucoadhesive properties 
[109]. They prepared NPs from Eudragit, a commercial available polymer for the fabrication 
of sustained release dosage forms, and loaded them with gatifloxacin and prednisolone. 
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These NPs were able to release their antibiotic and anti-inflammatory payloads over a period 
of up to ten hours in vitro, depending on their composition. In order to benefit clinically from 
this sustained drug release, NPs must also remain on the ocular surface for an extended 
period of time. Consequently, the authors coated their NPs with HA. With this HA-modified 
NP formulation, the corneal bioavailability of gatifoxacin was increased to 28 µg*hour/g 
compared to only 3.6 µg*hour/g for commercial eye drops.  
Instead of using NPs to simply retard lacrimal drainage of a drug substance, they can also 
serve as a vehicle for delivering diverse therapeutic agents into corneal epithelial cells. In 
order to succeed as an intracellular drug delivery vehicle, NPs must reach their target cells 
without being hindered by components of the ocular surface. Additionally, they must be 
stable until entering the cell, at which point they must be able to release their cargo. Hornof 
and de la Fuente, for example, exploited HA as a targeting moiety for delivery of genetic 
material into cells of the cornea and conjunctiva [115]. In general, complexation of DNA 
with polyethyleneimine (PEI) yields acceptable transfection efficiencies due to the cationic 
charge of the complexes and their endosomolytic properties. However, blood proteins or 
ECM-components as proteoglycans or glycoproteins tend to adsorb onto the complexes and 
limit their ability to interact with cell membranes. By coating the complexes with low MW 
HA, nonspecific binding of proteins and other anionic compounds was reduced and stability 
of the complexes was increased. Despite the negative surface charge of the HA-coated 
complexes, and their concomitantly reduced affinity to cell membranes, uptake and 
transfection efficiency into human corneal epithelia cells was similar to the uncoated control. 
In vitro, beta-galactosidase expression was increased by a factor of 10 to 15 compared with 
naked DNA. This result is surprising, as positively charged particles, such as uncoated 
polyplexes (complexes of anionic nucleic acids and polycations), are known to be 
significantly more effective at transfection than neural or anionic particles. By antibody-
mediated blockade of CD44 on the cellular surface, the group also showed that uptake must 
be a receptor-mediated process. 
In addition, the therapeutic potential of DNA-loaded HA-chitosan NPs was analyzed in vitro 
[116]. Here, higher HA content increased transfection efficiency in proliferative ocular cell 
lines (human corneal and conjunctival epithelia). Again, a connection between NP uptake 
and CD44 binding was found. In vivo experiments demonstrated the efficacy of this 
formulation after topical application to rabbit eyes [114]. Beside receptor-specific 
interactions, the general mucoadhesive properties of HA might promote NP uptake after 
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topical application. At therapeutic doses, in vitro toxicity of this delivery system is exceedingly 
low [116]. Tolerability and safety was further confirmed in vivo [112].  
A key benefit of incorporating HA into this type of NP formulation is its influence on the 
mechanism of cellular entry and intracellular targeting [113]. Often, particles are trapped 
within endosomes and lysosomes after internalization. This might cause degradation of the 
NP cargo and a loss in functionality. However, HA-chitosan-oligomer NPs were internalized 
by a receptor-mediated, caveolin-dependent internalization process in vitro, bypassing the 
cellular compartments dedicated to degradation and resulting in high transfection efficiencies 
for ocular surface epithelial cells.  
Macroscopic drug delivery systems 
Beside working on eye drops and NPs, efforts have been made to develop drug delivery 
systems in order to achieve a sustained liberation and dissolution of drug substances to the 
cornea and conjunctiva.  
Hume et al. succeeded in producing HA-based films for sustained delivery of the anti-
inflammatory steroid prednisolone [125]. They esterified HA with varying amounts of benzyl 
alcohol to obtain polymers with different degrees of hydrophilicity that were suitable for 
producing drug-loaded films. Higher degrees of esterification resulted in enhanced 
hydrophobicity and diminished polymer swelling capacity. HA derivatives with the highest 
hydrophobicity (100 % of carboxyl groups esterified) enabled the best drug release 
characteristics, with constant lacrimal prednisolone levels of 45-72 µg/mL over 24 h in 
rabbits. The Calles group developed HA-itaconic acid films, crosslinked with polyethylene 
glycol diglycidyl ether, that show excellent material properties and good biocompatibility in 
vitro and in vivo [124]. Timolol, a substance which reduces the production of AH in the ciliary 
body and lowers IOP, was physically incorporated into the film during manufacturing. A 
therapeutic effect on IOP could be observed for more than ten hours, as opposed to eight 
hours for the conventional eye drop formulation (Figure 12). Since this finding is significant 
but clinically not relevant, it remains to be seen whether the lengthened time of therapeutic 
impact is worth the difficult handling of the insert in this specific case. 
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Figure 12. IOP of rabbits after the administration of timolol as an eye drop formulation (TM 
Drop) or as an ocular insert (TM Film). The lowest IOP was observed two hours after 
application for both formulations (a). After eight hours, IOP reached the baseline value in the 
eye drop group (b) whereas it took additional two hours in the insert group (c). With permission 
taken from [124]. 
Possibly more common – as already known and applied by millions of people for vision 
correction - are contact lenses (CL). It has been shown that this approach is not only suitable 
for the  sustained delivery of small MW drugs but also for polymers such as HA [121,122]. 
An example is the strategy of biomimetic, molecular imprinting as shown in Figure 13A 
[123]. Here, modified Nelficon A – a polyvinyl alcohol derivative – was crosslinked with UV-
crosslinking monomers. The particular monomers used were chosen because of their 
chemical similarity to amino acids found at the HA-binding site of CD44. The hypothesis 
was that these monomers would generate a template for directed interactions between the 
hydrogel scaffold and the HA-polymer within the CL when the crosslinking reaction takes 
place in presence of HA. HA would have higher affinity for such “memory sites”, which 
would slow down release. Using this approach, CL with an HA dissolution profile of 
6 µg/hour over 24 hours was achieved, matching therapeutic doses. While such CL are 
suitable for long-term supply of the ocular surface with HA, incorporation of HA into CL 
can be applied more generally to improve wettability of the lens material and increase the 
comfort to wear. Other groups pursued this goal and fixed HA within the CL material, either 
by creating a crosslinked HA network within the CL, as in Figure 13B [117,120], or by 
covalent grafting of HA to the polymeric CL compounds, as in Figure 13C [118]. Beside 
higher hydrophilicity and wettability, this resulted in decreased adsorption and denaturation 
of proteins on the CL surface. Depending on the strategy of HA functionalization, the 
sorption of lysozyme was reduced to only 5 to 70 % compared to that of the unmodified 
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control. This reduces the risk of developing inflammatory eye diseases [119] and provides 
for the opportunity of an extended wearing time. 
 
Figure 13. Immobilization of HA in CL material. A) Molecular imprinting; directed interactions 
between HA and “memory sites” of the hydrogel scaffold. B) HA-crosslinking; fixation of HA 
due to convolution of individually crosslinked HA- and polymer network. C) Covalent linkage; 
immobilization of HA by covalent grafting to the polymer. 
4.2 Intracameral administration 
Related to the aforementioned CL, Wang et al. extended HA incorporation to produce 
modified intraocular lenses (IOL), which are used for cataract patients [126]. IOLs are 
artificial lenses that substitute the natural lens if it becomes cloudy or damaged. Common 
side effects of the surgical implantation procedure are opacification of the new lens as well 
as inflammation and infection. To overcome these effects, Wang et al. covalently grafted an 
HA-lysozyme composite to the surface of the IOL, providing it with anti-adhesive and 
antibacterial properties. HA modification appeared to reduce adsorption of lens epithelial 
cells and prevented opacification. Additionally, fewer bacteria adhered to the implant 
compared with the unmodified lenses. Lysozyme, a lytic enzyme which is naturally present 
in tear fluid, kills remaining bacteria and therefore prevents the spread of microorganisms, 
reducing the risk of developing sight-threatening infections. The efficacy of this approach 
was measured via fluorescence microscopy. 
4.3 Intravitreal administration 
Vitreous substitution 
HA has also been extensively investigated as a vitreous substitute. Vitreous substitution is 
required during vitro-retinal surgery or in cases where the retina detaches from the RPE, as 
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in DR. Conventional tamponade agents are inert gases, silicon oil or perfluorocarbon liquids 
[146–148]. However, these materials have significant disadvantages. Gases work for just a 
short period during and after surgery as they are rapidly absorbed by the bloodstream. 
Additionally, they might cause sight-threatening elevations of IOP under certain conditions. 
Due to their toxicity, perfluorocarbon liquids are used only during the surgical intervention 
itself, and not afterward. Silicon oils are suitable for long-term vitreous replacement but must 
eventually be removed, as glaucoma, cataracts and other complications have been reported. 
During this procedure, retinal re-detachment can also be induced. HA is a promising 
substitute as a result of its good biocompatibility – it is the principal component of the 
vitreous humor – its easy injectability and its biodegradability. Unfortunately, the process of 
degradation happens very rapidly, as total vitreal HA is replaced every 10 to 70 days (see 
“anatomy section”) [78]. In response, HA derivatives with slower biodegradation kinetics 
were developed.  
Crosslinking of HA with adipic dihydrazide or N-vinyl-pyrrolidinone / UV light reduced 
biodegradation in vitro to 10 % within the first four weeks, and with even slower degradation 
kinetics after that point [12]. UV-crosslinked hydrogels did not show any signs of toxicity in 
cell culture experiments and were well-tolerated after implantation in the vitreous cavity of 
rabbits. The vitreous substitutes were stable for more than six weeks and their optical and 
mechanical properties remained almost unchanged. Grafting of a thermogelling poloxamer 
F127 to HA resulted in a vitreous substitute that was readily injectable at room temperature 
and with properties reasonably well-matched to those of the vitreous upon gelation at 37 °C 
[127]. However, these graft copolymers were unable to provide the needed rheological and 
mechanical characteristics nor to slow degradation kinetics required for long term use [146].  
As already outlined, a general problem of all biomaterials of natural origin – including HA-
based vitreous substitutes - is a significant batch-to-batch variation. Therefore, synthetic 
polymers such as polyethylene glycol (PEG) derivatives, polymethacrylates and 
polyurethanes have been developed for this purpose. They combine reasonable rheological 
and refractive properties with high reproducibility and consistent quality. 
NP formulations 
If therapeutics must reach the posterior segment of the eye, application via eye drops is 
unsatisfactory, as the drug is required to cross several barriers and traverse relatively long 
distances [149]. Intravitreal injection represents one possibility for specific administration to 
this difficult to access area of the eye. Even then, applied substances must diffuse through 
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the vitreous cavity to reach their target. Xu et al. investigated the general factors influencing 
NP mobility in the vitreous body by multiple particle tracking on a fluorescence microscope 
[150] and found dependencies on NP colloidal stability, particle size, surface charge and 
concentration. Neutral, PEGylated NPs that tend not to interact with components of the 
vitreous humor are able to diffuse freely up to a size of 510 nm (Figure 14). Negatively 
charged NPs are hampered in their mobility if they are larger than 200 nm or if the 
concentration exceeds a certain threshold. Cationic particles in turn are fully immobile, 
independent of size or concentration. They stick to anionic vitreal collagen fibrils via 
electrostatic interactions and might only be considered therapeutically if drug release at the 
site of injection is required. 
 
Figure 14. Influence of surface charge, size and concentration of NPs on their mobility in the 
vitreous body. Electrostatic, steric and hydrophobic effects influence the diffusivity of NPs in 
the vitreous gel. PEGylated particles (PS-PEG) are able to diffuse freely up to a size of 500 nm. 
Anionic NPs (PS-COOH) smaller than 200 nm move unimpeded. If their size or concentration 
increases, diffusivity is reduced due to steric and hydrophobic effects. Cationic polystyrene-
amine NPs (PS-NH2) interact electrostatically and aggregate within the vitreous. With 
permission taken from [150]. 
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PEGylation of NPs reduces aggregation and nonspecific binding to ECM components and 
enhances the diffusivity of particles in the vitreous [151]. Unfortunately, in addition to 
reducing undesirable interactions, interactions with target cells and tissues are also reduced 
[152]. A possible solution could be the modification or coating of nanostructures with HA 
to enhance NP mobility in the vitreous without reducing cellular uptake or transfection 
efficiency. The movement of different types of NPs through the vitreous and retina was 
investigated by Koo et al. [130]. HA-NPs of about 200 nm in size with a negative surface 
charge of -26 mV diffused through the vitreal gel and accumulated in deeper regions of the 
retina following intravitreal injection. PEI-modified NPs (+ 33 mV) with a slightly larger size 
were almost completely immobile. Interestingly, the HA-NPs seemed to be eliminated from 
the posterior segment within a few days, which might be a beneficial property for candidate 
therapeutics. Further detailed investigations concerning the mobility and functionality of 
polyplexes were carried out by Martens et al. [129]. Martens determined the diffusion 
coefficients of polyplexes functionalized with HA of varying molecular weight by fluorescent 
particle tracking microscopy in excised bovine eyes. The unmodified probe (108 nm, 
+29 mV) reflects the reduced mobility of positively charged complexes in the vitreous 
(Figure 15). Diffusivity increased upon functionalization with HA and displayed the most 
improvement when modified with 137 kDa HA. Although the particles became larger 
(343 nm), the negative surface charge of -30 mV and the antifouling properties of HA seem 
to adequately compensate for the increase in size. HA 2700 kDa was not suitable as a 
diffusivity enhancer here, as the resulting particles became too large and aggregated. 
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Figure 15. Diffusion coefficients of polyplexes obtained by single particle tracking analysis in 
intact bovine vitreous. The strongest increase in diffusivity was found for polyplexes coated with 
HA 137 kDa (HA137-pplxs); no improvement was achieved with HA 2700 kDa (HA2700-
pplxs). The black, solid line represents the bimodal distribution of diffusion coefficients of 
uncoated, cationic polyplexes. The mobilities of the respective NP in HEPES-buffer are shown 
as dotted lines. With permission taken from [129]. 
Further in vitro experiments confirmed both the polyplexes’ ability to enter RPE cells via 
interactions with CD44 and their superlative cell transfection capabilities. Similar results were 
achieved by Gan et al. [128], who modified chitosan-lipo-NP (chitosan-NP capped with a 
lipid bilayer) with HA of different MW. The modified NP were able to diffuse freely through 
the vitreous and accumulated on the inner limiting membrane following intravitreal injection. 
In a model of retinal damage – experimental autoimmune uveitis – the group found that 
these HA-modified chitosan-lipo-NP were even able to specifically target the RPE, as CD44 
is upregulated in this disease. 
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4.4 Retinal administration 
Retinal patches 
During aging, compounds of the vitreous body become liquefied and collagen fibrils change 
their structure, forming bundles and becoming stiffer [153]. The tension on the retina 
increases and begins to peel the sensitive structure from the back of the eye, which may lead 
to impaired vision or blindness. Patients suffering from diabetes typically show faster 
liquefaction and run a higher risk of retinal detachment [154]. Holes and breaks in the retina 
accelerate the shedding, allowing vitreous fluid to leak into the subretinal space [155]. 
Therefore, it is critically important to seal retinal breaks and prevent the accumulation of 
fluids. Common options for the treatment of such breaks are laser-induced retinal fixation 
or the administration of anti-inflammatory steroids. Another possibility is the application of 
gel-like retinal patches. Sueda et al. developed an absorbable material based on HA and 
carboxymethylcellulose to close retinal breaks [132]. The patch was liquid-tight and stayed in 
place for 30 days on retinas of excised bovine eyes. No signs of toxicity were observed in 
vivo. Unfortunately, its application during vitrectomy surgery is quite difficult. In order to 
enhance the therapeutic effectiveness of retinal patches, 1,2,3,4-diepoxybutane crosslinked 
HA gels were prepared and loaded with triamcinolone acetonide [131]. This combined the 
retina stabilizing effect of a self-adhesive patch with the local delivery of an anti-
inflammatory agent. The gel was directly applied to the retinal injury via an injector system, 
a special kind of syringe. While the application process was still challenging, the patch was 
well-tolerated during initial trials and the approach is a promising therapeutic option to 
reduce retinal inflammation and accelerate healing. 
Hydrogels for protein and stem cell delivery 
Aside from small molecule drugs and genetic material, proteins represent a further 
opportunity in the treatment of ocular diseases. This therapeutic option has garnered intense 
interest, especially for CNV. Vascular endothelial growth factor (VEGF) contributes 
decisively to the development and progress of this disease, as it is known to boost 
proliferation of vascular endothelial cells and formation of new blood vessels [156]. Perhaps 
the most well-known of therapeutics in this field are biologics which inhibit the binding of 
VEGF to its receptor, such as the antibodies ranibizumab (Lucentis®) and bevacizumab 
(Avastin® - off label), or the recombinant fusion protein aflibercept (Eylea®). Anti-Flt1-
peptide is another candidate, a short, non-immunogenic hexapeptide that acts because of an 
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antagonistic effect on VEGF receptor 1 (VEGFR1). By chemical conjugation of HA to this 
peptide, its potency could be improved [157], possibly due to the formation of micelle-like 
NP in aqueous solution and improved solubility. After a single intravitreal injection, the 
severity of CNV lesions was reduced by 20 percent, the effect on the reduction of vascular 
hyperpermeability was even stronger compared to the unmodified peptide.  
Kontturi et al. extended this approach a step further by incorporating genetically modified 
RPE cells (ARPE-19), which secrete soluble VEGFR1, into a hydrogel of cross-linked 
collagen and HA [135]. This matrix promoted cellular survival and protein secretion for at 
least 50 days and may prevent the need for frequent application of the therapeutic protein. 
However, even if delivery of anti-VEGF-therapeutics slows down the progress of the 
disease, damaged cells are not replaced. Retinal stem-progenitor cells can differentiate into 
many kinds of retinal cells, including neurons and pigment epithelial cells. Ballios et al. 
developed an injectable, biodegradable hydrogel scaffold consisting of HA and 
methylcellulose (MC) for the successful delivery of stem cells to the sub-retinal space [134]. 
The polymers combine biocompatibility and anti-inflammatory properties with sufficient 
stability to support the application. In this way, applied stem cells distributed well in the sub-
retinal space, overcoming previous obstacles. To refine this approach, the HA-MC hydrogel 
was modified to serve as a delivery system for insulin-like growth-factor 1 (IGF-1) and cells 
at the same time [133]. Following a molecular imprinting strategy, two different peptides with 
weak and strong binding affinity to IGF-1 were conjugated covalently to the hydrogel. Thus, 
a sustained release of the growth factor was achieved and the viability of embedded RPE 
cells promoted in vitro. However, it was not reported whether or not IGF-1 promotes further 
neovascularization, an open question that must be subject of future investigations.
5 Summary and conclusion 
Taken together, HA is an extremely promising polymer for a wide array of biomedical 
applications. HA combines a number of unique biochemical properties: the ability to bind 
enormous amounts of water because of its extraordinary hydrophilicity, viscosity 
enhancement of aqueous solutions at low concentration, pseudoplastic flow characteristics, 
and accessible reactive groups along the polysaccharide chain for easy crosslinking and/or 
grafting to other compounds [158]. Since HA is an endogenous component present in most 
tissues of the body, it is well tolerated and toxicity issues are largely unheard of.  
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In this review we have focused on the ophthalmic applications of HA – an exceptionally 
promising area of clinical use. HA is thought to be an ideal excipient for this purpose, as 
given its naturally high concentration in the eye, and concomitantly good ocular tolerability. 
Furthermore, its transparency and other optical properties are suitable for use in the optical 
path. Topically applied, HA is used in eye drops as either a therapeutic ingredient itself or to 
increase the tolerability and efficacy of other drugs. When incorporated into CL, ocular 
comfort was enhanced and wearing time was extended. As the principal component of the 
vitreous humor, the polymer was additionally investigated for suitability as a vitreous 
substitute. In this special case, the fact that HA is an endogenous compound was 
unfortunately counterproductive, as biodegradation by hyaluronidases occurred too rapidly 
for long-term use. HA-modified NPs were also investigated for their therapeutic potential in 
the ocular environment after extensive investigation regarding their potential for cancer 
therapy. The mucoadhesive properties of the polymer are paramount if NPs are applied 
topically to the ocular surface. However, after intravitreal injection, HA’s capability to inhibit 
protein adsorption, promote high mobility through the collagen matrix and target cells in the 
posterior segment of the eye are of greater interest. HA has also been assessed in a variety of 
forms for its ability to deliver therapeutic proteins or cells. 
In some clinical applications, HA has been employed to relieve debilitating symptoms for 
many years, and presently forms an integral part of the standard treatment regime. Other 
approaches proposed are more speculative in nature; significant work must still occur to 
bring these ideas from bench to bedside. Nevertheless, with increasing scientific interest – 
and consequently, a steady uptick in the accumulated knowledge surrounding HA’s 
properties and multiform modes of use – it is becoming increasingly apparent that both novel 
HA-based therapeutics and HA-mediated refinements of existing approaches deserve to be 
pursued into the clinic. 
Chapter 1 – Introduction 
44 
 References 
[1] Zhang K, Zhang L, Weinreb RN (2012), Ophthalmic drug discovery: novel targets 
and mechanisms for retinal diseases and glaucoma, Nat Rev Drug Discov 11 541–
559. 
[2] Abdelkader H, G. Alany R (2012), Controlled and Continuous Release Ocular Drug 
Delivery Systems: Pros and Cons, CDD 9 421–430. 
[3] Eandi CM, Alovisi C, Sanctis U de, Grignolo FM (2016), Treatment for neovascular 
age related macular degeneration: The state of the art, Eur J Pharmacol 
[4] Kirchhof S, Goepferich AM, Brandl FP (2015), Hydrogels in ophthalmic 
applications, Eur J Pharm Biopharm 95 227–238. 
[5] Solinís MÁ, del Pozo-Rodríguez A, Apaolaza PS, Rodríguez-Gascón A (2015), 
Treatment of ocular disorders by gene therapy, Eur J Pharm Biopharm 95 331–342. 
[6] Kim YC, Chiang B, Wu X, Prausnitz MR (2014), Ocular delivery of macromolecules, 
J Control Release 190 172–181. 
[7] Carvalho IM, Marques CS, Oliveira RS, Coelho PB, Costa PC, Ferreira DC (2015), 
Sustained drug release by contact lenses for glaucoma treatment—A review, J 
Control Release 202 76–82. 
[8] Delplace V, Payne S, Shoichet M (2015), Delivery strategies for treatment of age-
related ocular diseases: From a biological understanding to biomaterial solutions, J 
Control Release 219 652–668. 
[9] Sze JH, Brownlie JC, Love CA (2016), Biotechnological production of hyaluronic 
acid: a mini review, 3 Biotech 6. 
[10] Liu L, Liu Y, Li J, Du G, Chen J (2011), Microbial production of hyaluronic acid: 
current state, challenges, and perspectives, Microb Cell Fact 10 99. 
[11] Clegg TE, Caborn D, Mauffrey C (2013), Viscosupplementation with hyaluronic acid 
in the treatment for cartilage lesions: a review of current evidence and future 
directions, Eur J Orthop Surg Tr 23 119–124. 
  
References 
45 
[12] Schramm C, Spitzer MS, Henke-Fahle S, Steinmetz G, Januschowski K, Heiduschka 
P, Geis-Gerstorfer J, Biedermann T, Bartz-Schmidt KU, Szurman P (2012), The 
Cross-linked Biopolymer Hyaluronic Acid as an Artificial Vitreous Substitute, Invest 
Ophth Vis Sci 53 613–621. 
[13] Collins MN, Birkinshaw C (2013), Hyaluronic acid based scaffolds for tissue 
engineering—A review, Carbohyd Pol 92 1262–1279. 
[14] Ossipov DA (2010), Nanostructured hyaluronic acid-based materials for active 
delivery to cancer, Expert Opin Drug Del 7 681–703. 
[15] Dosio F, Arpicco S, Stella B, Fattal E (2016), Hyaluronic acid for anticancer drug and 
nucleic acid delivery, Adv Drug Deliver Rev 97 204–236. 
[16] Xu K, Lee F, Gao SJ, Chung JE, Yano H, Kurisawa M (2013), Injectable hyaluronic 
acid-tyramine hydrogels incorporating interferon-ơ2a for liver cancer therapy, J 
Control Release 166 203–210. 
[17] Ueda K, Akiba J, Ogasawara S, Todoroki K, Nakayama M, Sumi A, Kusano H, 
Sanada S, Suekane S, Xu K, Bae KH, Kurisawa M, Igawa T, Yano H (2016), Growth 
inhibitory effect of an injectable hyaluronic acid–tyramine hydrogels incorporating 
human natural interferon-ơ and sorafenib on renal cell carcinoma cells, Acta 
Biomater 29 103–111. 
[18] Xu K, Lee F, Gao S, Tan M-H, Kurisawa M (2015), Hyaluronidase-incorporated 
hyaluronic acid–tyramine hydrogels for the sustained release of trastuzumab, J 
Control Release 216 47–55. 
[19] Lei Y, Rahim M, Ng Q, Segura T (2011), Hyaluronic acid and fibrin hydrogels with 
concentrated DNA/PEI polyplexes for local gene delivery, J Control Release 153 
255–261. 
[20] Mero A, Campisi M (2014), Hyaluronic Acid Bioconjugates for the Delivery of 
Bioactive Molecules, Polymers 6 346–369. 
[21] Meyer K, Palmer, John, W. (1934), The Polysaccharide of the Vitrous Humor, J Biol 
Chem 107 629–634. 
[22] Stern R (2004), Hyaluronan catabolism: a new metabolic pathway, Eur J Cell Biol 83 
317–325. 
Chapter 1 – Introduction 
46 
[23] Tripodo G, Trapani A, Torre ML, Giammona G, Trapani G, Mandracchia D (2015), 
Hyaluronic acid and its derivatives in drug delivery and imaging: Recent advances and 
challenges, Eur J Pharm Biopharm 97 400–416. 
[24] Liao Y-H, Jones SA, Forbes B, Martin GP, Brown MB (2008), Hyaluronan: 
Pharmaceutical Characterization and Drug Delivery, Drug Deliv 12 327–342. 
[25] Toole BP (2004), Hyaluronan: from extracellular glue to pericellular cue, Nat Rev 
Cancer 4 528–539. 
[26] Karbownik MS, Nowak, Jerzy, Z. (2013), Hyaluronan: Towards novel anti-cancer 
therapeutics, Pharmacol Rep 65 1056–1074. 
[27] Fouissac E, Milas M, Rinaudo M (1993), Shear-rate, concentration, molecular weight, 
and temperature viscosity dependences of hyaluronate, a wormlike polyelectrolyte, 
Macromolecules 26 6945–6951. 
[28] Laurent TC, Laurent UBG, Fraser, J Robert E (1996), The structure and function of 
hyaluronan: An overview, Immunol Cell Biol 74 A1-A7. 
[29] Arpicco S, Milla P, Stella B, Dosio F (2014), Hyaluronic Acid Conjugates as Vectors 
for the Active Targeting of Drugs, Genes and Nanocomposites in Cancer Treatment, 
Molecules 19 3193–3230. 
[30] Girish KS, Kemparaju K (2007), The magic glue hyaluronan and its eraser 
hyaluronidase: A biological overview, Life Sci 80 1921–1943. 
[31] Day AJ, Prestwich GD (2002), Hyaluronan-binding Proteins: Tying Up the Giant, J 
Biol Chem 277 4585–4588. 
[32] Goodison S, Urquidi V., Tarin D (1999), CD44 cell adhesion molecules, Mol Pathol 
52 189–196. 
[33] Banerji S, Wright AJ, Noble M, Mahoney DJ, Campbell ID, Day AJ, Jackson DG 
(2007), Structures of the Cd44–hyaluronan complex provide insight into a 
fundamental carbohydrate-protein interaction, Nat Struct Mol Biol 14 234–239. 
[34] Lesley J (2000), Hyaluronan Binding by Cell Surface CD44, J Biol Chem 275 26967–
26975. 
  
References 
47 
[35] Mizrahy S, Raz SR, Hasgaard M, Liu H, Soffer-Tsur N, Cohen K, Dvash R, 
Landsman-Milo D, Bremer MG, Moghimi SM, Peer D (2011), Hyaluronan-coated 
nanoparticles: The influence of the molecular weight on CD44-hyaluronan 
interactions and on the immune response, J Control Release 156 231–238. 
[36] Knudson W, Chow G, Knudson CB (2002), CD44-mediated uptake and degradation 
of hyaluronan, Matrix Biology 21 15–23. 
[37] Platt VM, Szoka FC (2008), Anticancer Therapeutics: Targeting Macromolecules and 
Nanocarriers to Hyaluronan or CD44, a Hyaluronan Receptor, Mol Pharm 5 474–
486. 
[38] Toole BP (2009), Hyaluronan-CD44 Interactions in Cancer: Paradoxes and 
Possibilities, Clin Cancer Res 15 7462–7468. 
[39] Choi KY, Saravanakumar G, Park JH, Park K (2012), Hyaluronic acid-based 
nanocarriers for intracellular targeting: Interfacial interactions with proteins in 
cancer, Colloid Surface B 99 82–94. 
[40] Xu X, Jha AK, Harrington DA, Farach-Carson MC, Jia X (2012), Hyaluronic Acid-
Based Hydrogels: from a Natural Polysaccharide to Complex Networks, Soft Matter 
8 3280–3294. 
[41] Kogan G, Šoltés L, Stern R, Gemeiner P (2006), Hyaluronic acid: a natural 
biopolymer with a broad range of biomedical and industrial applications, Biotechnol 
Lett 29 17–25. 
[42] Streilein JW (2003), Ocular immune privilege: therapeutic opportunities from an 
experiment of nature, Nat Rev Immunol 3 879–889. 
[43] Cholkar K, Patel SP, Vadlapudi AD, Mitra AK (2013), Novel Strategies for Anterior 
Segment Ocular Drug Delivery, J Ocul Pharm Th 29 106–123. 
[44] Remington LA (Ed.), Clinical Anatomy and Physiology of the Visual System: Chapter 
6: Aqueous and Vitreous Chambers, Second Edition ed., Elsevier Inc., 2005. 
[45] Goel M, Picciani RG, Lee RK, Bhattacharya SK (2010), Aqueous Humor Dynamics: 
A Review, The Open Ophthal J 4 52–59. 
[46] Nickerson CS, Park J, Kornfield JA, Karageozian H (2008), Rheological properties 
of the vitreous and the role of hyaluronic acid, J Biomech 41 1840–1846. 
Chapter 1 – Introduction 
48 
[47] Remington LA (Ed.), Clinical Anatomy and Physiology of the Visual System: Chapter 
4: Retina, Second Edition ed., Elsevier Inc., 2005. 
[48] Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, Skatchkov S, 
Osborne N, Reichenbach A (2006), Müller cells in the healthy and diseased retina, 
Prog Retin Eye Res 25 397–424. 
[49] Strauss O (2005), The Retinal Pigment Epithelium in Visual Function, Physiolog Rev 
85 845–881. 
[50] Zhu S-N, Nölle B, Duncker G (1997), Expression of adhesion molecule CD44 on 
human corneas, Brit J Ophthalmol 81 80–84. 
[51] Lerner LE, Schartz Daniel M., Hwang DG, Howes EL, Stern R (1998), Hyaluronan 
and CD44 in the Human Cornea and Limbal Conjunctiva, Exp Eye Res 67 481–484. 
[52] Yu FX, Guo J, Zhang Q (1998), Expression and Distribution of Adhesion Molecule 
CD44 in Healing Corneal Epithelia, Invest Ophthal Vis Sci 39 710–717. 
[53] García-Posadas L, Contreras-Ruiz L, López-García A, Villarón Álvarez S, 
Maldonado MJ, Diebold Y (2012), Hyaluronan receptors in the human ocular 
surface: a descriptive and comparative study of RHAMM and CD44 in tissues, cell 
lines and freshly collected samples, Histochem Cell Biol 137 165–176. 
[54] García-Posadas L, Contreras-Ruiz L, Arranz-Valsero I, López-García A, Calonge M, 
Diebold Y (2014), CD44 and RHAMM hyaluronan receptors in human ocular 
surface inflammation, Graefes Arch Clin Exp Ophthalmol 252 1289–1295. 
[55] Nishida T, Nakamura M, Mishima H, Otori T (1991), Hyaluronan Stimulates Corneal 
Epithelial Migration, Exp Eye Res 53 753–758. 
[56] Gomes, J A P (2004), Sodium hyaluronate (hyaluronic acid) promotes migration of 
human corneal epithelial cells in vitro, Brit J Ophthalmol 88 821–825. 
[57] Pauloin T, Dutot M, Joly F, Warnet J-M, Rat P (2009), High molecular weight 
hyaluronan decreases UVB-induced apoptosis and inflammation in human epithelial 
corneal cells, Mol Vis 15 577–583. 
[58] Miyauchi S, Morita M, Kuramoto K, Horie K (1996), Hyaluronan and chondroitin 
sulfate in rabbit tears, Curr Eye Res 15 131–135. 
References 
49 
[59] Frescura M, Berry M, Corfield A, Carrington S, Easty DL (1994), Evidence of 
hyaluronan in human tears and secretions of conjunctival cultures, Biochm Soc Trans 
22 228S. 
[60] Laurent UB (1981), Hyaluronate in aqueous humour, Exp Eye Res 33 147–155. 
[61] Acott TS, Kelley MJ (2008), Extracellular matrix in the trabecular meshwork, Exp 
Eye Res 86 543–561. 
[62] Lerner LE, Polansky JR, Howes EL, Stern R (1997), Hyaluronan in the Human 
Trabecular Meshwork, Invest Ophthalmol Vis Sci 38 1222–1228. 
[63] Gong H, Underhill CB, Freddo TF (1994), Hyaluronan in the Bovine Ocuar Anterior 
Segment, With Emphasis on the Outflow Pathways, Invest Ophthalmol Vis Sci 35 
4328–4332. 
[64] Navajas EV, Martins, João Roberto Maciel, Melo, Luiz Alberto S., Saraiva VS, 
Dietrich CP, Nader HB, Belfort R (2005), Concentration of hyaluronic acid in 
primary open-angle glaucoma aqueous humor, Exp Eye Res 80 853–857. 
[65] Jumper JM, Chang DF, Hoyt CS, Hall JL, Stern R, Schwartz DM (1997), Aqueous 
hyaluronic acid concentration: comparison in pediatric and adult patients, Curr Eye 
Res 16 1069–1071. 
[66] Budak YU, Akdogan M, Huysal K (2009), Aqueous humor level of sCD44 in patients 
with degenerative myopia and primary open-angle glaucoma, BMC Res Notes 2 224. 
[67] Knepper PA, Miller AM, Choi J, Wertz RD, Nolan MJ, Goossens W, Whitmer S, 
Yue, Beatrice Y. J. T., Ritch R, Liebmann JM, Allingham RR, Samples JR (2005), 
Hypophosphorylation of Aqueous Humor sCD44 and Primary Open-Angle 
Glaucoma, Invest Ophthalmol Vis Sci 46 2829–2837. 
[68] Nolan MJ, Giovingo MC, Miller AM, Wertz RD, Ritch R, Liebmann JM, Allingham 
RR, Herndon LW, Wax MB, Smolyak R, Hasan F, Barnett EM, Samples JR, Knepper 
PA (2007), Aqueous Humor sCD44 Concentration and Visual Field Loss in Primary 
Open-angle Glaucoma, J Glaucoma 16 419–429. 
[69] Koralewska-Makar A, Molander N, Madsen K, Lind M-L, Stenevi U, Ehinger B 
(1998), Endogenous hyaluronan in the normal and traumatized rabbit iris, Acta 
Ophthalmol Scand 76 391–395. 
Chapter 1 – Introduction 
50 
[70] Desai VD, Wang Y, Simirskii VN, Duncan MK (2010), CD44 expression is 
developmentally regulated in the mouse lens and increases in the lens epithelium after 
injury, Differentiation 79 111–119. 
[71] Kulyk WM, Zalik SE, Dimitrov E (1987), Hyaluronic Acid Production and 
Hyaluronidase Activity in the Newt Iris during Lens Regeneration, Exp Cell Res 172 
180–191. 
[72] Koralewska-Makár A, Johnsson C, Bruun A, Stenevi U, Ehinger B (2003), COX-2 
Inhibitors Prolong Trauma-Induced Elevations of Iris Hyaluronan, J Ocul 
Pharmacol Th 19 385–395. 
[73] Nishi O, Nishi K, Akaishi T, Shirasawa E (1997), Detection of Cell Adhesion 
Molecules in Lens Epithelial Cells of Human Cataracts, Invest Ophthalmol Vis Sci 
38 579–585. 
[74] Bishop PN (2000), Structural macromolecules and supramolecular organisation of 
the vitreous gel, Prog Ret Eye Res 19 323–344. 
[75] Kuppermann BD, Thomas EL, Smet MD de, Grillone LR (2005), Pooled efficacy 
results from two multinational randomized controlled clinical trials of a single 
intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the 
management of vitreous hemorrhage, Am J Ophthalmol 140 573–584. 
[76] Filas BA, Zhang Q, Okamoto RJ, Shui Y-B, Beebe DC (2014), Enzymatic 
Degradation Identifies Components Responsible for the Structural Properties of the 
Vitreous Body, Invest Ophthalmol Vis Sci 55 55. 
[77] Schwartz DM, Shuster S, Jumper MD, Chang A, Stern R (1996), Human vitreous 
hyaluronidase: isolation and characterization, Curr Eye Res 15 1156–1162. 
[78] Laurent UB, Reed RK (1991), Turnover of hyaluronan in the tissues, Adv Drug 
Deliver Rev 7 237–256. 
[79] Normand G, Hicks D, Dreyfus H (1998), Neurotrophic growth factors stimulate 
glycosaminoglycan synthesis in identified retinal cell populations in vitro, Glycobiol 
8 1227–1235. 
  
References 
51 
[80] Clark SJ, Keenan, Tiarnan D. L., Fielder HL, Collinson LJ, Holley RJ, Merry, 
Catherine L. R., van Kuppevelt, Toin H., Day AJ, Bishop PN (2011), Mapping the 
Differential Distribution of Glycosaminoglycans in the Adult Human Retina, 
Choroid, and Sclera, Invest Ophthalmol Vis Sci 52 6511. 
[81] Des Senanayake P, Calabro A, Nishiyama K, Hu JG, Bok D, Hollyfield JG (2000), 
Glycosaminoglycan synthesis and secretion by the retinal pigment epithelium: 
polarized delivery of hyaluronan from the apical surface, J Cell Sci 114 199–205. 
[82] Gross-Jendroska M, Lui G-M, Stern R (1992), Retinal Pigment Epithelium-Stromal 
Interactions Modulate Hyaluronic Acid Deposition, Invest Ophthalmol Vis Sci 33 
3394–3399. 
[83] Chaitin MH, Wortham HS, Brun-Zinkernagel A-M (1994), Immunocytochemical 
Localization of CD44 in the Mouse Retina, Exp Eye Res 58 359–366. 
[84] Shinoe T, Kuribayashi H, Saya H, Seiki M, Aburatani H, Watanabe S (2010), 
Identification of CD44 as a cell surface marker for Müller glia precursor cells, J 
Neurochem 115 1633–1642. 
[85] Nishina S, Hirakata A, Hida T, Sawa H, Azuma N (1997), CD44 expression in the 
developing human retina, Graefe's Arch Clin Exp Ophthalmol 235 92–96. 
[86] Ishikawa M, Sawada Y, Yoshitomi T (2015), Structure and function of the 
interphotoreceptor matrix surrounding retinal photoreceptor cells, Exp Eye Res 133 
3–18. 
[87] Hollyfield JG, Rayborn Mary E., Tammi M, Tammi RH (1998), Hyaluronan in the 
Interphotoreceptor Matrix of the Eye: Species Differences in Content, Distribution, 
Ligand Binding and degradation, Exp Eye Res 66 241–248. 
[88] Liu N-P, Roberts WL, Hale LP, Levesque MC, Patel DD, Lu C-L, Jaffe GJ (1997), 
Expression of CD44 and Variant Isoforms in Cultured Human Retinal Pigment 
Epithelial Cells, Invest Ophthalmol Vis Sci 38 2027–2037. 
[89] Kuhrt H, Härtig W, Grimm D, Faude F, Kasper M, Reichenbach A (1997), Changes 
in CD44 and ApoE immunoreactivities due to retinal pathology of man and rat, J 
Hirnforsch. 38 223–229. 
[90] Krishnamoorthy R, Agarwal N, Chaitin MH (2000), Upregulation of CD44 
expression in the retina during the rds degeneration, Mol Brain Res 77 125–130. 
Chapter 1 – Introduction 
52 
[91] Mochimaru H, Takahashi E, Tsukamoto N, Miyazaki J, Yaguchi T, Koto T, Kurihara 
T, Noda K, Ozawa Y, Ishimoto T, Kawakami Y, Tanihara H, Saya H, Ishida S, 
Tsubota K (2009), Involvement of Hyaluronan and Its Receptor CD44 with 
Choroidal Neovascularization, Invest Ophthalmol Vis Sci 50 4410. 
[92] Schroedl F, Brehmer A, Neuhuber WL, Kruse FE, May CA, Cursiefen C (2008), The 
Normal Human Choroid Is Endowed with a Significant Number of Lymphatic 
Vessel Endothelial Hyaluronate Receptor 1 (LYVE-1)–Positive Macrophages, Invest 
Ophthalmol Vis Sci 49 5222. 
[93] Xu H, Manivannan A, Liversidge J, Sharp PF, Forrester JV, Crane IJ (2002), 
Involvement of CD44 in leukocyte trafficking at the blood-retinal barrier, J Leuko 
Biol 72 1133–1141. 
[94] Wallman J, Wildsoet C, Xu A, Gottlieb MD, Nickla DL, Marran L, Krebs W, 
Christensen AM (1995), Moving the retina: Choroidal modulation of refractive state, 
Vis Res 35 37–50. 
[95] Summers JA (2013), The choroid as a sclera growth regulator, Exp Eye Res 114 120–
127. 
[96] Rada, Summers JA, Wiechmann AF, Hollaway LR, Baggenstoss BA, Weigel PH 
(2010), Increased Hyaluronan Synthase-2 mRNA Expression and Hyaluronan 
Accumulation with Choroidal Thickening: Response during Recovery from Induced 
Myopia, Invest Ophthalmol Vis Sci 51 6172. 
[97] Camilieri G, Bucolo C, Rossi S, Drago F (2004), Hyaluronan-Induced Stimulation of 
Corneal Wound Healing is a Pure Pharmacological Effect, J Ocul Pharm Th 20 548–
553. 
[98] Nakamura M, Sato N, Chikama TI, Hasegawa Y, Nishida T  (1997), Hyaluronan 
Facilitates Corneal Epithelial Wound Healing in Diabetic Rats, Exp Eye Res 64 1043-
1050. 
[99] Troiano P, Monaco G (2008), Effect of Hypothonic 0.4% Hyaluronic Acid Drops in 
Dry Eye Patients: A Cross-Over Study, Cornea 27 1126–1130. 
[100] Kaya S, Schmidl D, Schmetterer L, Witkowska KJ, Unterhuber A, Aranha dos 
Santos, Valentin, Baar C, Garhöfer G, Werkmeister RM (2015), Effect of hyaluronic 
acid on tear film thickness as assessed with ultra-high resolution optical coherence 
tomography, Acta Ophthalmol 93 439–443. 
References 
53 
[101] Schmidl D, Schmetterer L, Witkowska KJ, Unterhuber A, Aranha dos Santos, 
Valentin, Kaya S, Nepp J, Baar C, Rosner P, Werkmeister RM, Garhofer G (2015), 
Tear Film Thickness After Treatment With Artificial Tears in Patients With Moderate 
Dry Eye Disease, Cornea 34 421–426. 
[102] Camber O, Edman P, Gurny R (1987), Influence of sodium hyaluronate on the 
meiotic effect of pilocarpine in rabbits, Curr Eye Res 6 779–784. 
[103] Herrero-Vanrell R, Fernandez-Carballido A, Frutos G, Cadórniga R (2000), 
Enhancement of the Mydriatic Response to Tropicamide by Bioadhesive Polymers, 
J Ocul Pharmacol Th 16 419–428. 
[104] Cho K (2003), Release of ciprofloxacin from poloxamer-graft-hyaluronic acid 
hydrogels in vitro, Int J Pharm 260 83–91. 
[105] Bernatchez SF, Tabatabay C, Gurny R (1993), Sodium hyaluronate 0.25% used as a 
vehicle increases the bioavailability of topically administered gentamicin, Graefe's 
Arch Clin Exp Ophthalmol 231 157–161. 
[106] Gurny R, Ibrahim H, Aebi A, Buri P, Wilson CG, Washington N, Edman P, Camer 
O (1987), Design and evaluation of controlled relese systems for the eye, J Control 
Release 6 367–373. 
[107] Saettone MF, Giannaccini B, Chetoni P, Torracca MT, Monti D (1991), Evaluation 
of high- and low-molecular-weight fractions of sodium hyaluronate and an ionic 
complex as adjuvants for topical ophthalmic vehicles containing pilocarpine, Int J 
Pharm 72 131–139. 
[108] Camber O, Edman P (1989), Sodium hyaluronate as an ophthalmic vehicle: Some 
factors governing its effect on the ocular absorption of pilocarpine, Curr Eye Res 8 
563–567. 
[109] Ibrahim HK, El-Leithy IS, Makky AA (2010), Mucoadhesive Nanoparticles as Carrier 
Systems for Prolonged Ocular Delivery of Gatifloxacin/Prednisolone Bitherapy, Mol 
Pharm 7 576–585. 
[110] Yao J, Wu, Zhou, Dahmani FZ (2013), Enhanced and sustained topical ocular 
delivery of cyclosporine A in thermosensitive hyaluronic acid-based in situ forming 
microgels, Int J Nanomed 8 3587–3601. 
Chapter 1 – Introduction 
54 
[111] Yenice İ, Mocan MC, Palaska E, Bochot A, Bilensoy E, Vural İ, İrkeç M, Atilla Hıncal 
A (2008), Hyaluronic acid coated poly-ɛ-caprolactone nanospheres deliver high 
concentrations of cyclosporine A into the cornea, Exp Eye Res 87 162–167. 
[112] Contreras-Ruiz L, de la Fuente M, García-Vázquez C, Sáez V, Seijo B, Alonso MJ, 
Calonge M, Diebold Y (2010), Ocular Tolerance to a Topical Formulation of 
Hyaluronic Acid and Chitosan-Based Nanoparticles, Cornea 29 550–558. 
[113] Contreras-Ruiz L, de la Fuente M, Párraga JE, López-García A, Fernández I, Seijo 
B, Sánchez A, Calonge M, Diebold Y (2011), Intracellular trafficking of hyaluronic 
acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells, 
Mol Vis 17 279–290. 
[114] de la Fuente M, Seijo B, Alonso MJ (2008), Bioadhesive hyaluronan-chitosan 
nanoparticles can transport genes across the ocular mucosa and transfect ocular 
tissue, Gene Ther 15 668–676. 
[115] Hornof M, de la Fuente M, Hallikainen M, Tammi RH, Urtti A (2008), Low 
molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 
receptor mediated uptake in human corneal epithelial cells, J Gene Med 10 70–80. 
[116] de la Fuente, M, Seijo B, Alonso MJ (2008), Novel Hyaluronic Acid-Chitosan 
Nanoparticles for Ocular Gene Therapy, Invest Ophthalmol Vis Sci 49 2016–2024. 
[117] Weeks A, Luensmann D, Boone A, Jones L, Sheardown H (2012), Hyaluronic acid 
as an internal wetting agent in model DMAA/TRIS contact lenses, J Biomat App 27 
423–432. 
[118] Weeks A, Morrison D, Alauzun JG, Brook MA, Jones L, Sheardown H (2012), 
Photocrosslinkable hyaluronic acid as an internal wetting agent in model 
conventional and silicone hydrogel contact lenses, J Biomed Mater Res 100A 1972–
1982. 
[119] Brennan NA, Coles M-L (2000), Deposits and symptomatology with soft contact 
lens wear, Int Cont Lens Clin 27 75–100. 
[120] Vanbeek M, Jones L, Sheardown H (2008), Hyaluronic acid containing hydrogels for 
the reduction of protein adsorption, Biomaterials 29 780–789. 
[121] Maulvi FA, Soni TG, Shah DO (2015), Extended release of hyaluronic acid from 
hydrogel contact lenses for dry eye syndrome, J Biomater Sci Polym E 26 1035–1050. 
References 
55 
[122] Weeks A, Subbaraman LN, Jones L, Sheardown H (2013), Physical entrapment of 
hyaluronic acid during synthesis results in extended release from model hydrogel and 
silicone hydrogel contact lens materials, Eye Contact Lens 39 179–185. 
[123] Ali M, Byrne ME (2009), Controlled Release of High Molecular Weight Hyaluronic 
Acid from Molecularly Imprinted Hydrogel Contact Lenses, Pharm Res 26 714–726. 
[124] Calles JA, Tártara LI, Lopez-García A, Diebold Y, Palma SD, Vallés EM (2013), 
Novel bioadhesive hyaluronan–itaconic acid crosslinked films for ocular therapy, Int 
J Pharm 455 48–56. 
[125] Hume LR, Lee HK, Benedetti L, Sanzgiri YD, Topp EM, Stella VJ (1994), Ocular 
sustained delivery of prednisolone using hyaluronic acid benzyl ester films, Int J 
Pharm 111 295–298. 
[126] Wang B, Lin Q, Jin T, Shen C, Tang J, Han Y, Chen H (2015), Surface modification 
of intraocular lenses with hyaluronic acid and lysozyme for the prevention of 
endophthalmitis and posterior capsule opacification, RSC Adv 5 3597–3604. 
[127] Lin Y-K, Chen K-H, Kuan C-Y (2013), The synthesis and characterization of a 
thermally responsive hyaluronic acid/ Pluronic copolymer and an evaluation of its 
potential as an artificial vitreous substitute, J Bioact and Compat Pol. 
[128] Gan L, Wang J, Zhao Y, Chen D, Zhu C, Liu J, Gan Y (2013), Hyaluronan-modified 
core–shell liponanoparticles targeting CD44-positive retinal pigment epithelium cells 
via intravitreal injection, Biomaterials 34 5978–5987. 
[129] Martens TF, Remaut K, Deschout H, Engbersen JF, Hennink WE, van Steenbergen, 
Mies J., Demeester J, De Smedt, Stefaan C., Braeckmans K (2015), Coating 
nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene 
therapy, J Control Release 202 83–92. 
[130] Koo H, Moon H, Han H, Na JH, Huh MS, Park JH, Woo SJ, Park KH, Chan Kwon 
I, Kim K, Kim H (2012), The movement of self-assembled amphiphilic polymeric 
nanoparticles in the vitreous and retina after intravitreal injection, Biomaterials 33 
3485–3493. 
[131] Neffe AT, Kobuch KA, Maier M, Feucht N, Lohmann CP, Wolfstein A, Streufert 
D, Kamlage S, Lendlein A (2011), In Vitro and In Vivo Evaluation of a 
Multifunctional Hyaluronic acid Based Hydrogel System for Local Application on 
the Retina, Macromol Symp 309-310 229–235. 
Chapter 1 – Introduction 
56 
[132] Sueda J, Sakuma T, Nakamura H, Usumoto N, Okuno T, Arai M, Hirose T (2006), 
In Vivo and In Vitro Feasibility Studies of Intraocular Use of Seprafilm to Close 
Retinal Breaks in Bovine and Rabbit Eyes, Invest Ophthalmol Vis Sci 47 1142. 
[133] Parker J, Mitrousis N, Shoichet MS (2016), Hydrogel for Simultaneous Tunable 
Growth Factor Delivery and Enhanced Viability of Encapsulated Cells in Vitro, 
Biomacromol 17 476-484. 
[134] Ballios BG, Cooke MJ, van der Kooy, Derek, Shoichet MS (2010), A hydrogel-based 
stem cell delivery system to treat retinal degenerative diseases, Biomaterials 31 2555–
2564. 
[135] Kontturi L-S, Collin EC, Murtomäki L, Pandit AS, Yliperttula M, Urtti A (2015), 
Encapsulated cells for long-term secretion of soluble VEGEF receptor 1: Material 
optimization and simulation of ocular response, Eur J Pharm Biopharm 95 387-97. 
[136] Barar J, Javadzadeh AR, Omidi Y (2008), Ocular novel drug delivery: impacts of 
membranes and barriers, Exp Opin Drug Del 5 567–581. 
[137] Valim V, Trevisani, Virginia Fernandes Moça, de Sousa, Jacqueline Martins, Vilela 
VS, Belfort R (2015), Current Approach to Dry Eye Disease, Clinic Rev Allerg 
Immunol 49 288–297. 
[138] Baudouin C (2001), The Pathology of Dry Eye, Survey of Ophthalmology 45 S211-
S220. 
[139] Lee HS, Ji YS, Yoon KC (2014), Efficacy of Hypotonic 0.18% Sodium Hyaluronate 
Eye Drops in Patients With Dry Eye Disease, Cornea 33 946–951. 
[140] Doughty MJ, Glavin S (2009), Efficacy of different dry eye treatments with artificial 
tears or ocular lubricants: a systematic review, Ophthal Phyl Opt 29 573–583. 
[141] Aragona P, Papa V, Micali A, Santocono M, Milazzo G (2002), Long term treatment 
with sodium hyaluronate-containing artificial tears reduces ocular surface damage in 
patients with dry eye, Brit J Ophthalmol 86 181–184. 
[142] Paugh JR, Nguyen AL, Ketelson HA, Christensen MT, Meadows DL (2008), 
Precorneal residence time of artificial tears measured in dry eye subjects, Optometry 
Vision Sci 85 725–731. 
[143] Ludwig A (2005), The use of mucoadhesive polymers in ocular drug delivery, Adv 
Drug Deliver Rev 57 1595–1639. 
References 
57 
[144] Zignani M, Tabatabay C, Gurny R (1995), Topical semi-solid drug delivery: kinetics 
and tolerance of ophthalmic hydrogels, Adv Drug Deliver Rev 16 51–60. 
[145] Jeong B, Kim SW, Bae YH (2002), Thermosensitive sol–gel reversible hydrogels, Adv 
Drug Deliver Rev 54 37–51. 
[146] Su X, Tan MJ, Li Z, Wong M, Rajamani L, Lingam G, Loh XJ (2015), Recent 
Progress in Using Biomaterials as Vitreous Substitutes, Biomacromolecules 16 3093–
3102. 
[147] Kleinberg TT, Tzekov RT, Stein L, Ravi N, Kaushal S (2011), Vitreous Substitutes: 
A Comprehensive Review, Surv Ophthalmol 56 300–323. 
[148] Baino F (2011), Towards an ideal biomaterial for vitreous replacement: Historical 
overview and future trends, Acta Biomater 7 921–935. 
[149] Thrimawithana TR, Young S, Bunt CR, Green C, Alany RG (2011), Drug delivery to 
the posterior segment of the eye, Drug Discov Today 16 270–277. 
[150] Xu Q, Boylan NJ, Suk JS, Wang Y-Y, Nance EA, Yang J-C, McDonnell PJ, Cone 
RA, Duh EJ, Hanes J (2013), Nanoparticle diffusion in, and microrheology of, the 
bovine vitreous ex vivo, J Control Release 167 76–84. 
[151] Peeters L (2005), Vitreous: A Barrier to Nonviral Ocular Gene Therapy, Invest 
Ophthalmol Vis Sci 46 3553–3561. 
[152] Naik R, Mukhopadhyay A, Ganguli M (2009), Gene delivery to the retina: focus on 
non-viral approaches, Drug Discov Today 14 306–315. 
[153] Tozer K, Johnson MW, Sebag J, II.C. Vitreous Aging and Posterior Vitreous 
Detachment, pp. 131–150. 
[154] Deguine V, Menasche M, Ferrari P, Fraisse L, Pouliquen Y, Robert L (1998), Free 
radical depolymerization of hyaluronan by maillard reaction products, Int J Biol 
Macromol 22 17–22. 
[155] Lane JI, Watson RE, Witte RJ, McCannel CA (2003), Retinal Detachment: Imaging 
of Surgical Treatments and Complications1, RadioGraphics 23 983–994. 
[156] Amadio M, Govoni S, Pascale A (2016), Targeting VEGF in eye neovascularization: 
What's new?, Pharmacol Res 103 253–269. 
Chapter 1 – Introduction 
58 
[157] Oh EJ, Choi J-S, Kim H, Joo C-K, Hahn SK (2011), Anti-Flt1 peptide – Hyaluronate 
conjugate for the treatment of retinal neovascularization and diabetic retinopathy, 
Biomater 32 3115–3123. 
[158] Highley CB, Prestwich GD, Burdick JA (2016), Recent advances in hyaluronic acid 
hydrogels for biomedical applications, Curr Opin Biotechnol 40 35–40. 
  
 
 
 
 
Chapter 2 
 
 
Goals of the Thesis 
 
 
 
 
 
 
 
 
 
  
  
 
 
Goals of the Thesis 
61 
 
 
 
 
 
Glaucoma is a progressive neurodegenerative disease of the optic nerve and is one of the 
leading causes of blindness along with cataracts, age-related macular degeneration and 
diabetic retinopathy [1]. Estimations predict that more than 110 million people will be 
affected worldwide by 2040, with African and Asian population bearing a higher risk of 
developing the disease [2]. The pathology of glaucoma is not fully understood yet but there 
are some risk factors such as genetic predisposition, ethnicity and age [3]. An elevated 
intraocular pressure (IOP) is evaluated as the most critical aspect. Therefore, current 
therapies focus on lowering the IOP by topically or systemically applied drugs or surgery. 
Table 1 summarizes substances frequently used in glaucoma therapy. They all result in the 
same pharmacological effect which relies on reducing the production or increasing the 
outflow of aqueous humor (AH). At a first glance, glaucoma therapy with eye drops appears 
to be a reasonable, non-invasive treatment method, but the need for application several times 
a day reduces patient adherence. Furthermore, mistakes in administration, like the application 
of too many drops, are common[4,5] and studies have shown that nine out of ten patients 
were unable to apply their eye drops correctly [6]. Consequently, undesired systemic side 
effects or insufficient therapeutic benefits result. Surgical procedures (summarized in 
Table 2) are reserved for more severe cases. During surgery, parts of the trabecular 
meshwork (TM) are removed or other drainage pathways are opened to improve AH outflow 
using incisional or minimally invasive techniques. However, achieved outcomes decrease 
over time and surgery always carries risks like scarring, fibrosis, the development of cataracts 
or sight-threatening infections [7,8]. 
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Table 1. Frequently used drugs in glaucoma therapy. As an elevated intraocular pressure is 
regarded as most critical for the progression of the disease, current medications rely on lowering 
the intraocular pressure by topically applied eye drops. Adapted from [9]. 
drug type examples mechanism of action 
prostaglandin analogues latanoprost, travoprost, 
tafluprost, unoprostone, 
bimatoprost 
increase in aqueous humor 
(AH) outflow 
beta-adrenergic blockers betaxolol, carteolol, 
levobunolol, timolol 
reduction of AH production  
carbonic anhydrase inhibitors acetazolamide (oral), 
brinzolamide, dorzolamide,  
reduction of AH production 
alpha-adrenergic agonists brimonidine, apraclonidine reduction of AH production, 
increase in AH outflow 
cholinergic agonists pilocarpine, carbachol increase in AH outflow 
 
Table 2. Surgical options to reduce intraocular pressure. Trabeculectomy is the most frequently 
used procedure. However, newer minimally invasive techniques might become more important 
due to the reduced risk of side effects. Compiled from [10,11]. 
 method description mechanism of action 
incisional    
surgery trabeculectomy removal of parts of the 
trabecular meshwork (TM) 
and adjacent tissues 
subconjunctival 
filtration 
implant aqueous tube shunt, 
glaucoma drainage 
device 
shunt from anterior chamber 
to external reservoir 
external aqueous humor 
(AH) drainage 
minimal invasive   
surgery Trabectome electrocautery TM ablation, 
removal of angle tissue 
barrier 
increasing trabecular 
outflow 
 gonioscopy-assisted 
transluminal 
trabeculotomy 
circumferential 
trabeculotomy, removal of 
TM and adjacent structures 
increasing trabecular 
outflow 
stents iStent, iStent inject trabecular micro-bypass, 
connection between anterior 
chamber and Schlemm’s 
channel (SC) 
increasing trabecular 
outflow 
 Hydrus Microstent dilatation of SC increasing trabecular 
outflow 
 XEN Gel Implant, 
MicroShunt 
shunt from anterior chamber 
to subconjunctival space 
subconjunctival 
filtration 
 Cypass Micro-Stent fenestrated tube implanted 
between ciliary body and 
sclera 
suprachoroidal shunts 
laser excimer laser 
trabeculotomy 
photoablation of TM increasing trabecular 
outflow 
 Electrophoto-
coagulation 
blanching of ciliary processes reduction of AH 
production 
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The IOP is generated by the circulation and hindered outflow of AH in the anterior segment 
of the eye as demonstrated in Figure 1 [12]. Epithelial cells of the ciliary body produce AH 
and secrete it into the posterior chamber. It provides nutrients to lens, iris and cornea which 
are not supplied with blood vessels. A pressure gradient drives the fluid through the gap 
between lens and iris into the anterior chamber where it drains into the outflow pathways of 
the iridocorneal angle. Only a small portion of AH leaves the eye via the unconventional or 
uveocorneal outflow pathway and diffuses through intramuscular spaces of the ciliary body 
into capillaries and lymphatic vessels [13] while 85 to 95 % of AH use the conventional 
outflow pathway of the TM [3]. 
 
Figure 1. Anatomy of the anterior segment of the eye. Aqueous humor is produced in the ciliary 
body and secreted into the posterior chamber. The fluid passes the gap between lens and iris 
through the pupil into the anterior chamber and finally is drained into the trabecular meshwork, 
located in the iridocorneal angle. 
The detailed anatomy of the TM is schematically represented in Figure 2. Its typical sponge-
like structure results from connective tissue beams that span from Schwalbe’s line, the 
anterior border of the TM, to the scleral spur which is attached to the ciliary body [13–15]. 
These lamellae consist of collagenous and elastic fibers and are covered by flat TM cells 
residing on a basement membrane. TM cells share properties with epithelial cells and 
macrophages. For example, they exhibit a flat morphology, produce antithrombotic 
substances and are capable of phagocytosis which is an important self-cleaning-mechanism 
Chapter 2 – Goals of the Thesis 
64  
 
in the TM to keep the porous structure intact [16,17]. Connective tissue and cellular 
processes bridge adjacent beams and strengthen the network. AH first passes the uveal and 
corneoscleral meshwork which is characterized by this lamellae structure [13]. The 
juxtacanicular connective tissue (JCT) beneath contains star-shaped cells that are embedded 
in a loose connective tissue made up by fibrillar components and an amorphous ground 
substance. Finally, AH drains into Schlemm’s channel (SC), a modified blood vessel with 
high permeability [13]. Large pores within SC endothelia and an incomplete basal lamina 
facilitate the perfusion of AH from the TM into the lumen. 
 
Figure 2. Detailed structure of the TM. AH first passes the sponge-like structure of the uveal 
and corneoscleral meshwork. Star-shaped cells and a dense extracellular matrix characterize the 
juxtacanicular connective tissue (JCT) beneath.  Finally, AH drains into Schlemm’s Channel (SC) 
and is transported to collector channels and the episcleral vein (not shown). 
The loose network of the uveal and corneoscleral meshwork does not contribute to the 
buildup of IOP as the pore sizes are too wide to generate an outflow resistance [13]. 
However, spaces in the JCT region and the inner wall endothelium of SC are much smaller, 
and it is generally accepted that the outflow resistance to AH is generated in this region. The 
quality and quantity of extracellular matrix (ECM) in the JCT is highly regulated and strongly 
impacts AH flow [13,18]. Transforming growth factor (TGF)-β2 seems to be involved in this 
regulation as elevated levels in the AH of glaucoma patients were related to enhanced ECM 
deposition in the JCT. Furthermore, it was found that TGF-β2 stiffens the ECM by 
stimulation of fibronectin crosslinking and inhibition of ECM degrading enzymes. Some of 
these effects – especially ECM deposition - are transmitted by connective tissue growth 
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factor (CTGF). The system of TGF-β2 and CTGF also strengthens the contractile properties 
of the TM actin cytoskeleton, further increasing outflow resistance.   
Interference with the TGF-β/CTGF-system presents an opportunity to reduce the massive 
ECM deposition within the TM and lower the enhanced contractility of the actin 
cytoskeleton. As TGF-β2 is a growth factor involved in many physiological and 
pathophysiological processes like proliferation, apoptosis, tumor growth and autoimmune 
diseases, complete depletion might cause unpredictable effects. Therefore, attenuation of 
CTGF, the downstream mediator of TGF-β2, is more reasonable. An enhanced expression 
of fibronectin and collagen I, III, IV and VI was shown in vitro after treating human TM cells 
with recombinant CTGF by Junglas et al. [19]. Additionally, an increase in IOP and a 
progressive loss of optic nerve axons was demonstrated in CTGF overexpressing transgenic 
mice [20]. Hence, reducing CTGF levels has the potential to prevent the progression of the 
disease. 
A promising method to reduce the production of a protein is silencing gene expression with 
small interfering RNA (siRNA). siRNA are short, double stranded RNAs with a length of 21 
to 23 base pairs and two nucleotides overhang at the 3’ end [21]. The mechanism of gene 
knockdown is summarized in Figure 3.  In the cytosol of a cell, siRNA interacts with a protein 
complex called RNA-induced silencing complex (RISC). Double-stranded siRNA is 
unwound and the antisense strand is incorporated into the complex. This antisense strand 
pairs with a complementary messenger RNA (mRNA) strand and mediates its cleavage. 
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Figure 3. Mechanism of gene knockdown by small interfering RNA (siRNA). siRNA associates 
with the RNA induced silencing complex (RISC). Complementary messenger RNA (mRNA) is 
recognized by base paring and enzymatically cleaved by a RISC subunit with endonuclease 
activity. 
RNA interference was identified as promising approach for the therapy of diseases caused 
by the overexpression of specific proteins. However, the delivery of siRNA is difficult. The 
polar nature of the molecule and the high molecular weight hinder cellular access [22]. Rapid 
degradation by endogenous nucleases occurs immediately after injection into the blood and 
is the biggest obstacle for siRNA gene therapy. Hence, a suitable delivery system must be 
applied, protecting siRNA from degradation and facilitating cellular entry.  
The main goal of the thesis was the development of a nanoparticulate system for the delivery 
of siRNA to cells in the TM. These particles would be injected into the anterior chamber of 
the eye and follow the natural AH flow to the JCT where outflow resistance is generated. 
Therefore, the particles must comply with a number of requirements. First, the loading 
capacity has to be sufficiently high to have a therapeutic effect and siRNA must be protected 
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against degradation. Further, the nanoparticles (NPs) should move freely in the extracellular 
space but specifically interact with their target cells once they reach the inner TM. Layer-by-
layer (LbL)-NPs as described by Elbakry et al. [23] meet all criteria. As siRNA is 
electrostatically attached to the surface of a nanoparticulate template, high loading is possible, 
and the fragile molecule can facilely be protected by covering it with an oppositely charged 
polyelectrolyte. An outer layer of hyaluronic acid (HA) is intended to enhance the NP 
mobility in the extracellular space, as this polysaccharide is a naturally present in the TM. At 
the same time, interactions of HA with receptors on TM cells are predicted to enhance the 
accumulation of NPs and cells.   
In the first step, suitable NPs were designed and fabricated. A protocol was developed for 
the preparation of biodegradable poly(lactic-co-glycolic acid) (PLGA) nanoparticles and their 
coating with polyelectrolytes in a layer-by-layer process. Although the procedure of 
alternating deposition of oppositely charged polymers is easily feasible on planar substrates, 
the method is challenging to apply to colloidal templates because of their tendency to 
aggregate.  PLGA was chosen as a template because of its thorough characterization and 
ability to encapsulate drugs. A freeze-drying method was established for long term storage 
and quantification of the particles. NPs were characterized with regard to size and surface 
charge before, during and after coating by scanning electron microscopy and dynamic light 
scattering (DLS). Colloidal stability and NP disassembly was investigated in different 
environments simulating conditions prior to and after administration into the AH by further 
DLS-studies and in an approach based on Foerster Resonance Energy Transfer (chapter 3).  
Cluster of differentiation (CD) 44 receptors were identified as promising target for the LbL-
NPs as this cell surface protein is overexpressed in the TM of glaucoma patients. 
Functionalization with HA, the natural ligand of CD44, is a widely used approach for 
directing drugs or drug delivery systems to CD44 producing cells. The efficacy of this 
method has been demonstrated in various types of cancer [24–27]. However, targeting the 
TM with HA-functionalized NPs has not been reported so far. In vitro studies using flow 
cytometry and confocal laser scanning microscopy demonstrated the participation of CD44 
in and the impact of receptor density on the interactions of cells and HA-decorated NPs. 
Further, additional effects of HA, such as enhanced colloidal stability and permeation 
through the extracellular matrix were addressed in a 3D cell culture setup (chapter 4).  
The challenge of siRNA delivery does not end with the NPs reaching the target cell. 
Intracellular bottlenecks must be overcome as well. Major issues in particular include the 
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ability of NPs to quickly escape endosomes and also release the siRNA cargo. To evaluate 
the performance of LbL-NPs as an siRNA delivery system, an in vitro assay was established. 
The reduction of green fluorescent protein expression in stably transfected immortalized TM 
cells was detected by flow cytometry and used to study the gene silencing effect of NPs of 
different compositions. To clearly visualize the intracellular fate of the particles, their 
colocalization with different intracellular compartments such as early and late endosomes or 
lysosomes was determined by optical sectioning using a confocal laser scanning microscope. 
Finally, different fluorescence-based techniques were used to analyze whether the NPs were 
exocytosed (chapter 5). 
So far, general aspects like NP characterization, their interaction with cells and intracellular 
fate were discussed. In the last part of the thesis, however, the specific application of LbL-
NPs for CTGF silencing in the TM was addressed. First, it was investigated whether 
pathological alterations in the TM also affect CD44. Quantitative real-time polymerase chain 
reaction (qRT-PCR), western blotting and immunohistochemistry were used to analyze 
samples obtained in vitro, in vivo, in transgenic mice and ex vivo from human donors. NP 
distribution in the outflow pathways of porcine and human eyes was evaluated after 
perfusion with either HA-functionalized or unfunctionalized NPs. Fluorescent images of 
whole outflow rings and confocal micrographs of sagital sections were taken and the 
colocalization of NPs with CD44 and CD31 was evaluated. Finally, the CTGF silencing 
efficacy of the NPs was addressed in primary human trabecular meshwork cells by qRT-PCR 
and western blotting (chapter 6). 
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Abstract 
 
Nanoparticles (NPs) synthesized via layer-by-layer processes are promising candidates for 
successful drug and gene delivery. Widespread use of the layer-by-layer technique has 
resulted from its accessibility to every lab; to generate nanoscale structures, layer-by-layer 
processes require common lab equipment of only modest quality and do not involve the use 
of organic solvents. In addition, a wide range of different starting materials can be flexibly 
combined, enabling the production of a nearly unlimited number of different nanoparticles 
with various physicochemical properties. Here we describe the manufacturing of poly(lactic-
co-glycolic acid) NPs coated with small interfering RNA for gene silencing. Positively charged 
polyethyleneimine and negatively charged nucleic acids form the polyelectrolyte shell. Finally, 
the nanoparticles are functionalized with hyaluronic acid, a polysaccharide which targets the 
CD44 receptor. The particles were characterized with regard to size and zeta potential before, 
during and after the layer-by-layer deposition of the polymers. Additionally, their colloidal 
stability in different dispersants was monitored via dynamic light scattering and Foerster 
Resonance Energy Transfer. 
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1 Introduction 
“Layer-by-layer” (LbL) is a term used to describe film formation by depositing oppositely 
charged materials on a surface [1]. Decher was the first to characterize the underlying 
mechanism in 1991, assembling a 35-layer film, 170 nm in thickness, composed of alternating 
anionic and cationic bipolar amphiphiles on a planar surface [2]. Since then, the field has 
developed immensely. LbL techniques are now routinely leveraged for applications in 
material science, physical chemistry, electrochemistry and biomedical engineering [1]. In the 
fields of drug and gene delivery, LbL shell growth on nanoscale templates has emerged as an 
area of particular interest [3]. The structure of LbL-coated nanoparticles (NPs) allows the 
inclusion of therapeutics (e.g. small molecules or macromolecules like proteins and nucleic 
acids) into either the multilayer shell or the NP core. The technique is even suitable for 
extremely sensitive or labile molecules like RNA, as the layering process is performed under 
mild conditions without the need for harsh pH or elevated temperatures. The surface 
properties of the fully-assembled NPs can be tailored on a molecular level without 
significantly altering the shape and size of the particle as a whole, simply by selecting a 
suitable charged substance for the final layer. Substances with targeting functions can readily 
be attached to the nanoparticle surface by similar means. Additionally, inclusion of pH-
sheddable, redox-sensitive or enzymatically degradable materials enable spatially and 
temporally controlled or triggered release [4]. Despite these significant advantages, high-
quality LbL assembly is quite difficult, impeding broad application of the technique [5]. Of 
utmost importance is the complete removal of unbound polyelectrolyte after each layering 
cycle. Any oppositely charged polymers remaining in solution after a cycle will form 
complexes which are difficult to separate from coated particles. Purification processes must 
be thorough but gentle, as irreversible aggregation of particles poses a serious issue. 
Commonly applied strategies are repeated centrifugation and ultrafiltration. 
We developed a LbL-based protocol for manufacturing poly(lactic-co-glycolic acid) (PLGA) 
NPs for small interfering RNA (siRNA) delivery. Figure 1 summarizes the composition of 
the particles. The NP core is composed of PLGA, an FDA-approved biodegradable polymer 
that is commercially available in high quality and a wide range of molecular weights. The 
synthesis of PLGA-NPs is well established in the literature [6]. During synthesis of the PLGA 
core particle, we utilize polyethyleneimine (PEI) instead of poly(vinyl alcohol) as a stabilizing 
agent. As a well-known and highly effective transfection agent [7], PEI is intended to enhance 
the particles’ effectiveness as gene delivery vehicles. Further, PEI provides the NPs with the 
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cationic surface charge necessary for adsorption of an initial layer of negatively charged 
siRNA. To protect the siRNA from degradation, another layer of PEI was adsorbed on top 
of the siRNA. The negatively charged polysaccharide hyaluronic acid (HA) was used as a 
final, outermost layer. HA enhances the NP colloidal stability [8], increases NP mobility in 
the extracellular space [9] and serves as a targeting moiety [10]. As the main ligand of the 
cluster of differentiation (CD) 44-receptor, HA directs the NPs to cells with high receptor 
density, e. g. tumor cells [11] and others known to strongly interact with their extracellular 
matrix as for example in the trabecular meshwork [12]. References [13,14] are excellent 
review articles covering this topic.  
Here, we describe a protocol for the preparation of LbL-based NPs. Changing the ratio of 
PLGA and stabilizer during the synthesis resulted in NPs of different sizes as demonstrated 
by scanning electron microscopy (SEM) and dynamic light scattering (DLS). A freeze-drying 
method was developed for storage and quantification of the NPs. The deposition of 
oppositely charged polymers on the core was monitored by DLS, and the siRNA loading 
was photometrically estimated. Finally, the colloidal stability of the NPs was investigated in 
different dispersants by DLS and Foerster Resonance Energy Transfer (FRET).  
 
Figure 1. The LbL-based NP consists of a positively charged PLGA-PEI core and 3 
subsequently deposited polyelectrolyte layers. The first layer consists of negatively charged 
siRNA (blue). This is coated and protected by a layer of polycationic PEI (orange). A final layer 
of anionic HA (light blue) is then deposited to enable targeting of CD44 receptors. 
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2 Materials and Methods 
2.1 Materials 
Acid terminated poly(D,L-lactide-co-gylcolide) (PLGA) (lactide/glycolide 50/50) with an 
average molecular weight of 38-54 kDa (PLGA) and branched poly(ethylenimine) 25 kDa 
(PEI) were bought from Sigma-Aldrich (Taufkirchen, Germany). Sucrose, microbiological 
grade, was purchased from Merck (Darmstadt, Germany). Rhodamine B endcapped PLGA 
(lactide/glycolide 50/50, average molecular weight 30 kDa) (RHOD-PLGA) was obtained 
from Polyscitech (West Lafayette, Indiana, United States). siSCRBL 5’-UUC UCC GAA 
CGU GUC ACG UdTdT-3’ (with and without fluorescein-tag) and siCTGF 5’-AGA UUC 
CCA CCC AAU UCA ATT dTdT-3’ were from Qiagen (Hilden, Germany) and Eurofins 
(Ebersberg, Germany). Sodium hyaluronate (13 kDa) (HA) was bought from Lifecore 
Biomedicals (Chaska, Minnesota, United States). Cell culture media, phosphate-buffered 
saline (PBS) and fetal calf serum were purchased from ThermoFisher Scientific (Darmstadt, 
Germany). 
2.2 Methods 
Working with RNA 
RNAse-free working conditions were strictly applied. A separate work space that has been 
treated with RNAse-digesting substances was used and working in locations with turbulent 
airflow was avoided. A lab coat and gloves were worn at all times and changed on a regular 
basis. Barrier tips and other RNAse-free consumables from unopened boxes and bags were 
used exclusively. All glass ware was baked for at least 8 hours at 200°C prior to use. An extra 
set of chemicals and reagents was kept, and only RNAse-free equipment was used to remove 
them from their containers. RNAse-free water was obtained from a certified reverse osmosis 
facility. All solutions containing siRNA or siRNA-coated NPs were kept on ice if possible. 
Preparation of LbL NPs 
LbL-NP were prepared in a multi-stage process summarized in Figure 2. 
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Figure 2. Schematic illustration of the synthesis and LbL coating procedures for PLGA-NPs. 
PLGA-NPs were prepared by nanoprecipitation and freeze dried for further storage. 
Resuspended NPs were coated with siRNA, PEI and HA, in that order. Each coating step was 
followed by purification of NPs from excess polyelectrolyte. 
Synthesis of PLGA-NPs 
8 mL of 0.5 % PEI were stirred in a snap cap vial to create a vortex and 2 mL PLGA solution 
(10 mg/mL in acetonitrile) was slowly injected. For the preparation of other sizes, PLGA 
and PEI concentrations were varied. The dispersion was stirred for at least 4 hours to 
guarantee the complete curing of the particles and evaporation of the organic solvent. For 
the preparation of rhodamine (RHOD)-labeled NP, a mixture of PLGA and RHOD-PLGA 
(50/50) was used. 
NP purification 
The NP dispersion was split into several Eppendorf tubes and centrifuged for 7 min at 4°C 
with a speed of 5,000 x g. The supernatant was removed. The pellet was resuspended in 
ultrapure water and the supernatant was centrifuged again for 7 min at 4°C with a velocity 
of 7,000 x g. To increase yield, the last step was repeated with a centrifugation speed of 
9,000 x g. Supernatant of the last step was discarded and resuspended NPs were combined. 
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The entire process was repeated once. If the purified NPs were coated with siRNA, the final 
resuspension was performed in 10 mM sodium chloride.  
Freeze drying and storage 
Purified NPs were pooled, mixed with an equal volume of sucrose solution (4 % (w/v) in 
water) and filled into tared lyophilization vials. NPs were frozen at -80°C and dried for 5 
days at -20°C and for two days at +20°C under vacuum using a Christ LMC-2 freeze-drying 
facility (Osterode am Harz, Germany). Dried samples were weight and the NP mass in the 
lyophilizate was calculated by subtracting the mass of sucrose added initially. NPs were 
resuspended in ultrapure water to a concentration of 1 mg/mL and purified as described 
above prior to coating.  
Coating with polyelectrolytes 
The polyelectrolyte solution was placed into a snap cap vial equipped with a stir bar. For the 
preparation of 1 mL of coated particles a) 200 µL siRNA 20 µM + 800 µL purified NPs; b) 
10 µL PEI 100 mg/mL + 990 µL purified NPs; c) 100 µL HA 10 mg/mL + 900 µL purified 
NPs were used. Purified NPs were added dropwise into the gently stirred solution of 
polyelectrolyte and stirring was continued for approximately 30 min at room temperature. 
The concentration of the polymers during coating was 1 mg/mL in water or 4 µM in 10 mM 
NaCl for polymers (PEI and HA) and siRNA respectively. To monitor polyelectrolyte 
adsorption and NP aggregation, size and zeta potential measurements were carried out after 
every coating step. 
Characterization by dynamic light scattering (DLS) and electrophoretic mobility 
NPs were characterized in water by dynamic light scattering with a Zetasizer Nano ZS 
(Malvern Instruments, Herrenberg, Germany). 173° backward scatter and the general-
purpose mode with automatic measurement position and attenuator selection at a 
temperature of 25°C was used. Z-average values were stated. Zeta potential measurements 
were conducted in monomodal mode. 
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Scanning electron microscopy 
Purified NPs were added dropwise to conductive pads (Plano GmbH, Wetzlar, Germany) 
attached to aluminum specimen stubs (Agar Scientific, Stansted, Essex, UK) and air dried. 
The samples were sputtered with Au/Pd using a Polaron SC 515 SEM Sputter Coating 
System. Images were taken on a Zeiss DSM 950 scanning electron microscope (Jena, 
Germany). An acceleration voltage of 10 kV was used. The working distance was set to 
24 mm and a magnification of 20,000 x was chosen. 
Stability 
To determine their stability, NPs were stored in Millipore water at 4°C for several weeks and 
DLS measurements were performed at least once a week after equilibrating the samples to 
room temperature. Short term stability studies at different pHs were performed by mixing 
the NPs with a 10 mM citrate or phosphate buffer of the respective pH, with PBS or with 
Leibovitz containing 0.35 % serum. Particles were diluted to a final concentration of 
10 µg/mL. DLS measurements were initiated immediately after mixing the components. At 
least 40 measurement runs with a delay of 270 seconds were performed, covering a period 
of 5 hours.  
FRET Measurements 
For the preparation of NPs for FRET analysis, a RHOD-tagged PLGA core (RHOD-NP) 
and fluorescein-labeled siRNA (FITC-siRNA) were used. NPs were diluted to a final 
concentration of 10 µg/mL with PBS or serum containing Leibovitz media. siRNA 
concentration was set to 0.02 µM. Fluorescence emission spectra from 500 to 700 nm after 
excitation at 488 nm were recorded using a Perkin Elmer LS55 fluorescence spectrometer 
(Waltham, Massachusetts, United States). The slit width was set to 6 nm and the detector 
voltage to 700 V. Measurements were performed in triplicate, running 3 scans with 
200 nm/min each.
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3 Results and Discussion 
3.1 Size variability of PLGA-NP 
PLGA-NPs of different sizes were produced by varying the PLGA to PEI ratio during 
synthesis. Figure 3 shows a selection of scanning electron micrographs. While an increase in 
PLGA concentration resulted in larger particles, NPs became smaller if higher PEI 
concentrations were used. Similar findings were reported in literature [15,16]. These effects 
are related to the surface area of nascent NPs. If a high amount of stabilizer is available 
during NP formation, a large surface area can be stabilized and smaller particles form. If only 
few stabilizer molecules are present, larger particles are produced to keep the total surface 
area low. Dynamic light scattering measurements (Figure 4A) supported these findings. 
 
Figure 3. Scanning electron micrographs of NPs manufactured with different ratios of PLGA 
to PEI. The size of the NPs increased with PLGA concentration (from left to right) and with 
decreasing PEI concentration (from bottom to top). NPs were produced by combining 2 mL 
PLGA in acetonitrile and 8 mL of an aqueous PEI solution. A) 5 mg/mL PLGA + 0.5 % PEI. 
B) 10 mg/mL PLGA + 0.5 % PEI. C) 20 mg/mL PLGA + 0.5 % PEI. D) 20 mg/mL PLGA 
+ 1 % PEI. E) 20 mg/mL PLGA + 2 % PEI. The scale bar represents 1 µm. 
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In addition to size, the zeta potential was also determined (Figure 4C). The zeta potential of 
the NPs was higher when more PLGA was used for the preparation and when the NP were 
larger, but decreased with PEI concentration. One explanation for these findings is that there 
is a link between the surface curvature of the particles and the zeta potential. Small NPs with 
higher curvature might have bound only a small number of PEI molecules. As PEI was 
highly hydrated and stretched over a large area, surface charge was low. Less curved, larger 
particles bound more PEI and surface charge was higher. The formulations also differed in 
terms of their polydispersity (Figure 4B). PDI was low when 0.5 or 1 % PEI and 10 mg/mL 
PLGA was used for the preparation of the particles. A PEI-concentration of 2 % resulted in 
inhomogeneous samples. To ensure sample uniformity, NPs synthesized with 0.5 % PEI and 
a 10 mg/mL solution of PLGA were used for all further studies. 
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Figure 4. Characterization of PLGA-PEI-NP of different compositions by DLS and 
electrophoretic mobility. NPs were produced by mixing 2 mL of 5, 10 or 20 mg/mL PLGA in 
acetonitrile and 8 mL of a 0.5, 1 or 2 % aqueous PEI solution. A) The hydrodynamic diameter 
of the NP increased with PLGA concentration but decreased with PEI concentration. B) If low 
PGLA and PEI concentrations were used, polydispersity index was below 0.1. C) Higher 
concentrations of PLGA resulted in a higher surface charge whereas higher PEI concentrations 
led to lower values. Shown is the mean +/- SD of three independent experiments. 
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3.2 Freeze drying of PLGA-NPs 
For storage and quantification of PLGA-NPs, a freeze-drying procedure was established. 
The addition of 1 to 3 % sucrose was sufficient to protect the NP from aggregation (Figure 
5). Reconstituted NPs had a similar size and surface charge to the NPs before freeze drying 
(Figure 5A and C). Polydispersity index did not exceed 0.1 which indicates a narrow particle 
size distribution (Figure 5B) [17]. However, resuspension was not possible when NPs were 
frozen and dried without the addition of sucrose. Holzer et al. systematically investigated the 
influence of several cryoprotective agents on the reconstitution of freeze dried NPs [18]. 
They demonstrated that 1% sucrose or 2% trehalose is suitable for maintaining the colloidal 
stability of lyophilized PLGA-NPs stabilized with poly(vinyl alcohol). Here, this approach 
was applied to positively charged PEI-stabilized PLGA-NPs. Volume and mass of the 
lyophilization cake was considerably increased by the addition of sucrose. Thus, it was 
possible to gravimetrically determine the percentage of NPs of the lyophilizate. All NPs 
prepared made up 0.5 to 8 % of the lyophilized cake total mass (data not shown). The 
concentration of LbL-NPs after completed coating was determined by fluorescence intensity 
measurements in relation to a calibration curve of resuspended but unpurified NPs of known 
concentration (see supporting information). 
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Figure 5. Effect of sucrose on the properties of resuspended PLGA-NP after freeze drying. A) 
The hydrodynamic diameter of the NPs remained unchanged after freeze drying and 
resuspension when 1 to 3 % sucrose was added. However, freeze drying without protective 
agent resulted in the aggregation of NPs. B) Polydispersity index after resuspension was <0.1 
when sucrose was added during freeze drying. Complete resuspension was not possible without 
a lyoprotective agent. C) Zeta potential remained almost unchanged by the addition of sucrose 
for lyoprotection. Shown is the mean +/- SD of three independent experiments. 
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3.3 Layer-by-layer coating of PLGA-NPs and siRNA loading 
The successful coating of PLGA-NPs with two different siRNA molecules, PEI and HA was 
demonstrated by DLS and zeta potential measurements (Figure 6). Throughout the entire 
process, particle size distribution was narrow. The polydispersity index (PDI), which is an 
indicator for the heterogeneity of particle sizes in a mixture, was < 0.1, an excellent value 
representing a highly monodisperse sample (Figure 6B). Though it is described in literature 
[10,19–21], no continuous increase in particle size was visible during the layer-by-layer 
deposition (Figure 6A). Hydrodynamic diameter decreased when negatively charged siRNA 
or HA was adsorbed and increased only if PEI was attached to the NP surface. A reversal of 
the surface charge (Figure 6C), however, proved the successful deposition of the respective 
polyelectrolyte. Interestingly, higher absolute zeta potential values were measured for PEI-
terminated NPs than for those with a negatively charged terminal layer. As the zeta potential 
of a particle influences its hydrodynamic diameter [17], the formation of a thicker hydration 
shell around highly charged PEI-terminated NPs in comparison to less charged siRNA- or 
HA-NPs seems to be a rational explanation for the absence of size growth during the layer-
by-layer formation process. The purification state of the NPs influenced the parameter size 
and zeta potential too. On the one hand, loosely bound polyelectrolytes were removed during 
purification, and size as well as zeta potential decreased. On the other hand, washing changed 
the pH and ionic strength of the dispersant. As a consequence, the zeta potential and 
hydrodynamic diameter of PEI-NPs increased after washing. 
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Figure 6. Characterization of the NPs during the LbL-process with two different siRNA 
(siCTGF and siSCRBL). A) Hydrodynamic diameter of the particles as determined by DLS. The 
NP size decreased after adsorption of negatively charged polymers but increased when PEI was 
deposited onto the NPs. Further, the purification from excessive polyelectrolyte led to an 
increase in diameter. B) A polydispersity index lower than 0.1 for all samples represented the 
absence of aggregates and a narrow particle size distribution. C) Electrophoretic mobility of the 
NPs. A reversal of zeta potential was determined after each coating step, indicating the successful 
deposition of the respective polyelectrolyte. Shown is the mean +/- SD of three independent 
experiments. 
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Calculations indicate that 7,500 to 60,000 siRNA molecules were bound to one individual 
NP (see supporting information). Based upon the number of bound siRNA molecules and 
the NP surface area, a single siRNA molecule occupied an area of 2.5 to 20 nm2. This is a 
plausible range as the size of the siRNA is less than 10 nm [22,23]. A more precise indication 
may be the radius of gyration, which is the distance where the mass of a body may be assumed 
to be concentrated. As the radius of gyration was determined to be 2 nm [24], the area 
occupied by a sphere of this size would be approximately 12.5 nm² - which is perfectly within 
the calculated range.  
3.4 Stability 
While a delivery system for siRNA must protect the nucleic acid from degradation until it 
reaches the cell, it must also quickly release the therapeutic freight into the cytosol after 
endocytosis. Thus, LbL-NPs must show superior stability before application and in the 
extracellular space but disassemble quickly after successful uptake. During storage at 4°C, 
bare NP cores were stable in ultrapure water over several weeks (data not shown). However, 
NPs with siRNA coating were used within one week after preparation due to the fragility of 
the nucleic acid [25].  
Changes in size of fully assembled LbL-NP by swelling or aggregation were evaluated in 
buffers of different pHs, in PBS and in cell culture media by DLS (Figure 7). Both types of 
NPs were stable in low ionic strength buffer, but PEI-terminated particles showed a steady 
increase in hydrodynamic diameter when the pH of the dispersant dropped to 5.5. Although 
the particles were stable in 10 mM phosphate buffer pH 7, HA-coated particles showed 
strong aggregation in PBS of the same pH. During a period of five hours, the size of both 
NP types increased in Leibovitz supplemented with 0.35 % serum. Whereas particle growth 
of PEI-NP started immediately after mixing with cell culture medium, HA-NPs were 
unchanged for at least one hour. 
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Figure 7. Colloidal stability of HA- (top) and PEI-terminated (bottom), fully assembled LbL-
NP in 10 mM buffer of different pHs, PBS and Leibovitz with 0.35 % serum. Both NPs were 
stable in buffer of pH 6 and 7. However, aggregation occurred for both NPs in Leibovitz media 
with 0.35 % serum, for HA-NPs in PBS and for PEI-NPs in a buffer of pH 5.5. 
The dispersion state of NPs is influenced by pH, ions and proteins since particles are 
stabilized by electrostatic interactions, steric hindrance or a combination of both [26]. 
Changing the pH of the dispersant might reduce the surface charge to values lower than an 
absolute value of 20 to 30 mV, which is critical for sufficient electrostatic repulsion and 
stabilization [27]. Findings for PEI-NPs in buffer of pH 5.5, however, seemed to contradict 
this theory as more positive surface charges were expected with the lower pH. In general, 
high concentrations of ions in the dispersant interfere with the colloidal stability of the NPs 
as the electrostatic double layer around them might be compressed and surface charges 
screened. Hence, aggregation is more likely. In our study, PEI-NPs tolerated high ion 
concentrations better than HA-coated NPs, possibly because of the higher charge density of 
PEI compared to HA. Results regarding the influence of proteins on the stability of NPs are 
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contradictory. Depending on protein concentration and composition of the NPs, a 
stabilizing or destabilizing effect can be observed [26]. DLS measurements reported here 
show an enhanced stability of HA-NPs in Leibovitz supplemented with 0.35 % serum 
compared to PEI-NPs. Leibovitz with 0.35 % serum was used to mimic the concentration 
of proteins in the aqueous humor in the eye, which is the intended application site of the 
NPs. As HA-NPs were dispersed for a longer time until aggregate formation began, these 
particles are more likely to reach their target cells well dispersed. An additional stability study 
of the NPs in cell culture and the influence of serum proteins will be detailly discussed in 
chapter 4. 
The cohesion of the polymer shells of a LbL-NP can be monitored by FRET-studies [28]. 
FRET describes the radiation less energy-transfer of two fluorophores in close spatial 
proximity [29]. A donor chromophore transfers its energy by dipole-dipole coupling to 
another acceptor chromophore. As the FRET efficiency is irreversible proportional to the 
sixth power of distance, this method can be used to determine distances in the lower 
nanometer range. To observe this effect, an overlap of the emission spectra of the FRET 
donor and the extinction spectrum of FRET acceptor is required. Commonly used FRET 
fluorophores are fluorescein (FITC) and rhodamine (RHOD). We prepared NPs where the 
core was labeled with RHOD and siRNA with FITC (Figure 8A). Emission spectra of these 
particles were recorded after irradiation with light at a wavelength of 488 nm in PBS (Figure 
8B) or Leibovitz with 0.35 % serum (Figure 8C). As expected, a prominent maximum was 
detectable for FITC-siRNA at 525 nm. Nanoparticles without siRNA carrying only the 
RHOD fluorophore did not show any fluorescence signal after irradiation with light at 
488 nm. However, if RHOD-NP were coated with FITC-siRNA, fluorescence was 
detectable at 580 nm, the emission maximum of RHOD (see supporting information). 
Fluorophores seemed to be close enough for FRET energy transfer. As there was neither a 
difference between the HA- and PEI-terminated NPs nor between PBS and Leibovitz as a 
dispersant, it can be assumed that both NP types were stable in PBS and Leibovitz and no 
disassembly of the particles occurred during the investigated time frame. 
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Figure 8. Stability and disassembly of multilayered NPs was determined in PBS (B) and 
Leibovitz with 0.35 % serum (C) by Foerster resonance energy transfer (FRET). The FRET 
donor FITC was conjugated to siRNA and the NP core was labeled with the FRET acceptor 
RHOD (A). FITC-siRNA (green) showed a characteristic fluorescence emission spectrum after 
irradiation with 488 nm laser light. The maximum was detected at 525 nm. RHOD-NPs without 
siRNA did not show any fluorescence (red, both lines very close to x-axis). However, fully 
assembled NPs with both fluorophores (blue) showed an emission maximum at 580 nm which 
corresponds to the maximum of RHOD when excited with light at 543 nm. The differences 
between particle types and dispersants were neglectable. Shown is the mean of three independent 
measurements. SD was not presented to achieve better visualization of the curves. 
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4 Conclusion 
Here we demonstrated the development of a successful protocol for the preparation of LbL-
NPs for siRNA delivery. By choosing appropriate amounts of PLGA and stabilizer, NPs in 
a wide range of sizes could be produced without major changes in the protocol. Hence, 
particle size could be easily tailored to individual requirements. The addition of sucrose for 
lyoprotection enabled the complete resuspension of the particles after freeze drying without 
impeding their quality. By the establishment of this procedure, the quantification of the 
particles also became possible. With our coating strategy, we were able to produce NPs with 
a multilayered shell for siRNA delivery. During the process, the method of stepwise 
centrifugation was effective in removing all unbound polyelectrolytes without inducing 
aggregation before adsorption of the next polyelectrolyte shell. DLS stability studies showed 
an advantage of the HA-coating over uncoated NPs with regard to aggregation in an 
environment mimicking physiologic conditions. Further benefits of the HA coating will be 
discussed in the next chapters. 
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1 Quantification of nanoparticles 
The concentration RHOD-NP after completed LbL-coating was determined by fluorescence 
spectroscopy. Resuspended but unpurified NP of the same batch with known concentration 
were used for a calibration curve. The fluorescence intensity was measured on a microplate 
reader (FLUOStar Omega, BMG Labtech, Ortenberg, Germany) equipped with 544 nm 
excitation and 590 nm emission filter sets. 
 
S 1. Calibration curve as used for the quantification of fully assembled LbL-NP. Fluorescence 
intensities (FI) of diluted samples were covered by the calibration. Shown is the mean ± SD of 
a triplicate measurement. 
2 siRNA loading efficiency 
The number of siRNA molecules attached to a NP was determined by calculating the 
difference between the siRNA concentration during coating and the siRNA concentration 
of the supernatant after centrifugation of coated NP in relation to the NP concentration. 
One part of a 20 µM siRNA solution was mixed with four parts of NP during the coating. 
After stirring the particles for approximately 30 minutes, NP were purified as described in 
the material and method section. Absorbance of the supernatant and of the 20 µM siRNA 
solution was read at 260 nm with a Nanodrop 2000c (Peqlab, Erlangen, Germany). The 
concentration of uncoated NPs was determined by fluorescence as presented before. The 
hydrodynamic diameter was measured by dynamic light scattering as described. Each of three 
different PLGA-PEI NP batches were coated with two siRNA of distinct sequence.  
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Calculations were performed as follows: 
1. siRNA attached to NP 
Determination of absorbance at 260 nm:  ܱܦ(𝑠𝑖𝑅ܰ𝐴ଶ଴ µெ) 
       ܱܦ(𝑠𝑖𝑅ܰ𝐴௦௨௣௘௥௡௔௧௔௡௧) 
ܿ(𝑠𝑖𝑅ܰ𝐴௦௨௣௘௥௡௔௧௔௡௧) = ܱܦ(𝑠𝑖𝑅ܰ𝐴௦௨௣௘௥௡௔௧௔௡௧)ܱܦ(𝑠𝑖𝑅ܰ𝐴ଶ଴ µெ) ∙ ʹͲ µܯ ܿሺ𝑠𝑖𝑅ܰ𝐴௔௧௧௔௖ℎ௘ௗሻ = ͳͷ ∙ ܿ(𝑠𝑖𝑅ܰ𝐴ଶ଴ µெ) − ܿ(𝑠𝑖𝑅ܰ𝐴௦௨௣௘௥௡௔௧௔௡௧) = Ͷ µܯ − ܿ(𝑠𝑖𝑅ܰ𝐴௦௨௣௘௥௡௔௧௔௡௧)  
 
2. Molar concentration of NP during coating 
Quantification of PLGA-PEI-NP before coating: 𝛽௕௘௙௢௥௘  [𝑘௚௅ ] 
Hydrodynamic diameter:     ݀ [݉] 
Density of PLGA1:     𝜑𝑃௅𝐺𝐴 = ͳ͵ͲͲ 𝑘௚௠3 ݉ሺܲܮ𝐺𝐴 − ܲܧ𝐼/𝑠𝑖𝑅ܰ𝐴ሻ = 𝜑𝑃௅𝐺𝐴 ∙ Ͷ͵ ∙ 𝜋 ∙ (݀ʹ)ଷ 
ܰሺܲܮ𝐺𝐴 − ܲܧ𝐼/𝑠𝑖𝑅ܰ𝐴ሻଵ௅ = Ͷͷ 𝛽 ∙ ͳܮ݉ሺܲܮ𝐺𝐴 − ܲܧ𝐼/𝑠𝑖𝑅ܰ𝐴ሻ 
݊ሺܲܮ𝐺𝐴 − ܲܧ𝐼/𝑠𝑖𝑅ܰ𝐴ሻ = ܰሺܲܮ𝐺𝐴 − ܲܧ𝐼/𝑠𝑖𝑅ܰ𝐴ሻ?ܰ?  ܿሺܲܮ𝐺𝐴 − ܲܧ𝐼/𝑠𝑖𝑅ܰ𝐴ሻ = ݊ሺܲܮ𝐺𝐴 − ܲܧ𝐼/𝑠𝑖𝑅ܰ𝐴ሻͳܮ  
                                                 
1Information in literature varied from 1.2 to 1.5 g/cm³ [1–5]. Hence, a density of 1.3 g/cm³ 
was used for calculation.  
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3. siRNA molecules per NP 𝑠𝑖𝑅ܰ𝐴ܰܲ = ܿሺ𝑠𝑖𝑅ܰ𝐴௔௧௧௔௖ℎ௘ௗሻܿሺܲܮ𝐺𝐴 − ܲܧ𝐼/𝑠𝑖𝑅ܰ𝐴ሻ 
4. Area per siRNA molecule ݊݉ଶ𝑠𝑖𝑅ܰ𝐴 = 𝜋݀ଶ𝑠𝑖𝑅ܰ𝐴/ܰܲ 
Calculations showed that about 7,500 to 60,000 siRNA molecules adhered to one individual 
NP or that 2.5 to 20 nm² of the NP surface were occupied by one siRNA molecule. Detailed 
results are shown in Table 1.  
Table 1. siRNA loading of NP assembled via the LbL technique. Shown are the measured (OD, 
β, d) and calculated (siRNA/NP, nm²/siRNA) values of different batches. The number of 
siRNA molecules per NP and the space requirement of one siRNA molecule on the NP surface 
are shown in the last two columns. 
siRNA ۽𝐃 (ܛ𝐢𝐑ۼ𝐀𝟐𝟎 µۻ) ۽𝐃 (ܛ𝐢𝐑ۼ𝐀ܛܝܘ܍ܚܖ܉ܜ܉ܖܜ) 𝛃܊܍܎ܗܚ܍  [ܕ܏ۺ ] ܌  [ܕ] ܛ𝐢𝐑ۼ𝐀/ۼ۾ nm² /siRNA 
Batch GU179 
siSCRBL 5.544 0.816 227 216.6 24,256 6.1 
siEGFP 5.542 0.790 227 216.6 26,324 5.6 
Batch GU213 
siSCRBL 4.788 0.835 355 215.1 7,376 19.7 
siGFP2 6.281 0.379 355 215.1 17,270 8.4 
Batch GU238 
siSCRBL 5.260 0.249 268 216.5 59,261 2.5 
siCTGF 5.590 0.291 268 216.5 57,405 2.6 
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3 Fluorescence emission spectra of RHOD-NP  
and FITC-siRNA 
Rhodamine labeled HA- and PEI-NP were diluted to a final concentration of 10 µg/ml with 
PBS, FITC-siRNA was measured in a concentration of 0.02 µM. Fluorescence emission 
spectra from 510 to 700 nm and 570 to 700 nm after excitation at 488 nm or 543 nm 
respectively were recorded using a Perkin Elmer LS55 fluorescence spectrometer (Waltham, 
Massachusetts, United States). The slit width was set to 6 nm and the detector voltage to 
700 V. Measurements were performed in triplicate, running 3 scans with 200 nm/min each. 
  
S 2. Fluorescence emission spectra of FITC-siRNA and RHOD-NP. A) A prominent maximum 
at 525 nm was visible when FITC-siRNA was irradiated with light at 488 nm but no signal was 
detected for RHOD-NP. B) If the NP were excited with 543 nm light, RHOD-NP showed 
strong fluorescence emission at a wavelength of 580 nm.
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Abstract 
 
The targeting of cell surface receptors with ligand-decorated nanoparticles (NPs) is widely 
used to tailor interactions between NPs and cells. Targeting cluster of differentiation (CD) 
44 receptors with hyaluronic acid (HA) functionalized NPs (HA-NPs) is a frequently pursued 
strategy for cancer therapy. We applied the concept of CD44-targeting with HA-NPs to the 
ocular environment. The dependency of cell/NP interactions on the CD44 receptor were 
described using cell lines which differ in their CD44 expression. We compared NPs that were 
either functionalized with HA or the polycation polyethyleneimine (PEI). HA-decorated 
NPs showed a correlation between cell association and CD44-density and, unexpectedly, 
PEI-NPs behaved similarly. Receptor blockade studies confirmed the presence of 
interactions between cell membrane, CD44, and HA or PEI. Further, it was demonstrated 
that HA modification enhanced the colloidal stability of the NPs in vitro. An artificial 
extracellular matrix model was used to characterize the NP mobility and interaction with cells 
in a system closer to natural conditions in the eye. Our studies showed that HA-
functionalization of NPs is an exceptional method to improve the performance of 
nanomaterials. 
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1 Introduction 
Nanoparticles (NPs) are powerful tools for drug and gene delivery. Their high tailorability in 
terms of composition, size and surface functionalization makes it possible to precisely adjust 
their characteristics according to the individual requirements of specific applications. By the 
immobilization of receptor ligands on the surface of NPs, interactions with cells can be 
utilized to target defined organs and tissues [1]. Usually, targeted receptors are not only 
expressed in diseased but also in healthy organs. However, there is often a difference in 
receptor quantity or subtype. These principles apply to the cluster of differentiation (CD) 44 
protein. The protein is ubiquitously expressed in the human body [2,3] and mediates different 
effects including not only physiological cell adhesion and migration but also tumor growth, 
metastasis and angiogenesis depending on the isoform and glycosylation pattern. The 
subtype CD44v6, for example, is upregulated in various types of cancer but not in normal 
tissues and has been recognized as a possible target for cancer therapy [4,5]. 
Functionalization of drugs or NPs with the CD44-ligand hyaluronic acid (HA) provides the 
substances with a targeting moiety to the CD44 receptor, thus directing them to tumor cells 
[4]. Although most scientific effort has been put into CD44-targeting for cancer therapy, 
other fields can also benefit from this approach. In general, the eye is an interesting target 
for NP therapy [6]. As an immune-privileged organ, the risk of undesired immune responses 
is reduced. Furthermore, because local application of the NPs is possible, the off-target 
effects that result from systemic administration are reduced—important since CD44 is 
ubiquitously expressed throughout the body at a certain level.  
We developed HA-decorated layer-by-layer NPs for targeting cells in the trabecular 
meshwork (TM). NPs will be injected into the anterior chamber of the eye and follow the 
physiological aqueous humor flow to the outflow pathways of the TM. There, NPs are 
expected to interact with CD44-receptors on the surface of TM cells and deliver a therapeutic 
nucleic acid. In addition to CD44-targeting, we assume that the functionalization of NPs 
with the polysaccharide HA will enhance their mobility in the dense extracellular matrix, 
which often is a barrier to successful drug delivery. To confirm our hypotheses, we used 
model NPs described in Figure 1. The core is composed of poly(lactide-co-glycolide) (PLGA) 
and stabilized by polycationic polyethyleneimine (PEI). HA was electrostatically attached 
right onto the NP core. First, we studied the impact of HA-coating on the colloidal stability 
of the NPs in a physiologically relevant environment as well as the mobility in an artificial 
extracellular matrix (ECM) since these factors are crucial for successful drug delivery. Then, 
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CD44 receptor expression of immortalized TM cells was determined in comparison with two 
breast cancer cell lines. Finally, the dependency of NP uptake on the CD44 receptor density 
was investigated and receptor blockade studies were conducted.  
  
 
Figure 1. Model NP without siRNA freight. The NP core is made of poly(lactide-co-glycolide) 
(red) which was stabilized with positively charged polyethyleneimine (yellow). Hyaluronic acid 
(blue) was electrostatically assembled on the surface.
2 Material and Methods 
2.1 Materials 
Acid terminated poly(D,L-lactide-co-gylcolide) (PLGA) (lactide/glycolide 50/50) with an 
average molecular weight of 38-54 kDa (PLGA) and branched poly(ethylenimine) 25 kDa 
(PEI) were bought at Sigma-Aldrich Chemical Company (Taufkirchen, Germany). Sucrose, 
microbiological grade, was purchased from Merck (Darmstadt, Germany). Rhodamine B 
endcapped PLGA (50/50, 30 kDa) (RHOD-PLGA) and fluorescein conjugated PLGA 
(FITC-PLGA) (50/50, 20-40 kDA) were obtained from Polyscitech (West Lafayette, 
Indiana, United States). Sodium hyaluronate (HA) (13 kDa, 289 kDa) was bought at Lifecore 
Biomedicals (Chaska, Minnesota, United States). Alexa Fluor® 488 anti-mouse/human 
CD44 antibody (clone IM7) and the corresponding isotype control were purchased at 
BioLegend (Fell, Germany). Sodium azide was bought at Merk (Darmstadt, Germany). 
Bovine serum albumin (lyophilized powder, BioReagent), fetal bovine serum, collagen from 
bovine skin and propidium iodide were bought at Sigma-Aldrich Chemical Company 
(Taufkirchen, Germany). Matrigel was bought at Corning (Wiesbaden, Germany). All cell 
culture reagents were obtained from Gibco (Thermofisher Scientific, Darmstadt, Germany). 
The substances were used without further purification. 
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2.2 Methods 
Preparation of PEI- and HA-NP 
NPs were prepared as described in chapter 3. In brief, 2 mL of a 10 mg/mL solution of 
PLGA in acetonitrile was slowly injected into 8 mL of a continuously stirred PEI solution 
(0.5 % w/v). After evaporation of the organic solvent, NPs were purified by stepwise 
centrifugation and freeze dried using 2 % sucrose as a lyoprotective agent. For the synthesis 
of fluorescent PLGA-NPs, an equal mixture of PLGA and fluorescent PLGA was used. NPs 
were resuspended and purified by stepwise centrifugation. Resulting particles were termed 
PEI-NPs. For HA-functionalized NP, PEI-NPs were dropped into a stirring solution of 
1 mg/mL HA in water. Stirring was continued for approximately 30 minutes and excess 
polysaccharide was removed. 
3D cell culture 
5 mL of a 3 mg/mL collagen I solution was lyophilized with a Christ LMC-2 freeze dryer 
(Osterode am Harz, Germany) under sterile conditions. Powdered collagen I was 
resuspended in 1.6 mL of 0.1 N HCl on ice. After addition of 200 µL 10x EMEM cell culture 
media, the pH was adjusted to pH 7.4 using 1 N NaOH. The final volume was set to 2 mL 
with water. 200 µL of this 7.5 mg/mL collagen I solution was mixed with 50 µL PEI- or HA-
NPs and 80,000 HeLa cells in 50 µL DMEM containing 10 % serum. The final 
concentrations were 5 mg/mL of collagen I and 80 µg/mL of NPs. Cells were incubated at 
37°C for 48 h. When the gelation was completed after a few hours, 200 µL medium was 
added on top of the gel to avoid desiccation. If cells were embedded in Matrigel, the 
procedure was the same. However, Matrigel was used as supplied without freeze-drying and 
resuspension. Confocal images were taken on a Zeiss confocal laser scanning microscope 
(Zeiss Axiovert 200 coupled to a LSM 510 META, Oberkochen, Germany). 
CD44-expression 
MDA-MB-231, hTM, HTM-N and MCF-7 cells were grown in 75 cm² cell culture flasks in 
normal growth medium (McCoy’s, Ham’s F12, DMEM + pyruvate or EMEM + pyruvate 
with 10 % serum). When they reached 70% confluency, cells were washed with PBS and 
harvested by trypsinization. Cells were stained with an anti-CD44 antibody at a concentration 
of 0.05 µg / 100,000 cells in FACS-buffer (PBS containing 1 % BSA and 0.1 % sodium 
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azide) for 30 min in the dark on ice. Cells were washed twice and resuspended in FACS 
buffer. Live-dead staining with propidium iodide was performed directly before analysis on 
a FACS Calibur (BD GmbH, Heidelberg, Germany). 
Uptake and receptor blockade, colloidal stability 
To investigate the interactions of cells with NPs, cells were seeded in their usual medium and 
grown overnight. NP samples in Leibovitz with respective amounts serum were prepared 
and left for 1 h at room temperature. Cells were washed with PBS once and NP samples 
were added for 4 hours. For receptor blocking studies, the cells were treated with 10 mg/mL 
HA 13 kDa or HA 289 kDa in the respective media for 1 h before adding the particles. 
Flow cytometry 
Cells analyzed by flow cytometry were handled in 24-well plates. After treatment with NPs, 
cells were washed with PBS once, harvested by trypsinization, washed again and resuspended 
in 100 µL PBS. 0.25 µL of a 1 mg/mL propidium iodide solution in PBS was added to the 
samples directly before measurement on a FACS Calibur (Becton, Dickinson and Company, 
Heidelberg, Germany). Flowing software was used for analysis. 
Confocal microscopy 
For imaging, cells were kept in 8-well ibidi chamber slides. When the treatment period with 
NPs was finished, cells were washed with PBS once and supplemented with Leibovitz 
containing 10 % serum. Images were taken on a Zeiss confocal laser scanning microscope. 
Statistical analysis 
Sigma Plot 12.0 software was used for statistical analysis. For the evaluation of CD44-
expression and cell associated fluorescence after receptor blockade, a one-way ANOVA was 
conducted followed by a Holm-Sidak-test (Figure 4 and Figure 6). Figure 5 was analyzed by 
pairwise comparison of CAF-values obtained for cells treated with HA- or PEI-NP. 
.
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3 Results and Discussion 
3.1 Colloidal stability in cell culture 
Figure 2 summarizes the results of a microscopic study of the NP stability in the presence of 
cells. In a serum free environment (far left), both NP types behaved fairly similarly: NPs were 
not stable in high osmotic growth media and formed aggregates. 0.5 % serum was sufficient 
to reduce the aggregation tendency of HA-NPs while 0.75 % was able to completely prevent 
aggregation (top). PEI-NPs also showed a slight improvement in colloidal stability by the 
addition of serum, but even 1 % was not enough for complete stabilization. The highly 
cationic surface of PEI-NPs immobilized a large amount of proteins. Some proteins might 
even be attracted by two or more NPs and formed a bridge between them. With increasing 
serum concentration, the protein shells of the NPs become thicker and aggregation is 
reduced by steric hindrance. 
 
Figure 2: Colloidal stability of NPs in cell culture. HTM-N cells were treated with 10 µg/mL 
HA- or PEI-NPs and increasing serum concentrations. HA-NPs showed higher colloidal 
stability beginning at lower serum concentrations. The scale bar represents 50 µm. 
We intended to inject the NPs into the anterior chamber of the eye which is filled with 
aqueous humor, a fluid low in protein concentration (Tripathi et al. determined the total 
protein content to be 12.4 mg/100 mL [7]). Hence, a high colloidal stability at low protein 
concentrations is necessary to guarantee a therapeutic effect. This is possible by coating the 
NPs with HA since few proteins attach to a HA coated surface. This strategy is currently 
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used in contact lenses, for example, to improve biocompatibility, comfort and to prevent 
undesirable immune responses [8].  
3.2 Nanoparticles in 3D cell culture 
As illustrated, the functionalization of NPs with HA reduced the formation of aggregates 
and the attachment of substances like proteins onto the particles. These characteristics are 
essential to ensure high NP mobility in macromolecular systems like the ECM. We 
determined the performance of both NP types (HA- and PEI-coated) in terms of ECM 
penetration and cellular uptake in 3D cell culture. Two different ECM models were used. 
The first was a collagen I model in which loose networks of long fibers form a neutrally 
charged gel with a pore size of approximately 0.47 µm [9]. The second system was Matrigel, 
which is much denser. This basement membrane matrix forms pores of only 0.14 µm and is 
highly negatively charged. Both NPs were able to penetrate the gels and distributed into 
embedded cells to similar extents (Figure 3) despite the fact that the hydrodynamic diameter 
of the NPs (244 nm for PEI-NPs, 226 nm for HA-NPs) was higher than the pore size of 
Matrigel. Because pore size represents an average, a distribution of mesh sizes exists. Here, 
the small proportion of larger pores was sufficient for unrestricted diffusion of the NPs 
through the EMC models. PEI-NPs formed some aggregates within the models whereas 
HA-NP showed superior stability (see Figure 3, aggregates marked with an asterisk). 
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Figure 3. NP mobility in 3D cell culture. HeLa cells were embedded in an artificial extracellular 
matrix and mixed with rhodamine-labeled HA- or PEI-NPs. Left side: collagen I, right side: 
Matrigel. Top: HA-NPs, bottom: PEI-NPs. The scale bar represents 20 µm. 
A high mobility of HA coated polyplexes in bovine vitreous was previously reported by 
Martens et al. [10]. Even if the size was slightly increased, NPs maintained their higher 
mobility in comparison to unfunctionalized complexes. However, one should consider the 
different pore sizes of the vitreous (0.55 µm) compared to collagen I or Matrigel [11]. Xu 
and Boylan investigated the mobility of cationic, anionic and neutrally charged NPs in bovine 
vitreous by multiple particle tracking [11]. Unimpeded diffusion was reported for uncharged, 
PEGylated NPs up to a size of 500 nm and for negatively charged NPs smaller than 200 nm. 
Larger NPs, higher concentrations or positively charged, amine modified NPs were 
completely immobile. Xu attributed the results to electrostatic interactions of cationic NPs 
with negatively charged fibers in the vitreous. Clearly, gel or matrix composition is important 
when evaluating the mobility of NPs and one should adjust in vitro models as closely as 
possible to natural conditions. 
3.3 CD44 receptor expression  
The density of CD44 receptors of primary trabecular meshwork cells and three different cell 
lines was determined by immunostaining and flow cytometry (Figure 4). The human breast 
cancer cell line MDA-MB-231 showed a very high CD44 receptor expression whereas the 
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presence of the membrane protein was negligible for MCF-7 cells. These results supported 
the findings of various groups with respect to CD44-receptor expression of cancer cells [12–
14]. Primary human TM cells (hTM) had a medium CD44 density compared to the cell lines. 
Therefore, CD44 targeting is a promising approach for the specific delivery of NPs to TM 
cells. As CD44 expression of hTM and immortalized human trabecular meshwork cells 
(HTM-N) was similar, immortalized HTM-N were used for further studies.  
 
Figure 4. CD44-expression of different cell lines determined by immunostaining and flow 
cytometry. Shown is the geometric mean fluorescence intensity related to the isotype control 
averaged over three replicate measurements. 
3.4 CD44-exression and nanoparticle uptake 
The impact of cellular CD44 expression on the uptake of NPs with and without HA 
functionalization was investigated by flow cytometry. As it was not possible to distinguish 
between NPs that were taken up by the cell and NPs only sticking to the surface of the cell, 
the term “cell associated fluorescence” (CAF) was used to describe both effects. Figure 5A 
represents the results of the flow cytometry analysis after treating the cells for four hours 
with NPs without the addition of serum. The CAF was highest for MDA-MB-231 cells and 
decreased over the HTM-N to MCF-7 cells, which was expected based on the CD44 density 
as shown in Figure 4. Surprisingly, not only did NPs decorated with the CD44 ligand HA 
show a correlation between the CAF and receptor density but also PEI-NPs. In literature, 
no information about PEI-CD44 interactions was found but unspecific interactions with the 
cell membrane are frequently reported [15–17]. As expected, only the CD44-expressing cell 
lines MDA-MB-231 and HTM-N showed significantly higher CAF values when treated with 
HA-NPs compared to the treatment with PEI-NPs. Both NP types accumulated with MCF-
7 cells to a similar extent.  
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Figure 5. Cell associated fluorescence of cells treated with NPs (c = 120 µg/mL). Shown is the 
geometric mean fluorescence intensity related to untreated cells averaged over three replicate 
measurements. p = 0.05. A) without serum. B) with 5 % serum. Blank bars: HA-NPs, striped 
bars: PEI-NPs.  
In general, the CAF values were lower with the supplementation of serum compared to the 
setup without (Figure 5B). This is due to the adsorption of serum proteins onto the surface 
of the NPs [18]. This protein corona stabilizes the NPs (as described before) but often also 
reduces the interaction of the NPs with the cells. Consequently, the uptake rates or 
therapeutic effects are reduced [19,20]. Despite the low CAF values in general, a slight but 
statistically significant difference was observable between the treatment with HA- and PEI-
NPs for MDA-MB-231 cells. The receptor density of these cells appeared high enough to 
see this gap as no difference was detectable for HTM-N or MCF-7 cells which exhibit lower 
or no CD44 expression. Low CAF values of MCF-7 cells were attributable to the absence of 
CD44 expression and the growth habit of the cells. Because they form tight cell clusters, the 
surface area accessible for NP interactions is lower compared to more individually growing 
cells.  
As expected, there was a correlation between CD44 density and the extent of interactions 
between cells and HA-NPs. Unexpectedly, this relation was also visible for PEI-NPs. To 
demonstrate the participation of CD44 in HA-NP binding and to investigate the influence 
of CD44 on the interaction with PEI-NPs, receptor blockade studies were conducted. 
Because an increase in binding strength has been reported when the molecular weight of the 
ligand increased [21], HA of different molecular weights was used to block the receptor.  
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Figure 6. Receptor Blockade. HTM-N cells were treated with HA of different molecular weights 
prior NP uptake. Serum concentration was 0.35 %; NP were used in a concentration of 
40 µg/mL. Shown is the geometric mean fluorescence intensity related to the control averaged 
over three replicate measurements Blank: HA-NPs, striped: PEI-NPs. 
According to expectations, the CAF of HA-NPs was significantly reduced when CD44 
receptors were blocked with HA (Figure 6). However, this decrease was also detectable for 
PEI-NPs. Interestingly, high molecular weight HA (289 kDa) had a stronger effect for both 
particle species. Long polysaccharide chains show an increased avidity, as various receptors 
are spanned at the same time [21,22]. Therefore, the replacement of high molecular weight 
HA by HA-NPs is less likely compared with smaller fragments. However, this does not 
explain the results gained for the PEI-NPs. There must be an interaction between PEI and 
the CD44 receptor.  
To explain the behavior of the PEI nanoparticles, we first looked at microscopic patterns 
(Figure 7). In cell culture, PEI-NPs formed large aggregates which were even visible on 
brightfield images. These aggregates strongly stuck to the cell membrane at least in part due 
to electrostatic interactions between positively charged NPs and the negatively charged 
membrane. The addition of 13 kDa HA intensified this effect. The anionic polysaccharide 
HA adsorbed onto the surface of the positively charged NPs, gluing them together. These 
aggregates were removed during sample preparation for flow cytometry as CAF values 
determined by this method were lower with the addition of HA 13 kDa (Figure 6). 
Interestingly, less NP aggregates were detectable in the presence of high molecular weight 
HA. One explanation is that the macromolecule was tightly bound to the CD44 receptors 
and sealed the cellular surface. PEI-NPs – with a neutralized charge due to HA adsorption– 
were not able to bind to the membrane and could easily be removed during the washing 
procedure.
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Figure 7. Receptor Blockade. CD44 receptors on HTM-N cells were blocked by HA of different 
molecular weights prior to treatment with NPs. 0.35 % serum was added to the cell culture 
medium. NP concentration was 40 µg/mL. Left: HA-NPs, right: PEI-NPs. The scale bar 
represents 20 µm. 
Significant aggregation was detected for HA-NPs as well (Figure 7). The addition of 13 kDa 
HA, however, reduced the formation of aggregates considerably. As the negatively charged 
polysaccharide was bound to receptors on the cell membrane, interactions of HA-NPs with 
cells were reduced by electrostatic repulsion between the cell surface and NPs. Receptor 
blockage was even more pronounced when high molecular weight HA was used and fewer 
interactions between cell membrane and NPs were formed. 
4 Conclusion 
As demonstrated, the functionalization of NPs with HA is a promising approach to 
specifically direct NPs to cells in the TM. The coating of NPs with HA enhanced their 
colloidal stability in a low protein environment which is advantageous for therapeutic use in 
the eye where the NPs will be injected into the anterior chamber and follow the physiological 
outflow pathways to their target cells in the TM. NPs with a high colloidal stability will follow 
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this flow easily. Large aggregates, however, might get stuck in the sieve-like structure of the 
upper TM and, in the worst case, even clog the outflow pathways. Surprisingly, both NP 
types tested here (HA- and PEI-NPs), showed a correlation between cell association and 
CD44 expression. Receptor blockade studies confirmed the participation of CD44 in this 
interaction as fewer NPs were associated with cells when the receptor was occupied. In 
summary, HA functionalized NPs are expected to be ideally suited as drug delivery system 
for targeting of the TM.
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Abstract 
 
RNA interference is a biological process of specific post-transcriptional gene silencing by 
short double-stranded RNA. Gene silencing by small interfering RNA (siRNA) offers a great 
opportunity for the treatment of diseases resulting from protein overexpression. However, 
successful delivery of the molecule remains an issue as siRNA is highly unstable and cannot 
cross cell membranes. Nanoparticulate delivery systems are promising solutions for siRNA 
delivery that overcome these obstacles. We developed layer-by-layer nanoparticles (NPs) 
functionalized with a moiety to target cluster of differentiation 44 receptors on trabecular 
meshwork cells and tested them for their ability to serve as delivery systems for siRNA. To 
investigate the impact of the NP composition, an in vitro assay, which involves the silencing 
of artificially introduced green fluorescent protein in immortalized trabecular meshwork 
cells, was established. To determine their fate, the intracellular distribution of the NPs and 
their colocalization with defined intracellular compartments such as endosomes and 
lysosomes was studied. Finally, the possibility of NP exocytosis from the cells was addressed. 
 
  
Introduction 
131 
1 Introduction 
In 2006, the Nobel Prize in Physiology or Medicine was awarded to Andrew Z. Fire and 
Craig C. Mello for their discovery of RNA interference (RNAi) gene silencing by double 
stranded RNA [1]. This fundamental mechanism regulates the expression of proteins and is 
of utmost importance for the protection against viral infections, genome stabilization and 
the development of organisms [2–4]. Experimentally, small interfering RNA (siRNA) is used 
to specifically impede gene expression and tremendous effort has been made to transfer this 
method into clinics. However, no product is available on the market yet and relatively few 
are in clinical development [5–7]. Possibly the most promising product is patisiran, an RNAi 
therapeutic developed for familial amyloidotic polyneuropathy. Only recently, in September 
2017, the manufacturer Alnylam published a press release concerning the striking results of 
a phase III clinical trial (APOLLO) and a report indicating that all of the primary and 
secondary end points were met. According to their chief executive officer, these were the 
first ever positive phase III clinical trial results for an RNAi therapeutic [8].  
The primary reason for the low number of RNAi therapeutics might be the lack of a suitable 
delivery system. Nanoparticles (NPs) of different compositions and materials have been 
heavily investigated as they combine major properties which could be used to create a 
successful siRNA delivery system. Interestingly, Alnylam – the manufacturer of patisiran - 
used lipid NPs. NPs can protect siRNA from degradation by omnipresent nucleases which 
is of utmost importance for successful therapy. Further, a targeted delivery to certain organs 
or tissues is possible by functionalizing the NPs in an appropriate way [9]. But once the 
nanoparticulate carriers reach the target cells, other bottlenecks must be overcome until a 
therapeutic effect is observed [10–12] (Figure 1, left). First, NPs must be taken up by the cell 
in an adequate amount. Once endocytosed, NPs are commonly trapped within endocytic 
vesicles where they are destined to undergo digestion and degradation by endolysosomal 
enzymes. Therefore, an early escape from the endosomes is necessary. In addition, the 
delivery system must disassemble and release the siRNA into the cytosol to enable its 
incorporation in the “gene silencing machinery”.  
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Figure 1. NPs are taken up into the cell via endocytosis and are trapped within early or late 
endosomes. NPs can either escape into the cytosol where their siRNA freight is released or they 
are processed to further intracellular compartments like the lysosomes or the trans-Golgi 
network. There, the vesicular load is degraded or transported to the extracellular space. Vesicular 
Rab proteins follow a characteristic distribution pattern. Rab 5 is located in the membrane of 
early endosomes whereas Rab 7 and Rab 9 are anchored to late endosomes. 
Our concept is to use layer-by-layer NPs (LbL-NPs) for the delivery of siRNA to cells in the 
trabecular meshwork (TM) of glaucoma patients. The NPs consist of a poly(lactide-co-
glycolide) (PLGA) core and electrostatically adsorbed layers of negatively charged siRNA 
and polycations like polyethyleneimine (PEI) or poly-L-arginine (PLArg) (Figure 2). Both 
polymers are well established transfection agents, have a high endosomolytic activity and 
form complexes with siRNA [13–16]. The anionic polysaccharide hyaluronic acid (HA) was 
chosen as targeting moiety and assembled onto the particles to form the final, outermost 
layer. As HA is the main ligand of cluster of differentiation (CD) 44, a receptor on the cell 
surface, improvement of cellular uptake due to interactions of the NPs with CD44 receptors 
is possible [17–19]. Interestingly, elevated levels of CD44 were found in the TM of patients 
suffering from glaucoma [chapter 6] and a high NP uptake rate and therapeutic success is 
expected only in this patient group. 
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Figure 2. Structure of a LbL-NP. siRNA (green) is electrostatically attached onto a cationic 
PLGA core (red-yellow) and covered by polycationic PEI or PLArg respectively (yellow). The 
functionalization with HA (blue) stabilizes the particle and favors targeting and uptake of the 
NPs.  
To investigate the suitability of our NPs for the delivery of siRNA, we generated a TM cell 
line (HTM-N) for the in vitro gene silencing of artificially introduced green fluorescent protein 
(GFP). After optimizing transfection conditions, a suitable siRNA sequence directed against 
GFP was chosen and the gene silencing effect of NPs with different layering materials was 
studied. Although NP uptake was high, no gene silencing was detectable. Therefore, the 
intracellular distribution of the particles and colocalization with endosomes and lysosomes 
was visualized by confocal microscopy. Finally, we found that a considerable fraction of NPs 
was released from the cells after uptake. Based upon these results, consequential challenges 
and possibilities are discussed. 
2 Materials and Methods 
2.1 Materials 
If not otherwise stated all cell culture materials, reagents and chemicals were purchased from 
ThermoFisher Scientific (Darmstadt, Germany). Acid terminated poly(D, L-lactide-co-
gylcolide) (PLGA) (lactide/glycolide 50/50) with an average molecular weight of 38-54 kDa 
and branched poly(ethylenimine) 25 kDa (PEI) were purchased from Sigma-Aldrich 
Chemical Company (Taufkirchen, Germany). Sucrose, microbiological grade, was bought 
from Merck (Darmstadt, Germany). Rhodamine B endcapped PLGA (lactide/ 
glycolide 50/50, average molecular weight 30 kDa) (RHOD-PLGA) was obtained from 
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Polyscitech (West Lafayette, Indiana, United States). siGFP1 (5’- AACUAUAAUUCUCAC 
AAUdTdT -3’), siGFP2 (5’- GGUGAAGGAGAUGCAACUUAUdTdT -3’), siGFP3 
(5’- GAAGGUUAUGUUCAGGAGAGGdTdT -3’), siGFP4 (5’- GAAGGUGAUACA 
CUGGUUAACdTdT -3’) and siSCRBL (5’- UUCUCCGAACGUGUCACGUdTdT -3’) 
were designed with the siRNA wizard v3.1 online application from Invivogen and 
synthesized by Eurofins Genomics (Ebersberg, Germany). Sodium hyaluronate (HA) 
(13 kDa) was purchased from Lifecore Biomedicals (Chaska, Minnesota, United States). 
Hygromycin B was bought at PAN Biotech (Aidenbach, Germany). Thiazolyl blue 
tetrazolium bromide was obtained by Applichem (Darmstadt, Germany). pMONO-hygro-
GFP was bought at Invivogen (Toulouse, France). Plasmides for YFP-tagged fusion proteins 
of Rab5, 7 and 9 were a kind gift from Massachusetts Institute of Technology (Cambridge, 
Massachusetts, United States). All chemicals were used without further purification unless 
otherwise mentioned. 
2.2 Methods 
Hygromycin B Concentration 
HTM-N cells were passaged onto 96-well plates at a density of 3,000 cells per well and grown 
for 24 h in DMEM+ supplemented with 10 % serum. Fresh medium with varying amounts 
of Hygromycin B was added for 72 h. Then, bright field pictures were taken and an MTT 
assay was performed according to the method established in our group. Briefly, cells were 
incubated with 200 µl of 0.625 mg/mL thiazolyl blue tetrazolium bromide reagent in 
DMEM+ with 10 % serum for four hours and lysed with a solution of 10 % sodium dodecyl 
sulfate (SDS) in PBS. Absorbance was read at 570 nm using a microplate reader (FLUOStar 
Omega, BMG Labtech, Ortenberg, Germany). Measured values were corrected by 
subtracting background absorbance at 690 nm and related to untreated cells. 
Generation of GFP-positive cell line 
HTM-N cells at passage 60 were grown in 24-well plates for 24 h. Lipofectamine 3000 
transfection reagent was used to transfect HTM-N cells with pMONO-hygro-GFP. 
Lipoplexes were produced according to manufacturer instructions. Briefly, 1 µg plasmid and 
1 µL P3000 of the transfection kit were diluted to 25 µL with OptiMEM. 1.5 µL 
Lipofectamine 3000 were diluted to 25 µL with OptiMEM separately. Complexes were 
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formed by mixing the DNA with the Lipofectamine solution. Complexes were added to the 
cell culture medium for 8 h. Then, the media was changed to DEMEM+ with 10 % serum 
and 400 µg/mL hygromycin B. Media was replaced daily. Individual cells with bright 
fluorescence were picked, transferred to a 96-well plate and cultivated to form a population. 
Successfully transfected cells were termed HTM-N_GFP+. 
Optimization of gene silencing conditions 
For the optimization of the gene silencing conditions, Lipofectamine RNAiMAX reagent 
was used. Lipoplexes with siRNA were prepared according to manufacturer’s instructions. 
In brief, siRNA and Lipofectamine were diluted separately to one tenth of the intended final 
volume. The polymer was mixed with siRNA by pipetting up and down and left 15 min at 
room temperature to allow complete complex formation. Afterwards, the mixture was 
further diluted with OptiMEM and used immediately for transfection. 6 h later, lipoplexes 
were removed, cells were washed with PBS once and fresh media (DMEM+ with 10 % serum 
and 400 µg/mL hygromycin B) was added for 24 to 72 h. GFP-fluorescence was quantified 
by flow cytometry. Propidium iodide staining was conducted to exclude dead cells from data 
analysis. 
Flow cytometry 
For flow cytometry, HTM-N_GFP+ were handled in 24-well plates. Cells were washed with 
PBS once, harvested by trypsinization, washed again and resuspended in PBS immediately 
before measurements on a FACS Calibur (Becton, Dickinson and Company, Germany). 
Flowing software was used to perform the analysis. 
Layer-by-layer NPs (LbL-NPs) 
LbL-NPs were prepared as described previously in chapter III. Briefly, PLGA-NP were 
prepared by slowly dropping a 10 mg/mL solution of PLGA in acetonitrile into an aqueous 
0.5 % PEI solution. For the preparation of fluorescently tagged NPs, a mixture of PLGA 
and RHOD-PLGA (PLGA/RHOD-PLGA 50/50) or FITC-PEI was used. The NPs were 
stirred for 4 to 5 h to allow complete evaporation of the organic solvent. Purification of NPs 
was conducted by repeated centrifugation and resuspension steps. NPs were lyophilized with 
sucrose as a protective agent. Powdered NPs were resuspended in water to 1 mg/mL, 
purified from sucrose and coated with siRNA, PEI and HA in a LbL-approach. The 
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concentration of the polymers during coating was 1 mg/mL in water or 4 µM in 10 mM 
NaCl for the polymers and siRNA respectively. Hydrodynamic size and zeta potential were 
determined on a Zetasizer Nano ZS (Malvern Instruments, Herrenberg, Germany). For all 
measurements, 173° backward scatter in the general-purpose mode with automatic 
measurement position and attenuator selection at 25 °C was applied. Z-Average values and 
zeta potentials of the NPs lied within following intervals: HA-terminated NP [189;231] nm 
and [-25;-16] mV; PEI-terminated NP [200;260] nm and [37;52] mV; PLArg-terminated NP 
[216;217] nm and [38;39] mV. Concentration was determined in relation to the fluorescence 
intensity of a sample with known concentration on a microplate reader with 544 nm or 
480 nm (excitation) and 590 nm or 520 nm (emission) filter sets. NPs were termed according 
to their final polymer layer. 
Gene silencing with LbL-NP 
HTM-N_GFP+ cells were seeded in 24-well plates and grown overnight. NPs were mixed 
with Leibovitz medium and serum in a final concentration of 1 or 0.35 % for 1 h. Then, cells 
were washed and the samples were added for 6 or 4 h respectively. After the incubation 
period, NPs were aspirated, cells were washed once with PBS and fresh medium (DMEM+ 
with 10 % serum and 400 µg/mL hygromycin) was added. Cells were grown at 37 °C and 
5 % CO2 for 72 h. Microscopic images were taken directly after finishing the treatment 
period with NPs and again after the 72 h incubation interval on a Zeiss confocal laser scanning 
microscope (Zeiss Axiovert 200 coupled to a LSM 510 META, Zeiss, Oberkochen, Germany). 
Cells were prepared for flow cytometry as described previously but without propidium iodide 
staining. 
NP-Uptake 
For all uptake experiments (endolysosomal pathway, exocytosis), NPs without siRNA freight 
were mixed with Leibovitz containing 0.35 % serum to a final concentration of 80 µg/mL 
and incubated at room temperature for one hour. Then, cells where washed with PBS once 
and the samples where added. After 4 hours, samples where aspirated and cells where washed 
at least once with PBS and supplemented with medium containing 10 % serum (Leibovitz 
or DMEM+). 
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Endolysosomal pathway 
For the visualization of Rab-proteins, HTM-N cells were passaged to 8-well ibidi chamber 
slides at a density of 40,000 cells per well and grown for 24 h. Lipofectamine 2000 was used 
to transiently transfect the cells with YFP- or GFP-tagged fusion proteins of Rab 5, 7 and 9. 
Briefly, 0.3 µg pDNA and 1 µL Lipofectamine 2000 were diluted separately with serum free 
DMEM+ to 50 µL each and then mixed by pipetting. 20 min later, complexes were further 
diluted with 100 µL DMEM+ and added to the cells after washing them with PBS once. After 
4 h, complexes were removed and cells were grown overnight. This treatment was not 
conducted when staining the lysosomes. Here, HTM-N cells were seeded at a density of 
20,000 cells per well in 8-well ibidi glass bottom chamber slides only one day before the 
experiment. The NP uptake was performed as described above. In the case of lysosomal 
staining, 60 nM Lysotracker Deep Red in PBS was added to the cells one hour before 
finishing the uptake. Confocal images and z-stacks were taken on a Zeiss confocal laser 
scanning microscope. 
Exocytosis 
HTM-N cells were seeded in a 48-well plate at a density of 25,000 cells per well and grown 
overnight. The NP uptake was performed as described above. After NP treatment, cells were 
washed thoroughly with PBS twice and with serum containing medium once. Cells were 
provided with fresh media (without phenol red) and media samples were taken at defined 
time points. Fluorescence intensity of the media was determined on a microplate reader with 
544 nm (excitation) and 590 nm (emission) filter sets and related to PEI-NPs of known 
concentration. Cell culture medium of cells without NP-treatment was used for background 
correction.  
Two particle assay 
The endo- and subsequent exocytosis was investigated according to El-Dakdouki et al [20] 
with slight modifications. HTM-N cells were passaged onto 24-well plates at a density of 
80,000 cells per well and grown overnight. Cells were treated either with RHOD or FITC-
tagged PEI- or HA-NP as described above. 0.35 % serum Leibovitz served as a control. 
After a period of 4 hours, cells were washed with PBS twice, harvested by trypsinization and 
washed again with serum containing media. Differently treated cells were mixed in a ratio of 
1+1 (RHOD-HA + FITC-HA, RHOD-PEI + FITC-PEI, RHOD-HA + control, FITC-
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HA + control, RHOD-PEI + control, FITC-PEI + control) and transferred to an 8-well 
ibidi chamber slide at a density of 20,000 cells per well. Confocal images were taken on a 
Zeiss confocal laser scanning microscope after one, two and three days. Media was changed 
to 10% serum Leibovitz for imaging and back to serum containing DMEM+ for cultivation. 
The number of cells with FITC- and/or RHOD-fluorescent NPs was counted manually on 
10 images per sample and time point.
3 Results and Discussion 
3.1 Establishment of a GFP-expressing trabecular meshwork cell line 
The appropriate concentration of antibiotic was determined to guarantee satisfactory 
selection of immortalized human trabecular meshwork cells (HTM-N) that were successfully 
transfected with the plasmid pMONO-hygro-GFP, encoding the green fluorescent protein 
(GFP). The viability of HTM-N cells that were treated with increasing amounts of the 
selection antibiotic hygromycin B was measured by an MTT-assay (Figure 3). A 
concentration of 400 µg/mL was sufficient to reliably kill untransfected HTM-N cells and 
guaranteed satisfactory selection of hygromycin resistant clones. Higher concentrations were 
not beneficial and would possibly even damage cells that were resistant to hygromycin. The 
results of the MTT-assay were verified by brightfield microscopy (pictures in supporting 
information).  
 
Figure 3. Viability of HTM-N cells treated with increasing amounts of hygromycin for 72 h 
determined by an MTT assay. A hygromycin concentration of 400 µg/mL was considered 
sufficiently high enough for the selection of transfected clones. 
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Four clones of GFP producing trabecular meshwork cells (HTM-N_GFP+) were treated 
with complexes of siRNA and RNAiMAX to identify the most sensitive one. RNAiMAX 
was used as it is a common transfection reagent and has guaranteed high transfection rates 
[21]. GFP-expression could be reduced in all clones but clone 1 showed the greatest response 
with a decrease in fluorescence intensity (FI) of approximately 70 % (Figure 4A). Further 
improvement of transfection efficiency was achieved by varying the amounts of siRNA and 
RNAiMAX (Figure 4B). Complexes with 0.6 µL or 1.32 µL of transfection reagent showed 
superior performance as the GFP fluorescence was reduced to 25 % of the initial value. 
However, differences in the effectivity of these complexes were not statistically significant 
and complexes with lower siRNA and RNAiMAX amounts were regarded as most suitable 
due to their lower toxicity. Because of the long half-life of GFP [22], it was necessary to find 
the optimal time point for analysis. A GFP knockdown by nearly 80 % was observed for 
HTM-N_GFP+ clone 1 when analyzing the cells 72 h after transfection (Figure 4C). 
Complex composition did not have any influence. With the conditions for optimal 
transfection identified, the gene silencing potential of four siRNA-candidates with different 
targeting sequences within the GFP gene was determined. Figure 4D demonstrates the 
superior results of siGFP 2 and 4 compared to the other candidates. Although there was not 
a significant difference, siGFP 2 was applied for further gene silencing studies in HTM-
N_GFP+. 
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Figure 4. Generation of a suitable cell line for gene silencing. HTM-N cells stably expressing 
GFP (HTM-N_GFP+) were produced by transfection with pMONO-hygro-GFP plasmid and 
Lipofectamine 3000. The selection of clones was performed by the addition of 400 µg/mL 
hygromycin to the cell culture media. A) Four promising cell clones were tested for their 
sensitivity to lipoplexes containing 100 nM siGFP1 and RNAiMAX. B) The gene silencing 
efficiency of lipoplexes of different composition was investigated. siGFP 1 was used in 
concentrations of 50 and 100 nM and a volume of RNAiMAX varying between 0.1 to 1.32 µL. 
C) The gene silencing performance of lipoplexes (50 or 100 nM siGFP3 and 0.6 or 1.32 µL 
RNAiMAX) depended on the incubation time after transfection. D) The GFP knock down in 
HTM-N_GFP+ after optimized treatment (50 nM siRNA, 0.6 µL RNAiMAX, 72 h incubation) 
with different siRNA sequences is demonstrated. Shown is the mean +/- standard deviation of 
three replicate measurements. 
3.2 LbL-NP for GFP-silencing in a human trabecular meshwork cell line 
The suitability of LbL-NPs for siRNA delivery to HTM-N_GFP+ was determined. In a first 
attempt, NPs with an intermediate layer of PEI were investigated. Figure 5 summarizes the 
composition of the NPs (bottom) and the results of this study (top).  
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Figure 5. GFP silencing in HTM-N_GFP+ with LbL-NPs. Particles with and without HA 
functionalization were tested. Fluorescence intensity of cells 72 h after treatment with 20 or 
40 µg/mL of NPs for 6 h in the presence of 1 % serum is shown. Lipoplexes containing 50 nM 
siRNA served as a control. Cellular fluorescence was detected by flow cytometry and related to 
cells that were treated with an off-target siRNA. Shown is the mean +/- standard deviation of 
three replicate measurements. 
Lipoplexes with RNAiMAX, which were used as a positive control, reduced the FI of GFP 
to approximately 25 % of the initial value which was in accordance with previous results 
gained during optimization of the assay. However, the NPs were not able to significantly 
reduce GFP expression. Although a low molarity of siRNA is sufficient to effectively inhibit 
the synthesis of a protein [23], NP concentrations of 20 and 40 µg/mL might have been too 
low to observe any effect. However, toxicity increased considerably when the particle 
concentration was increased to 80 µg/mL (not shown).  
One explanation for the results is that siRNA release from the particle is insufficient as strong 
electrostatic forces between PEI and siRNA might prevent the disassembly of the polymer 
layers. The phenomenon of inadequate nucleic acid release from NPs is well documented, 
reflected by the high number of publications targeting this issue [24–27]. Common strategies 
to improve the intracellular disassembly of nanoparticles or polyplexes are the incorporation 
of charge reversal polyelectrolytes, disulfide linkers, ATP-sensitive moieties or substances 
that serve as an enzymatic substrate [27]. Common to all of them is the exploitation of 
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differences in the extra- and intracellular milieu in terms of pH, reductive potential, ATP 
content or enzymatic composition.  
To confirm the hypothesis that siRNA was insufficiently released, PLArg was introduced 
into the NPs as an alternative polycationic compound to weaken electrostatic interactions 
between the siRNA and protecting layers and to enhance the nucleic acid release from the 
particles [28,29]. Based upon the protonation state of the polymers under physiological 
conditions, the calculated distance between the cationic charges of PLArg is approximately 
1.65 nm. Compared to the 0.5 nm of PEI, a reduction in electrostatic interactions and an 
improved siRNA release was expected (see supporting information for calculations). In 
addition to the lower charge density, PLArg confers further benefits: toxicity is reduced 
compared to PEI [16,30] and – as it is a peptide – it is biodegradable [31]. This explains its 
frequent use as transfection reagent for DNA or RNA. However, using PLArg as an 
intermediate layer in the LbL-NPs in our studies did not improve the GFP gene silencing 
efficiency (Figure 6). None of the four investigated NP types (PEI or PLArg, with or without 
HA-functionalization) could overcome all obstacles on their way to successfully deliver 
siRNA to the cytosol. Besides insufficient siRNA release from the particles, there must be 
other problems like endosomal entrapment impeding the desired effect. 
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Figure 6. GFP-silencing in HTM-N_GFP+ with LbL-NP. Particles with and without HA 
functionalization and an intermediate layer of PEI (yellow) or PLArg (violet) were tested. 
Fluorescence intensity of HTM-N_GFP+ cells 72 h after treatment with 20, 40 or 80 µg/mL 
NPs for 5 h in the presence of 0.35 % serum is shown. Lipoplexes containing 50 nM siRNA 
served as a control. Cellular fluorescence was detected by flow cytometry and related to cells that 
were treated with an off-target siRNA. Shown is the mean +/- standard deviation of three 
replicate measurements. 
3.3 Intracellular distribution of LbL-NPs 
To investigate NP uptake and intracellular distribution, HTM-N cells were transfected with 
a YFP-tagged Rab-protein. Rab-proteins are small vesicular GTPases that are involved in 
vesicle formation, movement and targeting [32,33]. Different types of Rab-proteins can be 
found in distinct vesicles of the endolysosomal pathway. The distribution of common Rab-
proteins that are involved in relevant steps of endocytosis is summarized in Figure 1. The 
early endosome associated Rab 5 mediates endocytosis, endosomal fusion and maturation. 
Rab 7 and Rab 9 are located in the membrane of late endosomes. Rab 7 promotes the 
maturation of late endosomes and their fusion with lysosomes. Rab 9, however, marks late 
endosomes destined toward the trans-Golgi-network. Interestingly, Rab 9 is involved in the 
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recycling of mannose-6-phosphate receptors [33] and might also participate in CD44-
recycling [34].  
 
Figure 7. Orthogonal perspective of HTM-N cells stained for different endolysosomal 
compartments. NPs are shown in red, vesicles in green. Yellow spots (asterisk) indicate 
colocalization. The scale bar represents 20 µm. A) Rab-proteins. B) Lysosomes. 
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Figure 7A shows representative fluorescent images of cells with green fluorescent 
recombinant Rab-proteins after treatment with NPs (red). As expected (and already 
discussed in chapter IV), PEI-NPs formed large aggregates that stuck to the cell surface 
rather than being taken up by the cells. In contrast, HA-coated NPs showed improved 
colloidal stability. Special attention should be paid to the lateral view of the cells, illustrated 
as narrow bars to the right of and on top of the square image, which is the top view. The 
distribution of red HA-NPs among green stained endosomes and lysosomes was 
homogenous through all layers of the cells. In contrast, PEI-NPs formed large aggregates 
that stuck to the cell membrane and sometimes pushed against it, deforming the membrane, 
but were not taken up. Colocalization, indicated by a yellow color, was not visible for either 
particle type or for any of the investigated Rab-proteins. Only HA-NPs show a low degree 
of colocalization with Rab 9 (Figure 7A, marked with asterisk), a marker for late endosomes 
on their way to the Golgi [33]. To exclude the possibility of NP accumulation in lysosomal 
compartments, cells were stained with a lysotracker dye (Figure 7B). No clear colocalization 
of NPs (red) with vesicles (green) was detected, raising the question of where the particles 
were located intracellularly.  
To elucidate the fate of particles composed of PLGA, Cartiera et al. investigated the 
intracellular localization of blank PLGA-NPs of approximately 100 nm in size in opossum 
kidney cells and human bronchial epithelial cells [35]. They found the particles captured in 
vesicles associated with the Golgi apparatus or the endoplasmatic reticulum and concluded 
that the NPs follow an endocytosis-exocytosis route. The group of El-Dakdouki reported 
about receptor-mediated transcytosis of HA-modified silica-NPs [20]. The NPs were taken 
up by CD44-mediated endocytosis but were transported out of the cell during receptor 
recycling. The exported NPs could then be taken up by neighboring cells again. This allowed 
deep penetration into tissues which was shown in 3D multilayered cell culture and tumor 
spheroids.  
Similar to the approach by El Dakdouki, HTM-N cells were treated with fluorescently tagged 
HA- or PEI-NPs. The fluorescence intensity of supernatant growth medium after the 
removal of unbound or uninternalized NPs by thorough washing was monitored over a 
period of 20 hours (Figure 8A). Although low fluorescence was detectable in the beginning, 
the fluorescence intensity increased constantly and reached a plateau of about 7 µg/mL after 
10 to 15 hours. This makes up approximately 10 % of the maximal value if all available NPs 
were taken up by the cells and released into the growth medium again. El-Dakdouki related 
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his observation to the recycling of CD44 receptors and bound NPs. However, the effect also 
occurred for PEI-NPs and raised the question whether NP exocytosis is really related to 
receptor recycling. Furthermore, there is the possibility that a considerable fraction of the 
NPs was only loosely bound to the cell surface despite diligent washing steps. This might 
particularly count for the results of the experiments with PEI-NPs, as it can be assumed 
there are strong electrostatic interactions between the cationic NPs and negatively charged 
cell membranes [36]. NPs might detach from the membrane over time resulting in an increase 
in fluorescence intensity which is not caused by NP exocytosis.  
 
Figure 8. Exocytosis of HA- and PEI-NPs. A) Release of NPs into supernatant growth media 
from HTM-N cells. Solid line: HA-NPs, dashed line: PEI-NPs. B) Confocal images of HTM-N 
cells initially loaded with RHOD- or FITC-labeled NPs and cultivated together for 24 h. Some 
cells (marked with an asterisk) show both types of NPs because of NP-release and subsequent 
endocytosis from another cell. Scale bar: 50 µm. C) Fraction of cells with RHOD- and FITC-
labeled NPs as counted manually in confocal images. Blank: HA-NPs, striped: PEI-NPs. 
In order to elucidate the pathway of the NPs, an additional test was performed. Adherent 
HTM-N cells were separately treated with NPs tagged with either a rhodamine or fluorescein 
label, washed, harvested by trypsinization and then cultivated together for up to 72 h. The 
procedure of trypsinizatoin has been used frequently to remove loosely bound NPs 
[20,37,38]. Although cells were initially treated with only one type of fluorescently labelled 
NPs, a considerable number of cells with both red and green fluorescent NPs were detected 
after 24 h (Figure 8B, marked with an asterisk) and increased over time (Figure 8C). 
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Interestingly, the effect was slightly stronger for PEI-NPs instead of HA-NPs and the 
hypothesis that CD44 participates in NP exocytosis could not be supported. 
The exocytosis of NPs might be – at least in part – an explanation for the poor transfection 
efficiency of LbL-NPs in GFP-producing HTM-N cells as described previously. NPs entered 
the cell but were then transported to cellular compartments that secreted them back into the 
cytosol again. Hence, the NPs were not able to deliver their siRNA freight to the cytosol and 
RNA interference was not possible. However, this is not the sole cause of poor RNA 
interference as a high number of NP remained intracellularly (see Figure 8 B). A combination 
of different factors led to the poor effectivity of the NPs for gene delivery. These factors 
include insufficient unpacking and siRNA release. Furthermore, the inclusion of PLArg into 
the LbL-sheath of the NPs did not result in higher transfection rates. Most likely, PLArg was 
not the ideal alternative to PEI as a polycationic component to enhance the disassembly of 
the NPs. As the LbL coating procedure is complex with a high number of individual steps, 
there is also the risk of siRNA degradation. Even if all possible precautions were taken to 
avoid contamination with RNA digesting enzymes, this possibility cannot be ruled out 
completely. 
4 Conclusion 
With the successful preparation of HTM-N_GFP+, an in vitro assay for gene silencing was 
developed which combines the advantages of an easy read-out in cell culture without 
neglecting specific properties of the trabecular meshwork. The LbL-NPs investigated so far 
were not successful in reducing GFP expression which would indicate a successful siRNA 
delivery. PEI-terminated NPs suffered from insufficient colloidal stability and formed large 
aggregates. These aggregates stuck to the cell membrane rather than being taken up by the 
cell. HA-NPs, in contrast, showed enhanced colloidal stability and uptake rates are 
promising. No colocalization was observed with early and late endosomes or lysosomes but 
NPs were distributed evenly between the vesicles. A small fraction of NPs was found in 
spatial proximity with vesicles related to the Golgi network. This lead to the presumption 
that HA-NPs were caught in a cycle of repeated endo- and exocytosis but without releasing 
their cargo into the cytosol. However, further attempts could not fully support this thesis. 
Although exocytosis was clearly observed – for both PEI- and HA-terminated particles - a 
considerable fraction of NPs remained intracellularly. The usage of PLArg as an intermediate 
layer also did not lead to an appreciable improvement in the gene silencing effect. However, 
in this case, the advantages offered by the LbL-NPs are most obvious: Varying the particle 
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size (by using another core particle, possibly made from different material) or the inclusion 
of functional polymers into the shell (e. g. disulfide-cleavable linkers or pH-responsive 
polymers) is easily feasible. The diversity of LbL-NPs is enormous and further efforts in 
research should be made with respect to tailoring this type of NP to meet the requirements 
of an siRNA delivery system.
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1 Determination of suitable Hygromycin B concentration 
 
S 1. Representative brightfield images of HTM-N cells treated with increasing amounts of 
hygromycin B for 72 h. Tested hygromycin concentrations were 0 µg/mL (upper left), 5, 10, 25, 
50, 100, 200, 300, 400, 500, 600, 700, 800, 900 and 100 µg/mL (lower right). For concentrations 
higher than 50 to 100 µg/mL, cell growth is inhibited considerable and stops at 300 µg/mL. 
Scale bar represent 500 µm. 
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2 Calculation of distance between cationic charges 
S 2. Distance between cationic charges of PEI and PLArg were calculated as follows: 
brPEI 25 kDa pLArg 
 
 
Bonds between possible charges: 
1 x C-C (length: 154 pm) 
2 x C-N (length: 147 pm) 
 1 x 154 pm + 2 x 147 pm = 448 pm 
Bonds between possible charges: 
6 x C-C (length: 154 pm) 
2 x C-N (length: 147 pm) 
1 x N-CO (length: 133 pm) 
1 x N-alpha C (length: 146 nm) 
1 x CO-alpha C(length: 151 nm) 
 6 x 154 pm + 2 x 147 pm + 1 x 133 pm + 1 x 
146 pm + 1 x 151 pm = 1648 pm 
 
Protonation state: 
pKa = 8.4 
pH = pKa + lg (A-/HA) 
7.4 = 8.5 + lg (NH2/NH3+) 
0.1 = (NH2/NH3+) 
 
Protonation state: 
pKa = 13.2 
pH = pKa + lg (A-/HA) 
7.4 = 13.2 + lg (NH2/NH3+) 
1.6 x 10-6 = (NH2/NH3+) 
Only 90 % of amino groups are protonated, 10 % are 
not charged 
Nearly all amino groups are protonated 
Distance between charges increases by 10 % Distance between charges not changed 
Charge density: 492 pm (=0.5 nm) Charge density: 1648 pm (=1.65 nm) 
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Abstract 
 
An elevated intraocular pressure (IOP) is regarded as a causative risk factor for the 
development of glaucoma, a neurodegenerative ocular disease and one of the leading causes 
of blindness worldwide. IOP is regulated by the production of aqueous humor in the ciliary 
body and its drainage through the trabecular meshwork (TM). Recently, connective tissue 
growth factor (CTGF) was identified to increase the resistance to aqueous humor outflow 
by enhancing the deposition of extracellular matrix and contractility of cells in the TM. Gene 
silencing using small interfering RNA (siRNA) might be an opportunity to reduce the effects 
of CTGF and persistently lower IOP. However, with respect to therapeutic use, a suitable 
delivery system is required. Here we describe the development of hyaluronic acid 
functionalized layer-by-layer nanoparticles (NPs) for the delivery of siRNA to the TM. The 
coating with hyaluronic acid prevents the adhesion and nonspecific attachment of the 
particles to tissue and cells of the outflow system and enables a penetration deep into the 
TM after intracameral injection. Further, the NPs specifically address cluster of 
differentiation (CD) 44 receptors on the target cells in the TM and Schlemm’s channel 
guaranteeing high uptake rates. CD44 is particularly suitable as target for the particles, as 
glaucoma patients show a higher CD44 receptor expression in the relevant regions compared 
to healthy individuals. In vitro, the NPs were able to reduce CTGF mRNA levels depending 
on the basal expression of the growth factor, opening the door for a new causative glaucoma 
therapy with minimal risk for undesired side effects. 
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1 Introduction 
Glaucoma, a neurodegenerative disease of the optic nerve, is one of the leading causes of 
blindness. It is estimated that about 111.8 million people will be affected worldwide by 2040 
[1]. Among various sub-types, primary open angle glaucoma (POAG) is the most common 
form [2]. An elevated intraocular pressure (IOP) was identified as critical risk factor for the 
pathogenesis of glaucoma. Current medications rely on decreasing the IOP by administering 
topical eye drops, which have a long list of drawbacks such as poor compliance and 
inadequate application by patients, poor bioavailability and systemic side effects [3,4]. In 
addition, eye drops do not tackle the origin of disease thereby failing at sufficiently decreasing 
the IOP. Consequently, new causative therapeutic concepts are of utmost importance. 
The IOP is generated in the anterior chamber of the eye due to a resistance to the outflow 
of aqueous humor (AH) through the trabecular meshwork (TM) and Schlemm’s canal (SC) 
(Scheme 1A) [5]. A significant change in the quality and amount of extracellular matrix 
(ECM) in the TM [6–9] together with an enhanced contractility of TM and SC cells 
contribute to an abnormal increase in outflow resistance [10–12]. We recently identified 
connective tissue growth factor (CTGF) as a major mediator of these pathological effects, 
based on an increased expression rate of CTGF in glaucomatous SC cells [13] and its 
potential to cause increased ECM synthesis and contractility of TM cells [6,11]. Moreover, a 
direct implication of CTGF in the dysregulation of the AH outflow facility was demonstrated 
in transgenic animals, which had a significant elevated IOP leading to a progressive loss of 
axons in the optic nerve [11]. Hence, we speculate that a reduction of CTGF would achieve 
a more permanent and causative effect in regulating the IOP compared to available standard 
treatment regimes. 
A favorable tool to reduce the production of specific proteins is small interfering RNA 
(siRNA) [14,15]. The eye is particularly attractive for siRNA application because of a possible 
local administration and the immune privilege of the eye [14,15]. The principle feasibility of 
ocular siRNA therapy is being demonstrated in a limited number of ongoing clinical trials 
and pre-clinical studies [14–17]. For example, one recent study focused on glaucoma therapy, 
and naked siRNA was applied to the anterior chamber with the intention to reduce tight 
junction proteins of endothelial cells lining the SC [16,16]. Unfortunately, the approach was 
quite unspecific and may therefore have severe adverse effects on the integrity of the blood-
aqueous-barrier of the ciliary body. Moreover, all studies have a major shortcoming: siRNA 
drug candidates are delivered in their naked form, but naked siRNA is subjected to 
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degradation and not able to efficiently cross cellular membranes [14,18,19]. Thus, a huge 
amount of siRNA molecules would be required for eliciting a therapeutic effect. 
Consequently, our approach will decisively depend on the development of nanoparticles 
(NPs). The NPs will have to be injected into the anterior chamber of the eye (Scheme 1A). 
From there, we envision NPs to follow the natural trabecular outflow to reach the target cells 
in the outflow pathway. The TM consists of various morphologically and functionally 
different parts (Scheme 1B) [5]. The corneoscleral TM is due to its high porosity comparable 
to a filter with large pores. In the juxtacanalicular TM (JCT), pore size significantly decreases 
and the ECM, in which the JCT cells are embedded, becomes much denser [20]. The JCT is 
followed by the endothelial lining of the SC. The transport of particles through the interstitial 
space of the TM is poorly understood and scarcely investigated. A very early study of the 
1990s revealed that up to 45 % of polystyrene particles (0.176 and 0.46 µm) were captured 
in the TM of perfused enucleated human eyes [21]. Because particles were smaller than the 
morphologically determined pore dimensions and a significant fraction of all particle sizes 
were retained, particle retention was most likely due to adhesion interaction. A portion of 
intracamerally injected cationic gold NPs of 5 or 10 nm seemed to penetrate the JCT, but 
particles were then associated with the ECM beneath the inner wall endothelium [22]. These 
examples illustrate that preventing adhesive hindrance and overcoming the TM barrier poses 
a huge challenge. 
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Scheme 1. Strategy for delivering NPs to cells of the trabecular meshwork (TM) and Schlemm´s 
canal (SC). A) Aqueous humor (dashed red line) is secreted by the ciliary body and flows from 
the posterior chamber to the anterior chamber and is finally drained via the TM and SC into the 
veins. Nano-carriers will be injected into the anterior chamber of the eye and are envisioned to 
follow the natural trabecular outflow pathway. B) Magnified schematic drawing of the trabecular 
outflow pathway illustrating corneoscleral, juxtacanalicular (JCT) TM and inner endothelial wall 
of SC. NPs are envisioned to target TM cells of the JCT and endothelial cells of SC via the CD44 
receptor followed by knockdown of CTGF, which is known as glaucoma-inducing growth 
factor. 1 = sclera, 2 = TM, 3 = ciliary body, 4 = cornea, 5 = iris, 6 = lens, 7 = SC, 8 = JCT, 
9 = corneoscleral meshwork. 
After penetrating the ECM, delivering the therapeutic freight to TM and SC cells is an equally 
important challenge. Both cell types express the cluster of differentiation (CD) 44 receptor 
under normal, healthy conditions [20]. In addition, CD44 expression is highly elevated on 
TM cells of glaucomatous patients [23], which could be exploited for a potential therapy. 
Accordingly, patients with glaucoma would respond to a treatment in a different way 
compared to healthy individuals. If such a difference of the CD44 expression level also exists 
for SC cells has not been investigated. Nano-carriers have been surface coated with the 
naturally occurring polysaccharide hyaluronan (HA) to achieve CD44 targeting [24]. 
Although this principle has been successfully demonstrated for CD44-overexpressing cancer 
cells, a proof of concept remains to be demonstrated for other diseases such as glaucoma.  
In this study, we will address the key question: How have NPs to be designed to prevent 
adhesive hindrance in the TM and target TM and SC cells of glaucoma patients at the same 
time? To follow up our goal we will focus on NPs that are assembled in a layer-by-layer (LbL) 
approach [25] (Scheme 2). The siRNA will be sandwiched between two polycationic 
polyethylenimine (PEI) layers and most important, NPs will be coated with a final HA layer. 
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We ascribe this natural polymer a dual function. First, we speculate that HA-decorated NPs 
are not maintained in the ECM of the TM by interaction forces because HA is per se a highly 
abundant molecule in the ECM [20]. Second, HA-decorated NPs are expected to bind to the 
CD44 receptor of the TM and SC cells of glaucomatous patients which would potentially 
allow for precisely delivering therapeutic molecules for future therapies, in a way as it is 
envisioned in personalized medicine.  
 
Scheme 2. Schematic drawing of LbL assembled NPs applied in this study: PLGA NPs are 
stabilized with PEI (25 kDa) (red core, orange shell), followed by a layer of siRNA (green) and 
again PEI (orange). Finally, the particles are coated with HA (blue) with a MW of 13 kDa. 
2 Materials and Methods 
2.1 Materials 
Acid terminated poly(D,L-lactide-co-gylcolide) (PLGA) (lactide/glycolide 50/50) with an 
average molecular weight of 38-54 kDa and branched polyethylenimine (PEI) 25 kDa were 
purchased from Sigma-Aldrich Chemical Company (Taufkirchen, Germany). Rhodamine B 
(RHOD) endcapped PLGA (lactide/glycolide 50/50, 30 kDa) (RHOD-PLGA) was obtained 
from Polyscitech (West Lafayette, Indiana, United States). Sodium hyaluronate (13 kDa) was 
bought from Lifecore Biomedicals (Chaska, Minnesota, United States). Non-targeting 
siRNA (5’-UUC UCC GAA CGU GUC ACG UdTdT-3’) and siRNA directed against CTGF 
(5’-AGA UUC CCA CCC AAU UCA ATT dTdT-3’) were purchased from Qiagen (Hilden, 
Germany) and Eurofins (Ebersberg, Germany). Lipofectamine 2000 and RNAiMAX were 
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from ThermoFisher Scientific (Darmstadt, Germany). Cav1-GFP (plasmid #14433) was 
obtained from Addgen (Cambridge, Massachusetts, United States). Sucrose, microbiological 
grade, was from Merck (Darmstadt, Germany). 
2.2 Methods 
Cell culture 
Primary human trabecular meshwork (hTM) cells were cultivated in Ham’s F12 medium with 
the addition of 5 % serum and used until passage number 8. Immortalized human trabecular 
meshwork (HTM-N) cells were cultivated in EMEM+ containing 10 % serum. If indicated, 
cells were stimulated for 24 hours in serum-free medium, followed by another 24 hours in 
serum-free medium supplemented with 1 ng/mL human TGF-Ƣ2 (R&D systems, 
Wiesbaden, Germany) or 50 ng/mL CTGF (EMP Genetech, Ingolstadt, Germany), 
respectively. All cell culture reagents were obtained from Gibco (ThermoFisher Scientific, 
Waltham, Massachusetts, United States).  
mRNA analysis 
mRNA was isolated from hTM cells after CTGF silencing, anterior eye segments of 
transgenic and WT mice and primary SC cells as follows: Total RNA was extracted using 
TriFast™ (Peqlab, Erlangen, Germany) reagent according to the manufacturer’s 
recommendations. cDNA was prepared using the qScript™cDNA Synthesis Kit (Quanta 
Biosciencies, Gaithersburg, USA) according to the manufacturer’s instructions. All primers 
were from Invitrogen and extended over exon-intron boundaries. The sequence of the 
primers was as follows: 5'-gacacattccaccccagtg-3' (huCD44 forward), 5'-tggaatttggggtgtcctta-
3' (huCD44 reverse), 5'-gaagttcctggtccacaacg -3' (huRPL32 forward), 5'-gcgatctcggcacagtaag 
-3' (huRPL32 reverse), 5‘-actcaagtgcgaaccaggac-3‘ (msCD44 forward), 5‘-
gccaagatgatgagccattc-3‘ (msCD44 reverse), 5‘-gctgccatctgttttacgg -3‘ (msRPL32 forward), 5‘-
tgactggtgcctgatgaact -3‘ (msRPL32 reverse), 5’-ctcctgcaggctagagaagg-3’ (CTGF forward), 5’-
gatgcactttttgccgttctt-3’ (CTGF reverse), 5’- cctaaccgctactggctgtg-3’ (Gnb2L forward), 5-
ctacaatgatctttccctctaaatcc-3’ (Gnb2L reverse). RT-PCR was performed on a BioRad iCycler 
(BioRad, München, Germany) in 50 cycles with the temperature profile of 20 s melting at 
94°C, 10 s annealing at 60°C and 20 s extension at 60°C. RNA that was not reverse 
transcribed served as negative control. For relative quantification of the experiments, Gnb2L 
Chapter 6 – HA functionalized NPs for glaucoma therapy 
166 
or RPL32, respectively, were used as a housekeeping gene. Bio-Rad iQ5 Optical System 
Software (version 2.0) was used for analysis and ΔΔct-method was applied for normalization. 
Western Blot analysis 
Proteins of primary hTM cells for investigation of CD44 and CTFG expression were isolated 
after RNA separation according to the manufacturer’s instructions (TriFast™, Peqlab, 
Erlangen, Germany). Proteins were dissolved in 1 % SDS containing protease and 
phosphatase inhibitors. Protein concentration was determined by the bicinchoninic acid 
assay (Interchim, Montluçon Cedex, France). Thereafter, proteins were separated by SDS-
PAGE and transferred to polyvinylidene difluoride membranes (Roche, Mannheim, 
Germany). Western blot analysis was performed with specific antibodies as described 
previously [26]. Antibodies were used as follows: mouse anti-CD44 (1:1000, R&D systems, 
Minneapolis, USA), goat anti-CTGF (1:500; Santa Cruz, Dallas, USA; and horse anti-mouse 
(1:2000, Cell Signaling Technology, Danvers, USA). rabbit anti-ơ-tubulin (1:2500, Rockland 
Immunochemicals Inc., Gilbertsville, USA) was used as loading control. Chemiluminescence 
was detected on an LAS 3000 imaging workstation (Fujifilm, Düsseldorf, Germany) and 
signal intensity was estimated by the AIDA Image analyzer software (Raytest, Straubenhardt, 
Germany). 
Immunocytochemistry of in vitro samples 
hTM cells were seeded on coverslips and stimulated with 1 ng/mL TGF-Ƣ2, 50 ng/mL 
CTGF (24 h serum-free, followed by another 24 h in serum-free medium supplemented with 
TGF-Ƣ2 or CTGF) or left untreated as control. Cells were washed twice with PBS, fixed with 
4 % (w/v) paraformaldehyde (PFA) for 5 minutes and washed again three times with PBS. 
Specific antibodies were used as follows: mouse anti-CD44 (1:100) and Alexa Fluor 488-
conjugated anti-mouse IgG (1:1000, Invitrogen, Darmstadt, Germany). As a control for 
unspecific binding of the secondary antibody, negative controls were performed. Finally, 4,6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, USA) was added to 
counterstain nuclear DNA and the immunofluorescence was visualized using a Zeiss Axio 
Imager fluorescence microscope (Carl Zeiss AG, Göttingen, Germany).  
Materials and Methods 
167 
Nanoparticle preparation and characterization 
Particle preparation. RHOD-labeled PLGA NPs were prepared by nanoprecipitation. In 
brief, 2 mL of a 10 mg/mL solution of PLGA (PLGA/RHOD-PLGA=50/50) in 
acetonitrile was slowly injected into 8 mL of a solution of 0.5 % PEI in ultrapure water and 
stirred for 4 hours until the organic solvent totally evaporated. Excess PEI was removed by 
stepwise centrifugation at a speed of 5,000, 7,000 and 9,000 g for 7 minutes each, the 
complete centrifugation cycle was once repeated. Resulting PEI-coated NPs were 
subsequently resuspended in ultrapure water, then lyophilized with the addition of 2 % 
sucrose as a protective agent. NP yield was gravimetrically determined and particles were 
stored at -20°C until further use. For subsequent coating steps, lyophilized NPs were 
resuspended in ultrapure water at a concentration of 1 mg/mL and purified from sucrose 
according to the procedure described above. Then, NPs were dropwisely added to a stirring 
solution of the respective polyelectrolyte (final concentration: HA 1 mg/mL in water, siRNA 
4 µM in 10 mM NaCl, PEI 1 mg/mL in water), according to the process described by 
Elbakry et al [25]. Dispersions were kept on a stirring plate for 30 to 60 minutes. Unbound 
polyelectrolyte was removed by stepwise centrifugation, followed by resuspension in 
ultrapure water. If siRNA or HA was the outermost layer, centrifugation speed was reduced 
to 1,000, 2,000 and 3,000 g for 7 minutes each, without repetition of the complete 
centrifugation cycle. Concentration of assembled NPs was determined in relation to the 
florescence of resuspended, but unpurified NPs of known concentration on a microplate 
reader (FLUOStar Omega, BMG Labtech, Ortenberg, Germany) equipped with a 544 nm 
excitation and a 590 nm emission filter set. 
Physicochemical Characterization. Hydrodynamic diameter and zeta potential of diluted 
(in water) samples was determined by dynamic and electrophoretic light scattering using a 
Zetasizer Nano ZS (Malvern Instruments, UK). For all size measurements, 173° backward 
scatter in the general-purpose mode with automatic measurement position and attenuator 
selection at 25°C was applied. Z-Average values were determined from three independent 
samples, each measured three times with 11 runs per measurement. Zeta potential was 
determined in the monomodal mode using the Smoluchoswki approximation, measuring 
three independent samples three times each. 
Scanning electron microscopy. A drop of purified NPs was added to conductive pads 
(Plano GmbH, Wetzlar, Germany) attached to aluminum specimen stubs (Agar Scientific, 
Stansted, Essex, UK) and air dried. The samples were sputtered with Au/Pd using a Polaron 
SC 515 SEM Sputter Coating System. Images were taken on a Zeiss DSM 950 scanning 
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electron microscope (Jena, Germany). An acceleration voltage of 10 kV was used. The 
working distance was set to 15 mm and a magnification of 30,000 x was chosen. 
Colloidal stability. NPs were incubated at a concentration of 40 µg/mL in Leibovitz 
medium supplemented with 0 to 1 % serum for one hour at room temperature to allow for 
the formation of a protein corona. hTM cells that were seeded into -Slide 8 Well ibidi slides 
(ibidi, Planegg, Germany) at a density of 20,000 cells per well 24 hours before use, were 
rinsed with PBS and incubated with NPs for four hours. Thereafter, cells were washed two 
times with PBS, supplied with fresh Leibovitz medium containing 10 % serum and analyzed 
by confocal laser scanning microscopy (CLSM) (LSM 510 META, Carl Zeiss, Jena, 
Germany). RHOD-labeled NPs were excited at 543 nm and fluorescence emission was 
detected at 560 – 615 nm. The optical slice thickness was < 16.3 nm. 
Cellular uptake of nanoparticles 
HTM-N cells were seeded at a density of 40,000 into -Slide 8 Well ibidi slides. After 
24 hours, cells were transfected with a cav1-GFP plasmid. Lipoplexes were prepared 
according to manufacturer’s instruction, using 0.3 g DNA and 1 l Lipofectamine 2000 per 
well and added to the cells for 4 hours. The next day, cells were treated with 40 g/mL NPs 
in Leibovitz medium supplemented with 0.35 % serum as described above. Cells were 
observed by confocal laser scanning microscopy (CLSM) in the multitracking mode using 
488 and 543 nm lasers for excitation, and a 505-530 nm bandpass or a 560 nm longpass filter 
for fluorescence emission detection. Optical z-sections were taken with an optical slice 
thickness of 0.7 m. 
CTGF gene silencing in vitro 
hTM cells in passage 5 to 7 were grown in 6-well cell culture dishes. After reaching 80 % 
confluency, cells were cultivated for 24 hours without serum and another 24 hours with the 
addition of 1 ng/mL TGF-Ƣ2 or left as untreated control. NPs were prepared at a 
concentration of 80 g/mL in Leibovitz medium containing 0.35 % serum and 1 ng/mL 
TGF-Ƣ2 and left one hour at room temperature for the formation of a protein corona. Cells 
were incubated for additional four hours with NPs, washed with PBS once and left for 24 h 
in serum-supplemented medium. Thereafter, cells were cultured for additional 24 hours 
without serum before RNA and protein extraction followed by mRNA analysis and Western 
Blotting.  
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In vivo experiments with transgenic animals 
Transgenic ƢB1-CTGF mice were generated as described previously [11] and compared to 
wild type (WT) mice. Animals were housed under standardized conditions of 62 % air 
humidity and 21°C room temperature. Feeding was ad libitum. Animals were kept at a 12-
hour light/dark cycle (6:00 – 18:00). To evaluate differences of CD44 expression on the 
mRNA level, 8 week old ƢB1-CTGF and WT mice were killed by exarticulation of the 
atlanto-occipital joint. Corneal-scleral rings were dissected, the anterior eye segment was 
separated from the posterior part of the eye along the ora serata and the lens was taken out. 
The anterior eye segment was cut in half and most of the cornea was removed. Total RNA 
was extracted, analyzed by RT-PCR and quantified as described above. Alternatively, for 
immunohistochemistry, eyes of 8 week old ƢB1-CTGF transgenic and wild-type (WT) mice 
were enucleated and fixed in 4 % (w/v) paraformaldehyde for 4 hours. The eyes were 
equilibrated in 10 %, 20 % and 30 % sucrose, embedded in Tissue-Tek optimal cooling 
temperature compound (Sakura Finetek Europe B.V., Zoeterwounde, Netherlands), and 
stored at -20°C. Frozen 12 µm sections were cut on the cryostat. Cross sections of the ON 
were obtained. After blocking with 2 % bovine serum albumin (BSA), 0.2 % cold water fish 
skin gelatin (Sigma-Aldrich), 0.1 % Triton X-100 in 0.1 M phosphate buffer, frozen sections 
were incubated with rabbit anti-CD44 (1:100) at 4°C overnight. Afterwards, tissue sections 
were washed three times with 0.1 M phosphate buffer, followed by an incubation with the 
secondary antibody Cy3™ goat anti rabbit (1:2000, Jackson Immuno Research Europe Ltd., 
Suffolk, UK) for 1 h at room temperature. As a control for unspecific binding of secondary 
antibodies, negative controls were performed. After washing three times with PBS, the slides 
were mounted using the DakoCytomation fluorescent mounting medium with DAPI 1:10 
(Dako). Slides were dried overnight at 4°C before microscopy. 
Ex vivo perfusion of porcine and human eyes  
Fresh enucleated porcine eyes were obtained from a local abattoir. Eyes with a visible damage 
were excluded. Human eyes were obtained from body donors of the university of 
Regensburg. After the extraocular tissue was removed, the porcine and human eyes were 
submerged to the limbus in 0.89 % NaCl at 35°C. The perfusion system contained a 
perfusion chamber and a collection chamber. The infusion needle was intracamerally inserted 
through the transparent cornea into each eye and connected to the perfusion chamber. The 
needle was then carefully pushed through the pupil and the tip of the needle was placed in 
the posterior chamber. Then, a second needle was placed into the anterior chamber and 
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connected to the collection reservoir. The needle was closed during the perfusion excepted 
during the exchange periods. First, a volume of 3 mL glucose solution (5 %) was exchanged 
over a time period of about 10 to 15 minutes. In the next step, the collection reservoir was 
closed and the eyes were perfused with 3 mL NPs at a constant pressure of 10 mmHg for 
3 hours. Then, a second exchange with 3 mL glucose solution was performed, which took 
again 10 to 15 minutes, followed by a second perfusion for 2 hours with glucose. The anterior 
chamber of the porcine and human eyes was dissected and most of the sclera and the cornea 
were removed. The tissue was separated into small pieces and fixed with 4 % (w/v) PFA for 
4 hours and washed three times with 0.1 M phosphate buffer. Samples were prepared as 
described above for sectioning and staining with a mouse anti-human CD44 antibody 
(1:1000, R&D Systems, Minneapolis, Minnesota, United States) or an anti-CD31 antibody. 
As a control for unspecific binding of secondary antibodies, negative controls were 
performed. Confocal images and z-stacks were taken on a confocal laser scanning 
microscopy (CLSM) in the multitracking mode using 488 and 543 nm lasers for excitation, 
and a 505-530 nm bandpass or a 560 nm longpass filter. 
Statistical analysis.  
Sigma Plot 12.0 software was used for statistical analysis. For the evaluation of the gene 
silencing results, a one-way ANOVA of the ΔΔct-values was conducted followed by a Holm-
Sidak-test. 
3 Results 
3.1 CD44 prevalence in primary cells in vitro, in transgenic mice in vivo 
and in human eyes ex vivo 
To demonstrate the principle feasibility of our approach, the CD44 prevalence in 
glaucomatous versus healthy cells of the outflow pathway in the anterior eye chamber was 
investigated. In a first step, the expression level of CD44 was evaluated in primary human 
TM (hTM) cells in vitro. Tumor growth factor Ƣ2 (TGF-Ƣ2) is causatively involved in the 
pathogenesis of POAG and well known as glaucoma-inducing growth factor [7,27]. Hence, 
hTM cells were treated with TGF-Ƣ2 (1 ng/mL) and its down-stream mediator CTGF 
(50 ng/mL) in order to compare glaucomatous to untreated, healthy control cells [6,11]. 
Protein expression was detected by Western Blot analysis after 24 hours (Figure 1A). Both 
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TGF-Ƣ2 and CTGF treatment led to a significant increase of the CD44 protein level 
compared to untreated control cells. Immunocytochemical staining of CD44 in confluent 
hTM monolayers confirmed the results (Figure 1B). A characteristic fiber-like pattern of 
CD44 was revealed on the surface of hTM cells. Again, cells treated with the glaucoma 
factors TGF-Ƣ2 or CTGF, respectively, showed a brighter fluorescence compared to 
untreated controls. Presence of CD44 was also studied in primary SC cells that were isolated 
from healthy as well as glaucomatous human donors (Figure 1C). Consistently, real time RT-
PCR analysis showed a significant increase of the CD44 mRNA level in glaucomatous SC 
compared to healthy control cells. 
In a second step, transgenic mice with lens-specific CTGF overexpression (ƢB1-CTGF) were 
compared to healthy, wild-type (WT) mice. The transgenic animals develop POAG 
characterized by higher IOP and progressive loss of axons in the optical nerve head and 
show significant pathologic changes within the outflow pathway [11]. Anterior eye segments 
of 2-month old ƢB1-CTGF and WT mice were investigated to evaluate if morphological 
changes are connected to alterations in the amount and distribution of CD44. The relative 
mRNA level of CD44 was significantly increased in corneal-scleral rims of ƢB1-CTGF 
animals compared to their WT littermates (Figure 1D). Because the corneoscleral-rim 
contains not only the TM and SC, but also parts of the sclera, immunohistochemical staining 
was performed to precisely localize CD44 in the anterior eye segment. CD44 signal was 
detected in the iris, ciliary body, TM and the SC of 2-month old WT mice, and no signal was 
observed in the sclera (Figure 1E). In ƢB1-CTGF mice, a similar distribution of CD44 in the 
anterior chamber angle was observed, however, the signal was markedly increased in the 
tissues of the outflow pathway, namely the TM and SC, and no changes were observed in 
the sclera (Figure 1E). Consequently, changes of CD44 expression in the outflow tissues can 
be related to the CTGF-induced increase of CD44 mRNA. 
Finally and most important, the CD44 expression was investigated in the iridocorneal angle 
of glaucomatous and healthy human donors eyes. Immunohistochemical staining of 
cryosections clearly visualized a remarkably enhanced CD44 signal in the TM, SC and the 
iris of glaucomatous eyes (Figure 1F). 
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Figure 1. The CD44 prevalence was analyzed in healthy and glaucomatous cells in vitro (A-C), 
in transgenic mice in vivo (D, E) and in eyes of human donors ex vivo (F). A) Primary human TM 
(hTM) cells were treated with TGF-Ƣ2 (1 ng/mL) or its down-stream mediator CTGF 
(50 ng/mL), respectively, and compared to untreated control cells in vitro. Western blot analysis 
(inlet Figure 1A) with anti-CD44 antibody revealed a significantly enhanced CD44 expression of 
treated versus untreated cells. CD44 signal was related to the ơ-tubulin signal as a reference. 
Histograms represent densitometry-based average values (mean ± SD) of 5 independent 
experiments. B) Likewise, immunocytochemical staining of confluent hTM cells with an anti-
CD44 antibody and fluorescently-labeled secondary antibody revealed a brighter signal of TGF-
Ƣ2 and CTGF treated versus control cells. Blue: DAPI staining of cell nuclei; green: Alexa Fluor 
488 conjugated anti-CD44 antibody. Bar represents 50 µm. C) Primary SC cells of human 
glaucomatous versus healthy donor eyes were analyzed regarding their CD44 mRNA level. 
Relative amount of CD44 mRNA of glaucomatous SC cells was significantly enhanced 
compared to heathy cells. Values were normalized to the housekeeping gene RPL32. Values 
represent mean ± SD (healthy: n = 4, glaucomatous: n = 5). D) Corneal scleral rims of transgenic 
animals with lens-specific CTGF overexpression (ƢB1-CTGF) were compared to their wild type 
(WT) littermates regarding the CD44 prevalence. Relative mRNA level was significantly 
enhanced in corneal-scleral rims of ƢB1-CTGF compared to WT animals. Values represent mean 
± SD of four independent experiments. E) Immunohistochemical staining illustrated that the 
CD44 signal was primarily enhanced in TM and SC, but not in the sclera. Blue: DAPI staining 
of cell nuclei; red: Cy3-conjugated anti-CD44 antibody. Scale bar represents 100 µm. F) Analysis 
of the chamber angle of three human donor eyes also revealed a remarkably brighter CD44 signal 
in the TM, SC and iris of glaucomatous versus healthy donor cells. Blue: DAPI staining of cell 
nuclei; red: Cy3-conjugated anti-CD44 antibody. The scale bar represents 100 µm.   
Data was obtained and analyzed at the Department for Human Anatomy and Embryology 
(University of Regensburg) by Andrea Dillinger and Rudolf Fuchshofer. 
Results 
173 
3.2 Synthesis and characterization of nanoparticles 
To address the question how NPs have to be designed to prevent adhesive, nonspecific 
attachment to tissue and cells in the outflow pathway and target TM and SC cells of glaucoma 
patients at the same time, nanocarriers were fabricated in a first step without therapeutic 
siRNA and had either a final layer of PEI (PEI-NPs) or HA (HA-NPs) on the surface (Figure 
2). PEI-NPs served as control because they are known to nonspecifically interact with cells 
and tissue [28], while HA-NPs are envisioned – as already outlined - to bind to CD44 and 
prevent nonspecific, adhesive interactions. According to Figure 2A the core of the NPs 
consisted of biodegradable, FDA approved poly(D,L-lactide-co-glycolide) (PLGA) with a 
MW of 38-54 kDa. PLGA-NPs were prepared by nanoprecipitation and then stabilized with 
the polycationic polymer PEI with a MW of 25 kDa. PEI-NPs were then coated with 
negatively charged HA of 13 kDa resulting in HA-NPs (Figure 2A and B). To remove free, 
unbound polyelectrolyte, PEI- and HA-NPs were purified by stepwise centrifugation. 
Otherwise, ill-defined inter-polyelectrolyte complexes would have formed which are hard to 
separate from coated NPs. The hydrodynamic diameter of both NP species was in a similar 
range, the z-average value was about 255 nm and 240 nm for PEI- and HA-NPs, 
respectively, as determined by dynamic light scattering. The absence of additional peaks in 
the intensity distribution and a polydispersity index (PDI) lower than 0.05 confirmed a 
narrow size distribution (Figure 2C and D, respectively). As expected, PEI-NPs had a 
positive zeta potential of about 48 mV, HA-NPs were negatively charged with a zeta 
potential of about –18 mV. Scanning electron microscopy of dried NPs confirmed their 
spherical shape (Figure 2C and D, respectively).  
The colloidal stability of NPs was investigated after 1 hour of incubation in culture medium 
supplemented with serum in a concentration range from 0 to 1 %. Based on previous 
findings, a time frame of 1 hour was expected to be adequate for the formation of a potential 
protein corona [29–31]. Rhodamine B (RHOD)-labeled particles were then added to primary 
hTM cells and observed by confocal laser scanning microscopy (CLSM) after 4 hours of 
incubation (Figure 2E). Without serum, both types of NPs formed large aggregates on the 
surface of hTM cells as the high electrolyte ionic strength of cell culture medium with 
physiological osmolarity resulted in screening of electrostatic interactions [32]. Already 
0.35 % serum favorably enhanced the colloidal stability of HA-NPs, they were nicely 
distributed onto or most likely into hTM cells. In contrast, NPs decorated with PEI needed 
significantly higher serum concentration of about 1 % for a sufficient colloidal stability. 
Interestingly, 0.35 % serum is equal to the total protein content of the AH (12.4 mg/100 mL) 
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[33]. Hence, the functionalization of NPs with HA will guarantee for the colloidal stability 
of NPs in the therapeutic relevant milieu. We hypothesize that colloidally stable NPs most 
likely will follow the natural AH flow, while aggregates might stick to upper segments of the 
sieve-like TM or even clog the outflow pathway. 
 
Figure 2. Fabrication and characterization of NPs without therapeutic siRNA. A) PLGA (MW 
38-54 kDa) NPs were prepared by nanoprecipitation and stabilized with PEI (25 kDa). Resulting 
PEI-NPs (red-orange) were the coated with HA (blue) with a MW of 13 kDa (HA-NPs). The 
NPs were purified by centrifugation after each coating step. B) Cross-section through a 
schematic NP illustrating the type of charge of each layer. C and D) Physico-chemical 
characterization of PEI- and HA-NPs, respectively: Intensity distribution of hydrodynamic 
diameter averaged over three independent measurements as determined by dynamic light 
scattering. Particle size distribution was narrow and no aggregates were present in dispersion 
(PDI: PEI-NPs 0.05, HA-NPs 0.04). PEI-NPs had a zeta potential of +48 mV, while HA-NPs 
were negatively charged with a zeta potential of about -18 mV. Scanning electron micrographs 
display homogenous, spherical particles. The scale bar represents 500 nm. E) RHOD-labeled 
PEI- and HA-NPs (40 µg/mL) were incubated in culture medium with different serum 
concentrations ranging from 0 to 1 %. After 1 hour, NPs were added to primary hTM cells and 
imaged after for 4 hours of incubation by CLSM. A low serum concentration was sufficient to 
enhance the colloidal stability of HA-NPs, in contrast, PEI-NPs formed large aggregates. White: 
RHOD-labeled NPs. The scale bar represents 50 µm. 
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3.3 Cellular uptake of nanoparticles 
To reliably discriminate between extra- versus intracellular localization of NPs, caveolin-1 
(Cav1) -a structural protein of caveolin-dependent endocytosis- of immortalized human TM 
(HTM-N) cells was fluorescently labeled before incubation with NPs. To this end, HTM-N 
cells were transfected with plasmid DNA encoding a fusion protein of Cav1 and green 
fluorescent protein (Cav1-GFP) using the commercially available transfection reagent 
Lipofectamine 2000. After 24 hours, HTM-N cells were incubated with RHOD-labeled PEI- 
and HA-NPs at a serum concentration of 0.35 %. Z-sections of HTM-N cells were recorded 
after 4 hours by CLSM. Optical image sections were either illustrated as 3D rendering (which 
gives besides the XY image, the XZ and YZ images on a certain spot) or as composite image 
of the z-sections (Figure 3). As expected, PEI-terminated NPs formed large aggregates and 
were not taken up by HTM-N cells, but rather stuck to the outer membrane or were attached 
on the bottom of the culture ware. In contrast, HA-NPs were detected inside HTM-N cells. 
They were evenly distributed between Cav1 vesicles and located throughout all planes of the 
cell. This emphasizes the high potential of HA-coated NPs as vector for intracellular delivery. 
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Figure 3. Extra- versus intracellular distribution of PEI- and HA-NPs. Immortalized human 
TM (HTM-N) cells were transiently transfected with Caveolin-1 (Cav1) -GFP fusion protein and 
incubated with 40 µg/mL RHOD-labeled HA- or PEI-NPs, respectively for 4 hours in culture 
medium containing 0.35 % serum. Cells were observed by CLSM in the multitracking mode. 
Red: RHOD-labeled NPs; green: Cav1-GFP fusion protein. Left panel: 3D rendering of 8 z- 
sections through a HTM-cell with top (XY) and lateral (XZ and YZ) view. Right panel: 
composite image of same 8 z sections from bottom to top view of a HTM-N cell. PEI-NPs 
formed large aggregates that stuck to the cell surface and were not detected inside cells as 
illustrated by the top and lateral view on a cell (left panel) and the image sequence from bottom 
to top (right panel). HA-NPs homogeneously spread between green stained intracellular vesicles 
and were evenly distributed through all image planes. The scale bar represents 20 µm. 
3.4 Perfusion of porcine eyes with nanoparticles ex vivo 
To proof the hypothesis that HA-coated NPs would follow the natural outflow pathway and 
reach the TM and SC, both RHOD-labeled PEI- and HA-NPs were perfused into the 
anterior chamber of porcine eyes. After perfusion, the anterior chamber was dissected and 
fluorescent imaging of the whole outflow ring was performed as illustrated in Figure 4A. 
PEI-NPs were detected only in few areas of the outflow ring and fluorescence of NPs was 
irregularly distributed (Figure 4B). In contrast, HA-NPs were homogeneously localized in 
the whole outflow ring of perfused porcine eyes (Figure 4B). Quantitative measurement of 
integrated fluorescence density corroborated the significantly higher amount of HA-NPs 
compared to PEI-NPs in the outflow system after perfusion (Figure 4 C). 
To determine the exact localization of the NPs in the outflow system, sagittal tissue sections 
were stained with specific antibodies against CD44 after the perfusion procedure 
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(Figure 4D). As expected, the CD44 receptor was homogeneously distributed in all parts of 
the TM and the aqueous plexus (AP), which is an anatomic peculiarity of pigs and correlates 
to SC in human and mice. In more detail, the endothelial cells of the corneoscleral TM which 
is the first part of the TM, and TM cells of the JCT which is a deeper region of the TM, 
where the target cells for CTGF silencing are located, showed a bright fluorescence signal of 
the anti-CD44 antibody. In addition, endothelial cells of the venous plexus (VP), which are 
the second important target cells, showed also a pronounced signal (for better overview of 
different regions of the TM and SC also refer to Scheme 1). PEI-NPs accumulated at the 
entrance region of the TM which is the corneoscleral TM, and did not reach deeper regions 
such as the JCT or the AP at all (Figure 4D, left panel). PEI-NPs tended to build aggregates 
and were unable to pass TM’s pores due to their size or surface charge. In contrast, HA-NPs 
were distributed throughout the entire TM including the corneoscleral TM and JCT, and also 
seemed to have reached the lumen of the AP (Figure 4D, right panel). Optical z-sections that 
were reconstructed to a 3D image with top and lateral view on the section, also illustrated 
the homogeneous distribution and deeper penetration of HA- compared to PEI-NPs (Figure 
4D). 
To demonstrate the localization of HA-NPs in the porcine lumen of the AP, endothelial cells 
of tissue sections were stained with a fluorescently labeled anti-CD31 antibody (Figure 4E). 
Thus, venous vessels of the porcine AP were nicely highlighted. In none of the examined 
sections, PEI-NPs were detected in the lumen of the AP. In contrast, HA-NPs were 
distributed all over the outflow pathway, namely in the corneoscleral TM, the JCT - as already 
evaluated by CD44 staining- and also in the lumen of the AP, which is again underlined by 
z-stacks of optical sections with a higher magnification (Figure 4E). 
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Figure 4. Porcine eyes were perfused ex vivo with RHOD-labeled PEI- and HA-NPs. A) As 
illustrated in Scheme A, a needle was placed into the posterior chamber and the eye was perfused 
with RHOD-labeled NP with a pressure of 10 mmHg. After the perfusion, the anterior chamber 
was dissected and flat mounted or prepared for immunohistochemistry. B) Fluorescence imaging 
of whole outflow rings was performed using a Zeiss Observer Z1 microscope. RHOD was 
excited at 563 nm and fluorescence was detected at 581 nm. PEI-NPs were sparsely detected in 
limited areas of the outflow ring. In contrast, red fluorescence intensity of RHOD-labeled HA-
NPs was much higher and was detected over the whole outflow ring. Representative images of 
nine independent porcine eyes are shown. C) Fluorescence of 8 images for PEI-NPs and 9 
images for HA-NPs were quantified by ImageJ. D and E) To precisely localize NPs in the 
outflow tissue, sagittal sections were prepared and additionally stained with anti-CD44 (D) or 
anti-CD31 (E) antibody, respectively. Sections were analyzed by CLSM in the multitracking 
mode with excitation at 488 and 543 nm, respectively, and detection of emission with a bandpass 
filter 505 – 530 nm and a 630 longpass filter. Top row: 20x magnification, bottom row: 63x 
magnification. Green: anti-CD44 antibody in D and anti-CD31 antibody in E, red: RHOD-
labeled PEI- and HA-NPs. HA-NPs were distributed in the whole outflow pathway and lumen 
of the AP, but PEI-NPs were only detected in the entrance region of the TM.  
Data was obtained and analyzed at the Department for Human Anatomy and Embryology 
(University of Regensburg) by Andrea Dillinger, Franziska Scherl and Rudolf Fuchshofer. 
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3.5 Perfusion of human eyes with nanoparticles ex vivo 
In analogy to experiments with porcine eyes, two human donor eyes were perfused with 
NPs. Again, cryo-sections of the outflow pathway were counterstained with fluorescently 
labeled anti-CD44 antibody. According to perfusion experiments of porcine eyes, PEI-NPs 
were detected in a limited amount and only in the entrance region of the TM (Figure 5A). In 
contrast, a much higher amount of RHOD-labeled HA-NPs was detected in the outflow 
region. In addition, HA-coated NPs spread over a wider region and penetrated into much 
deeper areas of the TM (Figure 5B).  
 
Figure 5. Human eyes were perfused ex vivo with RHOD-labeled (A) PEI- and (B) HA-NPs. To 
precisely localize NPs in the outflow tissue, sagittal sections were prepared and additionally 
stained with anti-CD44 antibody. Sections were analyzed by CLSM in the multitracking mode 
with excitation at 488 and 543 nm, respectively, and detection of emission with a bandpass filter 
505 – 530 nm and a 630 longpass filter. Representative images of two independent experiments 
are shown. Green: anti-CD44 antibody, red: RHOD-labeled PEI- and HA-NPs. Bar represents 
50 µm (top row) and 20 µm (bottom row).  
Data was obtained and analyzed at the Department for Human Anatomy and Embryology 
(University of Regensburg) by Andrea Dillinger, Franziska Scherl and Rudolf Fuchshofer. 
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3.6 CTGF gene silencing in vitro 
After demonstrating that NPs are capable of being drained to the TM and SC after injection 
into the anterior chamber of the eye, the gene silencing capability of siRNA-loaded NPs was 
tested in hTM cells in vitro. To this end, NPs were assembled in a LbL process according to 
Figure 6A. The NP core again consisted of PLGA and was stabilized with the polycationic 
polymer PEI. PEI was chosen, as it is a well-established transfection agent [34], in addition, 
PEI also provided for a permanent positive surface charge, which was necessary for the 
electrostatic attachment of negatively charged siRNA in the next layer. NPs were fabricated 
either with functionally verified siRNA against human CTGF or non-targeted control 
siRNA. To protect the fragile siRNA from degradation by nucleases, an additional layer of 
PEI was applied (PEI(siRNA)-NPs). Finally, the particles were coated with the negatively 
charged polysaccharide HA (HA(siRNA)-NPs). Complete removal of unbound 
polyelectrolytes before addition of the next polyelectrolyte layer was of utmost importance 
and was again realized by stepwise centrifugation. With this coating procedure, it was again 
possible to compare NPs with a final PEI- or HA- layer, respectively. The size of 
PEI(siRNA)-NPs was about 260 nm, HA(siRNA)-NPs were with a hydrodynamic diameter 
of about 214 nm slightly smaller as determined by dynamic laser light scattering (Figure 6B). 
Both particle species had a narrow size distribution, which is reflected by a PDI below 0.1; 
the PDI of HA(siRNA)-NPs was even as small as 0.03 (Figure 6B). A reversal of the zeta 
potential after addition of each polycation layer indicated a successful coating (Figure 6C). 
PEI(siRNA)-NPs had a strong positive surface charge of about 56 mV, while HA(siRNA)-
NPs had a negative zeta potential of about –14 mV. Interestingly, polyanion coated NPs had 
a slightly lower size and absolute value of zeta potential than polycation coated ones most 
likely due to differences in thickness of the hydration shell. Altogether, the physicochemical 
characteristics of siRNA-loaded NPs were comparable to those applied for the perfusion 
studies without siRNA.  
CTGF gene silencing studies were performed in primary hTM cells taken from different 
body donors. hTM cells were stimulated with 1 ng/mL TGF-Ƣ2 and then incubated with 
80 µg/mL of PEI- or HA(siRNA)-NPs. The CTGF mRNA level was analyzed by real time 
polymerase chain reaction (RT-PCR) and related to Guanine Nucleotide-Binding Protein 
Subunit Beta-Like Protein (Gnb2L) as housekeeping gene (Figure 6D). Gene silencing with 
the commercially available LipofectamineTM RNAiMAX led to a reduction of relative CTGF 
mRNA to about 17 % and served as positive control. Both, HA- and PEI-terminated NPs 
reduced the CTGF mRNA level. HA(siRNA)-NPs caused a slightly stronger effect than 
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PEI(siRNA)-NPs (silencing by approximately 30 % or 20 %, respectively), but without 
statistical significance. It is an important point that relative CTGF mRNA values were an 
average of four different donor cells types. Having a closer look at the results of single donor 
cells, huge differences became evident (Figure 6E and F). CTGF silencing in primary cells 
with a high basal CTGF level was more efficient compared to donors with a lower basal 
CTGF expression (refer to donors no. 739 and 211). However, due to the lack of a source 
for further primary cells of human donors, this trend could not be further corroborated. 
However, if true, this relation might be a great therapeutic opportunity: As the silencing with 
HA-functionalized NPs was only effective in cells with high CTGF levels, healthy cells 
remain unaffected by therapy and undesired effects caused by “over-silencing” can be 
avoided. Finally, we performed Western Blot analysis of same samples. Here, the differences 
between PEI- and HA-coated NPs were more impressive. HA(siRNA)-NPs lead to a 
reduction of CTGF of about 50 %, in contrast PEI-NPs showed no effect. As expected, 
positive control with Lipofectamine RNAiMAX reduced CTGF levels to about 20 %. 
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Figure 6. Fabrication, characterization and CTGF gene silencing of siRNA-loaded NPs in hTM 
cells. A) LbL assembly of NPs for gene silencing studies in hTM cells. PLGA NPs were stabilized 
with PEI (25 kDa) (red core, orange shell) and then coated with siRNA (green). The next PEI 
layer (orange) protected siRNA from degradation. Finally, the particles were coated with HA 
(blue) with a MW of 13 kDa. The NPs were purified by stepwise centrifugation between the 
individual coating steps. B) Hydrodynamic diameter and polydispersity index of NPs during the 
coating process. The x-axis indicates the outermost layer of the NPs. A PDI lower than 0.1 
confirmed the absence of aggregates. The values represent the mean ± SD of three independent 
measurements. C) Surface charge reversal after each layering step demonstrated successful 
adsorption of the respective polyelectrolyte. The values represent the mean ± SD of three 
independent measurements. (D-G) In vitro CTGF-silencing efficacy of PEI- and HA(siRNA)-
NPs in hTM cells on the mRNA and protein level. hTM cells were treated with 1 ng/mL TGF-
Ƣ2 and incubated with PEI- or HA(siRNA)-NPs. Lipoplexes were built with Lipofectamine 
RNAiMAX served as control. (D-F) CTGF mRNA level was analyzed by RT-PCR and values 
were expressed as relative mRNA CTGF/Gnb2L and were related to non-targeted control 
particles. D) Both treatment with PEI- and HA(siRNA)NPs slightly reduced the CTGF mRNA 
level of hTM cells, but difference between both groups was not statistically significant. E) 
However, at the single donor levels differences were measured. F) hTM cells of donor no. 739 
had a higher basal CTGF mRNA level compared to other donor cell types. At the same time, 
relative mRNA CTGF reduction of donor no. 739 was also more pronounced compared to 
other donor cells. G) CTGF protein expression was detected by Western Blot analysis. Values 
were expressed as relative CTGF/ơ-tubulin and related to non-targeted control particles. 
HA(siRNA)NPs reduced the CTGF protein expression of hTM cells to about 50 %, while 
PEI(siRNA)NPs did not elicit any effect. Shown is the mean ± SD of three (PEI(siRNA)-NPs 
and lipoplexes) or four (HA(siRNA)-NPs) individual experiments each performed in triplicate. 
Western blot for CTGF and Gnb2L was conducted and analyzed at the Department for Human 
Anatomy and Embryology (University of Regensburg) by Andrea Dillinger and Rudolf 
Fuchshofer.
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4 Discussion 
The progression of glaucoma is characterized by an irreversible damage of optic nerve fibers 
in the back of the eye. An elevated IOP is regarded to be causatively involved in this process. 
Pathological alterations in the TM, namely an enhanced deposition and stiffening of the 
ECM and an increased contractility of actin stress fibers, raise the resistance to AH flow and 
IOP consequently. Junglas et al. identified CTGF, a down-stream mediator of TGF-Ƣ2, to 
cause these effects, and demonstrated a suppression of TGF-Ƣ2 induced effects on the ECM 
[6] and an attenuation of the cellular actin cytoskeleton [11] by siRNA gene knock-down of 
CTGF in vitro. However, for a therapeutic use of siRNA directed against CTGF, a suitable 
delivery system was needed.  
In this study, LbL-NP were developed for the delivery of siRNA to cells in the TM. Our 
approach was to functionalize the NPs with HA, a polysaccharide with naturally high 
concentration in the TM. HA was intended to reduce the interactions of the particles with 
the dense ECM-network, which might hinder their distribution into the deeper TM, where 
outflow resistance is generated. Further, HA served as targeting structure to CD44 receptors 
on TM cells, specifically increasing uptake rates in relevant cells and reducing side effects.  
We were able to support previous findings of Knepper et al. regarding elevated CD44 levels 
in the TM of glaucoma patients [23] and could show, that changes of CD44 expression in 
the outflow pathways are related to the CTGF induced increase in CD44 mRNA. 
Interestingly, CD44 levels were only elevated in the TM and SC where outflow resistance is 
generated [35,36] but not in the sclera. Hence, by using CD44 receptors as targets for a 
nanoparticulate siRNA delivery system, diseased cells with high receptor expression in TM 
regions will be addressed whereas healthy cells with low receptor density will not be affected. 
The risk of undesired off-target effects is reduced and deposition of NPs in regions, where 
no therapeutic effect is expected, is avoided. 
NP for this investigation were assembled in a LbL approach by alternating deposition of 
oppositely charged polyelectrolytes on a NP core. Although this technique is leveraged for 
applications in material science, physical chemistry, electrochemistry and biomedical 
engineering [37], the coating of templates on the nano-scale is challenging due to their 
tendency towards aggregation [25]. With the protocol developed by us it was possible to 
produce monodisperse NPs with up to three polyelectrolyte layers without the formation of 
aggregates. Interestingly, although HA-functionalized particles consisted of one additional 
layer compared to PEI-NPs, their hydrodynamic diameter was smaller (214 nm compared to 
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260 nm). Most likely, this effect was caused by differences in surface charge values. As PEI-
NPs were highly positively charged, a thick hydration shell formed around the particles. 
Lower absolute zeta potential values of negatively charged HA-NPs resulted in a thinner 
hydration shell. As only minor size differences were determined by scanning electron 
microscopy on dried samples, this seems to be a rational explanation.  
The size of the particles was chosen carefully. On the one hand, NPs had to be small enough 
to circumvent sterically hindrance in the TM. Johnson et al. calculated that most pores in the 
TM have a size of 0.15 µm but yet a high number of larger pores allowed particles of 200 to 
500 nm to pass [21]. On the other hand, as TM cells share properties with endothelial cells 
and are capable of phagocytosis [38], a particle size larger than 250 nm was desired for high 
uptake rates [39]. Consequently, the HA-decorated NPs developed by us with a size of 
214 nm were expected to be large enough to be barely taken up via phagocytosis but small 
enough to freely move through the larger pores of the TM. One might assume, that this 
particle size will initiate a strong immune response and that particles are not only taken up 
by TM cells but also by macrophages. However, due to the immune privilege of the eye, only 
few immune cells are located in the ocular environment [40,41] and problems due to 
undesired activation of the immune system can be avoided by local application, which is 
intended for the LbL-NPs.  
Even if individual particles are not maintained in the sieve-like structure of the TM due to 
their size, NP aggregates might still be too large to pass unhindered. Because of the unique 
structure of LbL-NPs with charged polyelectrolytes on the surface, electrostatic repulsion 
was expected to guarantee a high colloidal stability. However, in an environment with an 
electrolyte concentration of physiological osmolarity (e. g. cell culture media, AH), the 
charges on the NP surface are screened and aggregation becomes a severe problem [32]. 
Proteins, which are commonly present under these physiological conditions, contribute to 
the stability of the particles as they form an additional layer around them (which is called 
protein corona) and sterically stabilize the particles. Unfortunately, the protein concentration 
in the AH is very low (only 12.4 mg/ 100 mL [33]) and we could demonstrate, that this 
amount of protein is not sufficient to prevent the aggregation of positively charged PEI-NP. 
Due to its physicochemical properties, less proteins are adsorbed onto HA-decorated 
surfaces and low amounts of protein are adequate to maintain colloidal stability in fluids of 
high osmolarity like cell culture media or physiologic liquids. Hence, the formation of 
aggregates was prevented by the sheath of HA and particles were assumed to freely follow 
the AH flow to their target cells in deeper regions of the TM.
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Steric hindrance is not the only limitation to unrestricted transport. Interaction forces 
between NPs and components of the ECM network also might retain the particles [21]. We 
assumed that possible sites of interaction are already occupied by HA, which is naturally 
present in the TM. In perfusion studies of porcine and human eyes we were able to 
demonstrate the feasibility of this concept. Whereas NPs without HA-functionalization were 
detected only in the upper regions, HA-NPs distributed into the whole outflow system 
including the deep TM and the SC. In further in vitro assays we could show that HA-NPs are 
sufficiently taken up by hTM cells, an absolute necessity for particles serving as siRNA 
delivery system. Nevertheless, additional bottlenecks have to be overcome for successful 
gene silencing.   
Hence and finally, the gene silencing potential of siRNA loaded HA-decorated LbL-NP was 
investigated in vitro. HA-NPs were able to reduce CTGF protein expression by approximately 
50 %. It implicates, that the particles protected the fragile siRNA from degradation, were 
taken up to a sufficient extent, escaped the endolysosomal pathway and released the nucleic 
acid into the cytosol of the cell, where it is incorporated into the gene silencing machinery.  
To our surprise, CTGF-silencing was more pronounced when the initial CTGF mRNA levels 
were high. This finding bears an enormous potential as it may be understood as protection 
against “over-silencing” and significantly improves the safety profile of the NPs. CTGF is a 
physiologically active substance involved in a plethora of different processes like wound 
healing, endochondral ossification or angiogenesis [42,43] and a concentration below a 
certain limit may have unforeseen consequences. This CTGF-silencing therapy, however, 
limits itself. As untreated patients show a high CD44 receptor density in the TM and SC, a 
remarkable accumulation of the NP can be expected in glaucomatous but not in healthy eyes. 
Additionally, CTGF silencing will only work when the levels are elevated and comes to an 
end when concentrations decline. Because of lower CTGF levels, also CD44 expression will 
decrease and less NP will be taken up into the cells, resulting in a smaller gene silencing 
effect. 
5. Conclusion 
In conclusion, we have identified CD44 as a promising target receptor to deliver NPs to the 
outflow pathway tissue. The assumption is based on the induction of CD44 by CTGF in vitro, 
the increased presence of CD44 in the anterior chamber angle in a glaucoma mouse model 
and the marked increase of CD44 in TM and SC cells of glaucomatous patients. The 
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development of HA-decorated NPs addresses directly the CD44 receptor. The uptake of 
HA-decorated NPs into the outflow pathway cells was much more efficient than the 
conventionally used PEI-NPs as shown by cell culture and perfusion experiments of porcine 
and human organ culture. The in vitro experiments revealed that an efficient knock-down by 
the delivery of a specific siRNA was dependent on the expression profile of CTGF in TM 
cells, which in turn demonstrates the high specificity of the HA-decorated NPs to pathologic 
expression changes in the outflow tissues. We suggest that the HA-decorated NPs are an 
excellent therapeutic approach to deliver specific agents like CTGF-siRNA to the outflow 
tissues and thereby to prevent the progression of the glaucomatous disease. 
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Summary 
The incidence of glaucoma is on the rise. By the end of this decade almost 80 million people 
will be affected by this vision threatening disease [1]. Current therapeutic concepts rely on a 
reduction of intraocular pressure by pharmacological substances or surgery [2]. Thus far, 
however, no treatment is available which address the underlying mechanisms of the disease. 
As knowledge about pathological processes on the molecular level increases, other 
therapeutic strategies also come into focus. One such promising approach is interference 
with connective tissue growth factor (CTGF), a matricellular protein mediating intraocular 
pressure (IOP) elevation. Post transcriptional gene silencing using small interfering RNA 
(siRNA) is an elegant strategy to reduce elevated levels of CTGF and consequently IOP. 
Nevertheless, delivering nucleic acids of this type remains a challenge. Nanoparticles (NPs) 
of different composition are a frequently applied system as they protect the fragile siRNA 
from degradation and facilitate cellular uptake.   
An extremely versatile and valuable excipient for ocular drug delivery systems is hyaluronic 
acid (HA). Several dosage forms benefit from its excellent biocompatibility and properties 
like transparency, high water binding capacity and mucoadhesivity. For example, HA has 
been used in eye drops as pharmaceutical ingredient itself or to enhance the bioavailability 
of other substances. Ocular inserts, implants or lenses benefit from an HA coating which 
improves wettability and biocompatibility and prevents fouling. As shown in this work, 
properties of more innovative technologies like nanoparticles (NPs) are also improved by 
HA functionalization (chapter 2). It was hypothesized that NPs designed for the delivery of 
siRNA to the trabecular meshwork (TM) in the anterior segment of the eye might also benefit 
from this approach. HA was expected to improve the mobility of the particles in the 
extracellular space and simultaneously generate high uptake rates due to interactions with 
cluster of differentiation (CD) 44 receptors on the surface of TM cells.  
The negative charge of HA can be used to electrostatically attach the polysaccharide to a 
suitable, positively charged NP. As siRNA is also negatively charged, assembly of the NP in 
a layer-by-layer (LbL) process is reasonable. However, the coating of nanomaterials with 
polyelectrolytes is challenging. Thus, it was first necessary to develop a robust protocol. 
Using the method described here, the manufacturing of monodispersed siRNA-loaded and 
HA-functionalized NPs with a size of approximately 220 nm was possible. Dynamic light 
scattering (DLS) and fluorescence based techniques were used to monitor NP aggregation 
and disassembly in different dispersants, mimicking conditions before and after ocular 
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application. The coating with HA seemed to improve the colloidal stability of the particles 
as an increase in size was delayed by one hour and the individual layers of the particles did 
not detach (chapter 3).  
HA-functionalization of NPs is a widely investigated approach in cancer therapy to enhance 
penetration into tumors and cellular uptake via interactions with CD44 cell surface receptors. 
This concept might also work for targeting the trabecular meshwork (TM) as a considerable 
receptor density was found on immortalized and primary TM cells. In vitro studies 
demonstrated a dependence of cell-associated NPs on the density of CD44 receptors, which 
was more pronounced when NPs were coated with HA. Additionally, HA decoration 
improved the colloidal stability of the NPs in 2D or 3D cell culture, which is in accordance 
with DLS measurements as reported above. This is beneficial regarding the therapeutic use 
of the NPs, as larger aggregates might clog pores in the TM outflow pathways (chapter 4). 
Frequently, the real difficulty is not the delivery of siRNA to the cell but the intracellular 
release of the nucleic acid from the NP into the cytosol. By determining the gene silencing 
effect of the drug delivery system, both, the delivery and release could be studied. LbL-NPs 
of different composition were not able to reduce the artificially induced production of green 
fluorescent protein in immortalized TM cells. Detailed investigations of the intracellular fate 
of the particles by analyzing their colocalization with various intracellular compartments did 
not result in any information about the missing gene silencing effect. However, further 
experiments indicated that NP exocytosis might contribute at least in part to the observed 
results (chapter 5). 
Finally, basic investigations and model systems were left behind. As demonstrated in 
perfusion studies of pig and human eyes, the targeting of CD44 receptors proved to be an 
effective strategy to increase NP accumulation in the TM as three times more NPs were 
found in this region when functionalized with HA compared to positively charged control 
particles. Glaucoma patients might especially benefit from this approach as CD44 
upregulation by CTGF and tumor growth factor β2 was demonstrated in vitro and a higher 
receptor density was found in the TM of transgenic mice and glaucoma patients. LbL-NPs 
proved to be effective in significantly reducing CTGF expression at the mRNA and protein 
level in primary TM cells. Interestingly, mRNA analysis indicated a dependence of the 
silencing effect on basal CTGF values which might be of interest with respect to 
individualized therapeutic use of the particles. Furthermore, HA decorated NPs reduced 
CTGF protein synthesis by 50 % whereas positively charged PEI-NPs did not show any 
effect (chapter 6).
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Conclusion  
In the present work, initial assumptions were confirmed: HA functionalization improved the 
colloidal stability and consequently the mobility of the particles. Additionally, targeting CD44 
cell surface receptors proved to be a successful strategy to increase accumulation of the 
particles in the TM as well as the cellular uptake. Initial in vitro data convincingly 
demonstrated the potential of the NPs in reducing CTGF expression. As these results 
indicate a promising development, the project should be pursued further. Additional research 
is needed to answer all remaining and emerging questions. A critical next step towards 
therapeutic application is the scale-up of manufacturing processes as larger quantities of 
particles will be needed. Then, in vivo studies and ex vivo organ cultures might give a first 
indication as to whether glaucoma patients will benefit from this new therapeutic concept in 
future. 
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Abbreviations 
 
3D   three-dimensional 
AH   aqueous humor 
AP   aqueous plexus 
ATP   adenosine triphosphate 
Cav1   caveolin-1 
CD44   cluster of differentiation 44 
CLSM   confocal laser scanning microscope/microscopy 
CTGF   connective tissue growth factor 
DAPI   4',6-diamidino-2-phenylindole 
D(E)MEM  Dulbecco's modified eagle medium 
DLS   dynamic light scattering 
ECM   extracellular matrix 
EMEM  Eagle's minimum essential medium 
FDA   Food and Drug Administration 
FI   fluorescence intensity 
FITC   fluorescein 
GFP   green fluorescent protein 
Gnb2L   guanine nucleotide-binding protein subunit beta-like protein 
HA   hyaluronic acid 
HA-NPs  hyaluronic acid functionalized nanoparticles 
hTM   primary human trabecular meshwork cells 
HTM-N  immortalized human trabecular meshwork cells 
IOP   intraocular pressure 
JCT   juxtacanalicular connective tissue 
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LbL   layer-by-layer 
LbL-NPs  layer-by-layer nanoparticles 
mRNA   messenger ribonucleic acid 
NPs   nanoparticles 
PBS   phosphate buffered saline 
PDI   polydispersity index 
PEI   polyethyleneimine  
PEI-NPs  polyethyleneimine functionalized nanoparticles 
pH   potential of hydrogen 
PLArg   poly-L-arginine 
PLGA   poly(lactic-co-glycolic acid) 
POAG   primary open angle glaucoma 
RHOD  rhodamine 
RISC   RNA-induced silencing complex 
RNA   ribonucleic acid 
RNAi   RNA interference 
RT-PCR  real time polymerase chain reaction 
SC   Schlemm’s canal 
SD   standard deviation 
SEM   scanning electron microscopy, standard error of the mean 
siRNA   short interfering RNA 
TGF-β2  tumor growth factor β2 
TM   trabecular meshwork 
VP   venous plexus 
WT   wild type 
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